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The prevalence and severity of obesity have been increasing in children, 
adolescents and adults of developed countries 1-3.  Obesity during childhood and 
adolescence predisposes to adult obesity and is associated with various 
cardiovascular co-morbidities in adult life 4. Many of these cardiovascular co-
morbidities are related to anthropometric and metabolic imbalances that jointly 
characterize the metabolic syndrome (MetS) 5. Furthermore, the increasing 
prevalence of MetS in childhood and adolescence 6, 7 is alarming as it promotes 
premature development of cardiovascular disease in the pediatric population 8.  
 
THE METABOLIC SYNDROME 
 
Definition 
The metabolic syndrome (MetS) represents a daunting global health and economic 
challenge as its prevalence has reached alarming dimensions 9-11 paralleling those 
of the obesity epidemic.  In its early stages, MetS is characterized by a 
constellation of metabolic derangements, including obesity and insulin resistance, 
which over years may progress to more overt diseases such as type 2 diabetes 
and cardiovascular disease 12-16.  Although the concept  of such a metabolic 
disease state has existed for over 80 years 17, it was not until 1998 that the array of 
metabolic derangements comprising the MetS was defined by the World Health 
Organization 17.  This initial definition of metabolic risk factors was further modified 
by the National Cholesterol Education Program’s Adult Treatment Panel III to be 
easily applied in the clinical and research setting 18.  Herein, the MetS traits include 
abdominal obesity, hyperglycemia, insulin resistance, atherogenic dyslipidemia, 
hypertension, inflammation and impaired endothelial function 19, 20.  Affected 
individuals typically are at increased risk to develop type 2 diabetes and 
cardiovascular diseases and premature mortality 21, 22. In fact, the most common 
complication of MetS is type 2 diabetes. Type 2 diabetes manifests by elevated 
plasma glucose levels underlying either the inability of tissues to clear glucose 
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from the blood or an increased hepatic glucose production or both.     
Cardiovascular disease is the major cause of morbidity and mortality in patients 
with type 2 diabetes and cardiovascular risk is two to fourfold increased in type 2 
diabetics over non-diabetic subjects 23, 24.   Altogether, MetS represents a 
complicated pathological state comprised of risk factors that are interrelated and 
can act to induce serious cardiovascular complications over years (Figure 1).  
The work in this thesis pertains to two major risk factors of the Mets, 
hypercholesterolemia and hyperglycemia.  A short overview on these two risk 
factors is given subsequently. (For further reading over the other risk factors, refer 
to BOX 1.) 
 
 
Figure 1. Risk factors and complications of the Metabolic Syndrome. The MetS risk factors 
are comprised of a variety of metabolic derangements which are interrelated and can act to 






Hypercholesterolemia as risk factor for the Metabolic Syndrome 
Raised total cholesterol levels predispose to atherosclerosis, a disease 
characterized by inflammation of the vascular wall.  Elevated blood cholesterol 
levels manifest as abnormalities in blood concentrations of lipoproteins. 
Lipoproteins are the carriers of cholesterol in the blood. High levels of low density 
lipoprotein (LDL) and small dense LDL are regarded pro-atherogenic, and in MetS 
LDLs are more easily oxidized 25. Oxidized LDL stimulates an array of 
atherosclerotic processes, herein oxidized LDL is rapidly taken up by 
macrophages which promotes foam cell formation, oxidized LDL produces 
chemotractive effects on monocytes and stimulates cytokine production which 
promote an inflammatory state. LDL particles vary in size and density, the smaller 
and denser (i.e. containing fewer triglycerides but a higher proportion of cholesterol 
esters) the LDL particle is, the more atherogenic. For example, small dense LDL 
has less affinity for the LDLR and thereby increases formation of foam cells 26. 
Moreover, small dense LDL has a higher susceptibility for oxidation 25 and it is 
believed to more easily damage the endothelium of the vessel wall 27. Due to its 
adverse health effects, LDL has been termed the “bad cholesterol”.  Based on 
numerous epidemiological studies, high levels of another lipoprotein, the high 
density lipoprotein (HDL) is believed to have anti-atherogenic properties 28 and 
thus, contrary to LDL, HDL has been termed the “good cholesterol”. One of those 
anti-atherogenic properties relevant to hypercholesterolemia is the role of HDL in 
the reverse cholesterol transport (RCT) pathway. RCT represents a major 
physiological pathway to clear excess cholesterol from the body. This pathway is 
comprised of a series of HDL-mediated steps that brings about removal of 
cholesterol from peripheral tissues, including cholesterol-laden macrophages in 
vessel walls, its subsequent transport to the liver, secretion into the bile as 
cholesterol or bile acid and further excretion into the feces 29, 30. Thus, low HDL 
levels are generally considered to impair this hepatobiliary clearance route of 
cholesterol, although recent work indicates that this concept needs 
reconsideration. 
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Importantly, within the MetS risk stratification, hypercholesterolemia 
comprises part of atherogenic dyslipidemia, which is characterized by elevated 
plasma triglycerides levels. Hypertriglyceridemia leads to an increased catabolism 
of HDL.  In short, hypertriglyceridemia promotes an increased transfer of 
triglycerides to HDL via cholesteryl ester transfer protein (CETP). This leads to the 
formation of triglyceride-rich HDLs  which can be easily catabolized by hepatic 
lipase 26. HDL particles have been shown to be more triglyceride-rich in insulin 
resistant and type 2 diabetic populations, where HDL levels are low 26. 
 
Hyperglycemia as risk factor for the Metabolic Syndrome 
Depending on the severity, hyperglycemia can be divided into either impaired 
fasting glycemia (8-hour fasting glucose levels ≥ 7.0 mmol/L) or type 2 diabetes (8-
hour fasting glucose levels ≥ 11.1 mmol/L) 31. The severity of hyperglycemia can 
change over time, reflecting the severity of underlying metabolic derangements. 
However, both conditions qualify as hyperglycemia and display undesirably high 
glucose levels, which chronically exert physiological stress, organ damage and 
dysfunction, especially to the eyes, kidneys, nerves, heart and blood vessels 31. 
 Underlying causes of hyperglycemia include obesity and abnormalities in 
adipose tissue 32, peripheral and hepatic insulin resistance, impaired beta-cell 
function which can all give rise to an abnormal hepatic glucose production and 
impaired peripheral and hepatic glucose uptake. Thus, the net effect is that either 
too much glucose is release into the blood by hepatic production, or the glucose 
cannot be cleared from the blood due to impaired uptake mechanisms of tissues, 
or both. For additional information on the relationships between obesity, insulin 
resistance and MetS, refer to BOX 1. 
 
As the prevalence of MetS is dramatically increasing, so is the ever-increasing 
economic burden of the MetS and its associated complications like type 2 
diabetes, atherosclerosis and cardiovascular disease. Cost-effective and efficient 
treatment strategies are in high demand.  This thesis describes how alterations of 




hypercholesterolemia and hyperglycemia. We specifically address the effects of 
bile acid sequestration (BAS) on hyperglycemia and hypercholesterolemia and 
further investigate whether physical activity modulates bile acid metabolism and 
thereby cholesterol homeostasis. For these studies, well-defined (genetically 
engineered) mouse models were used. 
 
 
BILE ACIDS AND THE METABOLIC SYNDROME 
 
Bile acids activate a number of signaling pathways involved in the regulation of 
lipid and glucose, but also energy metabolism 33. Their involvement in this wide 
array of metabolic pathways makes them attractive candidates for pharmaceutical 
intervention in the Mets where lipid, glucose and energy metabolism are 
imbalanced.  
 
Bile acids: Function, metabolism and implication for Mets 
Bile acids were originally identified as detergents to facilitate the digestion and 
absorption of fats and fat-soluble molecules in the intestine and to keep cholesterol 
from precipitating into the bile.  
Bile acids are synthesized by enzymatic conversion from cholesterol in the liver.  
Additionally, with a species dependent ~10-100 times higher concentration in bile 
compared to cholesterol, bile acids also comprise the most sterol and sterol-
derived compounds in bile. Thus, bile acids represent important end-products in 
cholesterol metabolism. The biosynthesis of bile acids is mediated by 2 pathways: 
the classic (or neutral) pathway and the alternative (or acidic) pathway, each 
involving a series of enzymatic steps 34.  The rate-controlling enzyme for the 
classic pathway is cholesterol 7 α-hydroxylase (CYP7A1) and that for the 
alternative pathway is sterol 27 hydroxylase (CYP27A1) 34. Bile acids can regulate 
their own synthesis by controlling the expression of genes involved in their 
synthesis, thereby creating a feedback loop. Herein, the nuclear receptor farnesoid 
x receptor (FXR) has a central role; when activated by bile acids, FXR acts to 
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inhibit the bile acid synthetic pathway on various levels 33. In short, activated 
hepatic FXR triggers small heterodimer partner (SHP) to inhibit the expression of 
CYP7A1 and thereby inhibit de novo bile acid synthesis. Moreover, activation of 
FXR by bile acids in the distal ileum induces the expression of fibroblast growth 
factor 15 (FGF15) which is subsequently released into the portal blood stream and 
acts to reduce the activity of hepatic CYP7A1 via binding to fibroblast growth factor 
4/β-klotho receptor complex (FGFR4) in the liver and subsequent activation of 
signal transduction pathways including the JNK/ERK pathway. Contrarily, under 
situations of low bile acid availability, FXR is not active and these two pathways 
that prevent de novo bile acid synthesis are not activated thus allowing the 
biosynthesis of bile acids to increase.   
Commonly referred to as the enterohepatic circulation, bile acids circulate 
between the liver and intestine by bile and portal blood (Figure 2). Ninety-six % of 
biliary bile acids is reabsorbed by active transport into the enterocytes of the 
terminal ileum, while a small fraction, ~4%, escapes absorption and is excreted 
into feces 34.  The body tries to keep the bile acid pool size constant as both the 
accumulation of bile acids in the body and a decreased bile acid pool can have 
serious pathophysiological consequences.  Thus, any fraction of bile acids that 
escapes reabsorption is newly synthesized from cholesterol in the liver. Fecal bile 
acid secretion, therefore, equals de novo bile acid synthesis and thereby has a 
major contribution to cholesterol turnover.  Intriguingly, perturbations that provoke 
an increase in fecal bile acid excretion induce an enhanced cholesterol turnover 
and thereby represent attractive treatment strategies for hypercholesterolemic 
patients.  
 
Bile acid sequestration and cholesterol homeostasis 
Bile acid sequestrants (BAS) are agents that induce an enhanced fecal bile acid 





Figure 2. Enterohepatic cholesterol and bile acid metabolism.  Cholesterol is either secreted 
from the liver into the gallbladder as cholesterol or as a bile acid after undergoing enzymatic 
conversion.  Cholesterol and bile acids are transported across the canalicular membrane 
into the bile. The gallbladder secretes cholesterol and bile acids into the intestine, where 
bile acids mix with cholesterol to form micelles for cholesterol absorption.  In the proximal 
intestine ~20-70% of cholesterol is absorbed into the intestinal lumen in humans (~35-45% 
in mice), subsequently expelled into the portal blood and returned to the liver. Cholesterol 
can also be secreted from the   Most bile acids (~96%) are absorbed in the terminal ileum 
and recycled back to the liver (enterohepatic circulation), while the remaining 4% are 
excreted with the feces. To maintain the bile acid pool size in equilibrium, the amount of bile 
acids lost via the feces is compensated for by de novo bile acid synthesis from cholesterol in 
the liver. 




lowering actions.  The older generation BAS e.g., cholestyramine and colestipol 
were the first choice treatment to reduce LDL cholesterol levels in patients with 
hyperlipidemia in the pre-statin era. Later, human studies have demonstrated that 
the BAS-induced decrease in total cholesterol and LDL cholesterol, were not only 
accompanied by considerable relative risk reductions in fatal and nonfatal 
myocardial infarction 36 and coronary heart disease death 37 but also by increased 
regression and decreased progression in coronary artery lesion 38-42. Moreover, 
BAS have been shown to increase HDL levels slightly, by 4-8% 43. 
BAS are positively charged non-absorbable resins; in the intestinal lumen 
BAS bind to negatively charged bile acids and bound to bile acids they are 
subsequently excreted into feces. By forming these non-absorbable complexes 
with bile acids, thereby disrupting the enterohepatic circulation of bile acids and 
provoking their malabsorption, BAS stimulate the liver to convert endogenous 
cholesterol into bile acids to maintain the bile acid pool size 44.  Thus, the BAS-
induced bile acid malabsorption subsequently leads to an increased cholesterol 
conversion to bile acids.  Herein, a compensatory increase in hepatic LDL receptor 
activity has been proposed to clear LDL cholesterol from the circulation, thereby 
reducing LDL cholesterol levels 45.  
Although the cholesterol lowering actions of BAS are well established, it is 
not, yet, clear what the effect of BAS are on atherosclerotic lesion size 
development.  Moreover, the exact effects of BAS on bile acid metabolism upon 
MetS are unknown, while also a thorough characterization of bile acid metabolism 
under MetS has not been established. 
 
Bile acid sequestration and glucose homeostasis 
In fact, recent evidence suggests that bile acid metabolism in itself is altered in 
type 2 diabetes 46, a complication of MetS. For example, an increased bile acid 
pool size has been reported for db/db mice 47 and liver-specific insulin receptor 
knockout mice 48, two widely utilized type 2 diabetic mouse models. Intriguingly, 




shown to not only improve insulin sensitivity but also reduce the bile acid pool size 
49. Moreover, administration of insulin to cultured rat hepatocytes reduced 
expression of CYP7A1 and CYP27A1 50.  These observations indicate a close link 
between hepatic insulin sensitivity and bile acid metabolism. Additionally, 
disrupting the enterohepatic circulation of bile acids by BAS was shown to benefit 
various parameters important for glycemic control, e.g., to reduce plasma glucose, 
glycosylated hemoglobin and the urinary glucose excretion but also to improve 
glycemic control and reduce the body mass index in patients displaying type 2 
diabetes and dyslipidemia 35, 44, 46, 51-53. Indeed, Colesevelam HCl, a second-
generation BAS, has been indicated by the FDA to improve glycemic control in 
patients with type 2 diabetes 54-56.  Furthermore, administering BAS to a diabetic 
mouse model improved insulin resistance and fatty liver 57. These data opened 
new perspectives for the treatment of MetS and cardiovascular disease risk 
factors.  
The mechanisms behind the BAS-induced reduction in plasma glucose 
levels are so far unknown but are thought to be mediated through direct 
interference of BAS with bile acid signaling pathways. Bile acid signaling pathways 
involve nuclear receptors, like FXR, which also has an established role in glucose 
metabolism 47, 58.  Granted that bile acids by themselves have been found to 
mediate the regulation of hepatic gluconeogenesis 59, it appears possible that BAS 
might modulate glucose homeostasis by FXR-dependent signaling pathways, 
thereby regulating the expression of enzymes implicated in hepatic 
gluconeogenesis and glucose utilization. FXR-independent pathways might entail 
a BAS-induced secretion of insulino-tropic incretins such as glucagon-like-peptide-
1 and gastric inhibitory polypeptide.  By attaching to bile acids in the intestine, BAS 
are believed to interfere with proper chylomicron formation, thus preventing 
adequate intestinal fatty acid absorption thereby provoking an increased fatty acid-
pass to more distal parts of the intestine where fatty acids can stimulate the 
release of GLP-1 60 . However, the mechanisms concerning the glucose-lowering 
actions of BAS remain speculative to date. 
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It is noteworthy that next to their cholesterol-lowering and glucose-lowering 
actions BAS have additional therapeutic effects specific for other risk factors of 
MetS (Figure 3).  Those pleiotrophic effects entail improvements in energy 
metabolism 35, 44, 46, 51-53, 61 and inflammation 35, 51, 62, 63 as observed in type 2 
diabetic patients and in animal models of diabetes. Thus, it is fascinating that 
originally developed as an efficient strategy for the lowering of circulating 
cholesterol levels, BAS have secondary actions that extend beyond their effects 
plasma cholesterol levels. 
 
 
PHYSICAL ACTIVITY AND THE METABOLIC SYNDROME 
 
Abundant evidence gathered from epidemiological, prospective and intervention 
studies suggest that MetS is a condition associated with physical inactivity. It is not 
surprising that physical activity is associated with a reduced cardiovascular risk. 
Moreover, a rapidly progressing body of human and animal data confirms an 
important beneficial role for physical activity for a number of metabolic 
derangements associated with MetS (Figure 3) and thus physical activity 
constitutes an essential part in managing those derangements. For example, 
exercise training has been shown to reduce body weight and visceral fat 
accumulation 64-67, improve insulin sensitivity 64-66, increase high-density lipoprotein 
cholesterol and decrease triglyceride levels 67, 68, as well as decreasing blood 
pressure 67, 69.  
Altogether, physical activity has mild to moderate effects on the metabolic 
and cardiovascular risk factors entailed in MetS. In fact, individuals who engage in 
regular moderate or intensive physical activity are half as likely to develop MetS as 
sedentary individuals 14. Importantly, a physically active lifestyle does not only 
prevent MetS but also acts beneficial in its treatment, by beneficially modulating its 
risk factors.  Hereby regular physical exercise also decreased complications 
associated with MetS like type 2 diabetes 70, 71, atherosclerosis 72-75, cardiovascular 




active lifestyle is highly beneficial in the prevention and treatment of the MetS by 
modulation of its risk factors.   
Current recommendations for the prevention and treatment of MetS are 
based on evidence from epidemiological and intervention studies.  Herein, the US 
Center for Disease Control and Prevention (CDC), the American College of Sports  
Medicine (ACSM) and the US Surgeon General have recommended that adults 
engage in at least 30 min of moderate-intensity physical activity on most, and 
preferably all, days of the week 67, 78.  Most studies investigating the effect of 
physical activity on MetS and its individual risk factors have focused on vigorous 
endurance training, but the benefits of brisk walking and lifestyle activities are 
becoming increasingly recognized.  
 
 
Figure 3. The effects of physical activity or bile acid sequestration on risk factors of the 
Metabolic Syndrome. A dashed arrow with stripes denotes a beneficial effect of physical 
activity while an arrow dashed with points denotes a beneficial effect of bile acid 
sequestration on a specific risk factor. No arrow is equivalent to currently unknown.  The risk 
factors hyperglycemia, insulin insensitivity and glucose intolerance are depicted jointly  to 
denote major problems in glucose homeostasis associated with MetS risk. 
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Physical activity and cholesterol homeostasis 
Physical activity has shown to not only effect total cholesterol and lipoprotein levels 
favorably, but also those of triglycerides. This is evident from acute and chronic 
physical activity interventions. For example, a single bout of physical activity 
decreased plasma triglycerides and increased plasma high density lipoprotein 
(HDL) cholesterol 79. Increases in plasma HDL have also been observed upon 
chronic physical activity, along with decreases in plasma triglycerides and the 
atherogenic low density lipoprotein (LDL) cholesterol 68, 80-84.  
Although physical activity imposes a rather small effect (about 3-5%) on 
decreasing LDL and increasing HDL cholesterol 82,  this small effect of exercise on 
dyslipidemia should not be underestimated.  As stated earlier, HDL is an important 
player in RCT and an increase in HDL potentially increases cholesterol excretion 
from the body via RCT.  Surprisingly the concept of an enhanced RCT induced by 
physical activity has never been explored fully. However, few and limited studies 
indicate that RCT might be enhanced upon physical activity. For example athletes 
have shown a greater capacity for cholesterol efflux from fibroblasts 85  as well as 
mouse macrophage cells 86 compared to sedentary controls.  This is intriguing, 
because the beneficial effects of physical activity on various MetS risk factors (for 
further reading refer to BOX 2) and cardiovascular disease have been widely 
documented but the mechanisms behind the beneficial effects of physical activity  
remain elusive.   
Specifically, little is known about the effects of physical activity on the 
turnover of cholesterol into bile acids, and its effects on bile acid metabolism per 
se. Limited past work indicates that exercise potentially modulates cholesterol and 
bile acid metabolism 87-90.  For example, an increased fecal bile acid and neutral 
sterol production has been observed in middle aged long distance runners 87. 
Furthermore, early studies on female rats showed that six weeks of voluntary 
wheel running promoted an increased biliary bile acid, cholesterol and 
phospholipids secretion 89 and either increased or had no effect on bile flow 89, 90.  
A recent study in mice also showed that twelve weeks of forced treadmill exercise 




characterized by an abnormally high biliary cholesterol to bile acid and 
phospholipids ratio 91. Granted from these previous observations, it is likely that 
exercise enhances pathways leading to increased fecal sterol excretion and that 
these pathways might play an important role in the beneficial effects of physical 
activity on MetS risk factors and MetS induced complications.  
 
 
SCOPE OF THIS THESIS 
 
MetS can, over years, lead to type 2 diabetes, atherosclerosis and life-threatening 
cardiovascular events. The dauntingly increasing prevalence and economic burden 
of MetS throughout the world warrants efficient treatment strategies. Herein, BAS 
represent an attractive pharmacological interjection, while physical activity 
represents an attractive lifestyle intervention. Both strategies display pleiotrophic 
effects on a variety of complications associated with MetS; however, underlying 
mechanisms are not understood. In this thesis the effect of BAS treatment and 
physical activity was tested on specific metabolic imbalances associated with 
MetS.   We elucidated the effects of BAS treatment or physical activity on 
parameters of cholesterol and glucose homeostasis. Thereby the work presented 
in this thesis provides novel mechanistic insights on how BAS treatment and 
physical activity bring about their beneficial effects in the MetS and its associated 
complications. 
Originally developed as cholesterol lowering agents, BAS have recently 
emerged as agents that improve glucose homeostasis and insulin sensitivity. 
However, the underlying mechanisms are largely unknown. We speculated that 
BAS-induced changes in hepatic lipid and glucose metabolism are underlying 
mediators herein. In Chapter 2, we first evaluated how BAS affects bile acid and 
lipid metabolism. First, we show that BAS surprisingly did not alter the bile acid 
pool size in diabetic mice despite a massive fecal loss. Second, we show that BAS 
induced de novo fatty acid synthesis in the livers of lean and diabetic mice, while 
plasma glucose levels decreased upon BAS in diabetic mice. Subsequently, we 
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investigated whether specific modifications in hepatic glucose homeostasis 
mediate the BAS-induced reduction in blood glucose in diabetic mice (Chapter 3). 
We found that BAS modulated blood glucose levels by increasing the metabolic 
clearance rate of glucose in diabetic mice. Concomitantly, BAS-treatment 
decreased skeletal muscle acylcarnitine contents, which have been associated 
with insulin resistance.  In another set of studies we then evaluated whether 
physical activity decreases MetS risk by modulating cholesterol homeostasis. 
Here, we first investigated the effect of voluntary wheel running on parameters of 
cholesterol and bile acid metabolism in healthy chow-fed mice (Chapter 4) and 
show that voluntary wheel running increased whole-body cholesterol turnover by 
stimulating bile acid synthesis and decreasing cholesterol absorption. To our 
surprise, we observed in a next study (Chapter 5) that in vivo macrophage-to-
feces RCT was not increased in healthy chow-fed mice exposed to a voluntary 
running wheel. However, exposing hypercholesterolemic, atherogenic mice to the 
voluntary wheel running intervention led to a reduced atherosclerotic lesion size 
development which coincided with an increased bile acid synthesis, biliary 
secretion and fecal excretion (Chapter 6). Lastly, we tested the effects of BAS on 
atherosclerotic lesion size development and cholesterol homeostasis in 
hypercholesterolemic, atherogenic mice (Chapter 7). Next to the dramatic 
improvements in plasma lipids and lipoprotein profiles, we found a ~78% reduction 
in atherosclerotic lesion size development which was accompanied by a switch 
from cholesterol accumulation to cholesterol loss upon BAS treatment. 
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Metabolic syndrome, type 2 diabetes and atherosclerosis 
The central features of MetS comprise visceral obesity, insulin resistance, 
hyperglycemia, atherogenic dyslipidemia, hypertension and endothelial 
dysfunction.  Of these the first two seem more critical in the development of MetS 
than the others, as other risk factors are associated with obesity and insulin 
resistance. For example, weight loss can lead to an improvement of various 
metabolic risk factors simultaneously. Thus, adiposity is, to a certain degree, 
required for the manifestation of MetS.  However, there are also individuals who 
are obese but who do not display any of the other metabolic derangements that 
comprise MetS.  Therefore, both insulin resistance and a metabolic disposition for 
obesity appear to be required for the expression of MetS. Endothelial dysfunction 
is a consequence of both insulin resistance and visceral adipose tissue.  Thus, the 
constellation of metabolic derangements comprising MetS are interrelated, share 
common mediators, pathways and pathophysiological mechanisms.  This 





Central abdominal obesity, but not general obesity, has consistently been shown to 
represent a strong risk factor for cardiovascular disease in prospective population 
studies 92. Further, strong correlations between the waist / hip ratio, the waist 
circumference, but not the body mass index, and a clustering of MetS risk factors 
93 have demonstrated that central obesity plays a key factor in MetS. Enlarged 
visceral adipose tissue contribute to an increased free fatty acid production and 
release of pro-inflammatory adipokines and cytokines, which all impair insulin-
mediated glucose uptake and promote insulin resistance 94.  Moreover, it has been 
suggested that visceral obesity may derive from chronic maladaptation to 
environmental stress factors 95.  Herein, the individual’s inability to cope with stress 
is thought to increase hypothalamus-pituitary-axis (HPA) activity and activation of 
the sympathetic nervous system which can bring about visceral obesity. In fact, a 
dysregulation of the HPA-axis has consistently been demonstrated upon visceral 
obesity 95. In addition to visceral fat depots, fatty liver has recently also been 
shown to explain variations in plasma triglyceride, glucose, HDL, cholesterol, 
insulin, and hepatic insulin sensitivity and thus been suggested to be an important 
predictor of MetS 96.  
 
Insulin Resistance 
Insulin is an anabolic hormone that is produced by the pancreas in response to 
high plasma glucose levels and stimulates glucose utilization by various tissues 
and thereby the clearance of glucose from the circulation. In addition, insulin also 
effects vascular function and promotes vasodilation and blood flow to target 
tissues for an efficient glucose clearance. The target tissues of peripheral glucose 
disposal are the liver, skeletal muscle and the adipose tissue.  Through intricate 
signaling pathways, insulin promotes peripheral glucose uptake by translocating 
specific glucose transporters to the cell surface; GLUT 4 (SLC2A4) in skeletal 
muscle and adipose tissue and GLUT2 (SLC2A2) in liver.  Insulin clearly promotes 
glucose storage over breakdown as demonstrated by insulin’s actions to stimulate 
glycogen synthesis in the liver and skeletal muscle and to inhibit glycogenolysis 
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(breakdown of glycogen) but also the production of new glucose in the liver 
(gluconeogenesis). Hereby insulin thus prevents an increase of glucose flux 
towards the blood.  Additionally, insulin prevents fat break down (lipolysis) but 
stimulates glucose uptake in fat tissues.  Insulin resistance is characterized by high 
circulating plasma glucose levels at prevailing (high) insulin concentrations due to 
an inability of liver, skeletal muscle and adipose tissue to respond to insulin.  
Specific impairments in the cellular insulin signaling pathways interfere with the 
translocation of the glucose transporter to the cell surface in insulin resistance 
leading to an impaired glucose uptake.  Insulin resistance moreover constitutes a 
condition where signaling pathways that promote vasodilation are impaired while 
processes that stimulate endothelial dysfunction are up-regulated, thus 
predisposing to atherosclerosis.  Hyperglycemia, toxicity from free fatty acids, 
obesity, dyslipidemia and pro-inflammatory conditions, all contributors to insulin 
resistance can also affect vascular function. 
 
Metabolic syndrome and endothelial dysfunction 
Endothelial dysfunction is a consequence of many cardiovascular risk factors, 
leads to hypertension and has major contributions in the development of 
atherosclerosis 97-99. Endothelial cells line the inner surface of blood vessels.  They 
act and respond to physiological and pathological stimuli and produce vasoactive 
substances for proper endothelial function.  Visceral adiposity and insulin 
resistance give rise to increased levels of circulating glucose, free fatty acids, pro-
inflammatory cytokines, adipokines and oxidative stress, all substances that 
promote endothelial damage eventually leading to endothelial dysfunction. 
 
BOX 2: PHYSICAL ACTIVITY AND MetS RISK FACTORS NOT DISCUSSED IN 
THIS THESIS 
Physical activity and obesity 
Epidemiological studies have shown that sedentary behaviors such as watching 
TV, playing video games and computer-related work promote unhealthy weight 




indicate that in order to decrease adiposity, the amount of physical activity is more 
important than its intensity 65, 105-107.  It is currently not understood whether exercise 
preferentially decreases visceral or subcutaneous abdominal fat 65, 105, 107, 108. 
However, it has been shown that exercise training decreases total, visceral and 
subcutaneous abdominal fat even without weight loss in normal weight, obese, 
abdominal obese and type 2 diabetic individuals  108.  
 
Physical activity and insulin sensitivity 
Insulin sensitivity improves by physical activity in an acute and chronic manner. 
The acute benefits of physical activity on insulin sensitivity are mediated by 
exercise-induced modulations of the insulin signaling response to muscle 
contraction.  Herein, an exercise-induced increase in insulin-dependent glucose 
transporter 4 (GLUT4) translocation to the muscle cell surface has been 
demonstrated 109, 110.  Moreover, it was found that this particular effect lasts for only 
48–72 h post exercise, which strengthens the general recommendation to maintain 
a daily exercise regime in order to maximize the benefits of exercise on insulin 
sensitivity.   
Clearly, exercise training also has beneficial effects on reducing obesity, which 
in itself constitutes an important mechanism for the improvements in insulin 
sensitivity.  The differentiation between the independent effects of exercise on 
obesity and insulin sensitivity proofs difficult 111.  
Nevertheless, chronic exercise interventions have shown to result in specific 
skeletal muscle adaptations including increased GLUT4 content, glycogen 
synthase activity, mitochondrial enzyme activity, capillary and mitochondrial 
density, improvements in endothelial function and potentially switching to a more 
oxidative fiber type 109, 110.  All these favorable modulations induced by physical 
activity in skeletal muscle tissue are indicative of an improved glucose uptake and 
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Physical activity and hypertension 
During a bout of physical activity systolic blood pressure increases relative to the 
physical effort. Intriguingly, 2-4 hours after at least 20 min of low and moderate 
physical activity systolic blood pressure decreases below the resting level, about 8-
10 mmHg in normo-tensive individuals, while the decrease can be 16-20 mmHg in 
hypertensive individuals  79, 112. Meta-analysis of randomized controlled trials 
revealed that the chronic effect of exercise training yields a decrease of about 3.8 
mmHg in systolic and 2.6 mmHg in diastolic blood pressure in normo-tensives and 
a slightly stronger reduction in hypertensive individuals 113, 114.  It is currently 
believed that exercise decreases blood pressure by its beneficial effects on body 
composition, insulin sensitivity, endothelial function and autonomic nervous system 
balance  115. 
 
Physical activity and inflammation 
It is known that a single bout of exercise induces an acute inflammatory response, 
as demonstrated by an increased release of pro-inflammatory cytokines and 
increased plasma concentrations of C-reactive protein 116, 117, while also increasing 
oxidative stress 118.  From a chronic viewpoint, however, lower plasma levels of 
inflammatory markers have consistently been observed in individuals with high 
cardio-respiratory fitness compared to those with low cardio-respiratory fitness 117, 
119, 120. Yet, data on the effects of physical activity on inflammatory markers in 
individuals at low to moderate cardiovascular risk are conflicting, and while some 
report beneficial effects 121-125 others report no effect of physical activity on 
inflammatory markers 126. Despite the apparent discrepancies between studies, 
regular physical activity and maintenance of cardio-respiratory fitness may reduce 
low-grade inflammation contrary to the acute inflammatory response of a single 
bout of exercise.  The proposed mechanisms mediating the exercise-induced 
reduction of inflammation are associated with reductions in body fat and 
associated production of pro-inflammatory cytokines, improved dyslipidemia as 




antioxidant enzymes, an increased production of anti-inflammatory cytokines as 
well as a reduced expression of adhesion molecules 67, 117, 127-129. 
  
Physical activity and endothelial function 
Obesity, hypertension, type 2 diabetes and hypercholesterolemia are all risk 
factors of the MetS and are all associated with impaired endothelial function. 
Physical activity has consistently shown to improve endothelial function, as 
measured via flow-mediated dilation of the brachial artery in obese, hypertensive, 
diabetic and hypercholesterolemic individuals 129, 130. Additionally, physical activity 
has shown to improve endothelial function as demonstrated by an enhanced 
endothelial nitric oxide synthase activity 131, 132.  Enhancing endothelial nitric oxide 
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Diabetes is characterized by high blood glucose levels and dyslipidemia. Bile acid 
sequestration has been found to improve both plasma glycaemic control and 
cholesterol profiles in diabetic patients. Yet, bile acid sequestration is also known 
to affect triglyceride metabolism, possibly via signaling pathways involving FXR 
and LXRα. We quantitatively assessed kinetic parameters of bile acid metabolism 
in lean C57Bl/6 and in obese, diabetic db/db mice upon bile acid sequestration 
using colesevelam HCl (2% wt/wt in diet) and related these to quantitative changes 
in hepatic lipid metabolism. As expected, bile acid sequestration reduced intestinal 
bile acid reabsorption. Importantly, bile acid pool size and biliary bile acid secretion 
remained unchanged upon sequestrant-treatment due to compensation by de novo 
bile acid synthesis in both models. Nevertheless, lean and db/db mice showed 
increased, mainly periportally confined, hepatic triglyceride contents, increased 
expression of lipogenic genes and increased fractional contributions of newly 
synthesized fatty acids. Lipogenic gene expression was not induced in 
sequestrant-treated Fxr-/- and Lxrα-/- mice compared to wild-type littermates, in line 
with reports indicating a regulatory role of FXR and LXRα in bile acid-mediated 
regulation of hepatic lipid metabolism. Conclusion: Bile acid sequestration by 
colesevelam induces the lipogenic pathway in an FXR- and LXRα-dependent 
manner without affecting the total pool size of bile acid in mice. We speculate that 
a shift from intestinal reabsorption to de novo synthesis as source of bile acid upon 
bile acid sequestration affects zonation of metabolic processes within the liver 
acinus.  
 





Diabetes is a multifactorial disease characterized by increased fasting blood 
glucose levels and dyslipidemia i.e., high plasma triglyceride and low-density-
lipoprotein cholesterol (LDL-C) levels. Controlling blood glucose and cholesterol 
levels in diabetic patients is critical for delaying the progression of clinical 
complications e.g., neuropathy and cardiovascular diseases. An efficient way to 
reduce plasma cholesterol levels is to induce cholesterol secretion in bile, either as 
bile acid or as free cholesterol. Bile is secreted into the ileum to facilitate 
absorption of lipids and lipid soluble vitamins. About 95% of secreted bile acids are 
reabsorbed in the terminal ileum and transported back to the liver via the portal 
vein (enterohepatic circulation). Besides their function in absorption of dietary fats, 
bile acids are signaling molecules and exert an important role in regulation of lipid 
metabolism1. Interestingly, bile acid metabolism is affected in diabetes which might 
contribute to the altered lipid profile observed in these patients2. Knowledge of 
potential disturbances in bile acid metabolism in type 2 diabetic humans and 
animal models, however, is still very limited3.  
Increasing fecal bile acid loss by preventing their intestinal reabsorption 
(sequestration) increases bile acid synthesis and, hence, hepatic cholesterol 
turnover. As a consequence, LDL-C levels are reduced in hyperlipidemic subjects4, 
5.  Interestingly, bile acid sequestration also improves glucose levels in type 2 
diabetic patients6-8. Yet, use of bile acid sequestrants has been associated with 
elevated plasma triglyceride levels9, 10. Bile acid feeding on the other hand has 
been shown to improve plasma lipid profiles in these patients11, 12. The regulation 
of the interrelationship between bile acid and lipid metabolism is still only partly 
understood. At a molecular level, a key regulatory role is assigned to the bile acid-
activated nuclear receptor FXR (NR1H4)13. Pharmacological activation of FXR has 
been shown to improve hypertriglyceridemia in mouse models of insulin 
resistance14, 15 whereas Fxr-/- mice have increased serum triglyceride levels16. 
Moreover, administration of the natural FXR-ligand cholate improved plasma 
triglyceride levels of high fat diet-fed mice via SHP-dependent modulation of the 





oxysterol receptor LXRα (NR1H3) is involved in the regulation of lipogenic gene 
expression upon bile acid feeding.  
At a physiological level, bile acid-activated signaling pathways are regulated by 
bile acid concentrations in the liver. We hypothesized that an altered flux of bile 
acids returning to the liver underlies, at least in part, the consequences on hepatic 
metabolism observed upon bile acid sequestration. We quantitatively assessed the 
kinetics of bile acid and hepatic fatty acid metabolism in lean C57Bl/6 mice and in 
obese and diabetic db/db mice treated with the bile acid sequestrant colesevelam 
HCl18. Additionally, we studied the contribution of FXR and LXRα to sequestrant-
induced changes in lipogenic gene expression.  
Bile acid sequestration reduced intestinal reabsorption of bile acids by 30%. 
Nevertheless, the bile acid pool size remained unchanged in both models due to a 
compensatory increase in de novo synthesis of bile acids. Remarkably, 
sequestrant-treatment significantly increased hepatic triglyceride contents which 
primarily accumulated in periportal areas. Expression levels of lipogenic genes as 
well as the fractional contribution of de novo synthesized fatty acids were 
increased. This lipogenic response appeared to be FXR- and LXRα-dependent. 
We speculate that a shift from reabsorption to de novo synthesis as the source of 




METHODS AND MATERIASL 
 
Animals 
Male lean C57Bl/6 and obese, diabetic db/db mice on a C57Bl/6 background 
(B6.Cg-m +/+ Leprdb/J) were purchased from Charles River Laboratories 
(L'Arbresle, France and Brussels, Belgium, respectively). Fxr-/-- 19 and Lxrα-/- 
mice20 were generated as described. All animals were housed individually in a 
temperature- and light-controlled facility. Mice were fed commercially available 
laboratory chow (RMH-B; Arie Blok, Woerden, The Netherlands), when indicated 
supplemented with 2% (w/w) colesevelam HCl (Daiichi Sankyo, Inc., Parsippany, 
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NJ, USA), for 2 weeks. Mice were used for experimental procedures at 12 weeks 
of age. All experiments were approved by the Ethical Committee for Animal 
Experiments of the University of Groningen. 
 
Experimental procedures 
Postprandial blood glucose levels were measured at the start of the experiment 
and subsequently after 1 week and after 2 weeks of treatment. Additionally, body 
weight and food intake were determined at these time points. [1-13C]-acetate (2% 
w/v in drinking water) was provided for 24 h (7AM-7AM), starting at day 13 of the 
experiment. Blood spots were collected from the tail on filter paper (Schleicher and 
Schuell No2992, ‘s Hertogenbosch, The Netherlands) before and after 
administration of the label. Blood spots were air-dried and stored at room 
temperature until analysis. After two weeks on the diets, mice were sacrificed by 
heart puncture under isoflurane anesthesia. Plasma was stored at -20°C until 
analyzed. The liver was removed, weighed and snap-frozen in liquid nitrogen. The 
intestine was excised, flushed with cold (4°C) PBS and subsequently snap-frozen 
in liquid nitrogen. Both liver and intestine were stored at -80ºC until biochemical 
analysis and RNA isolation. 
In a separate experiment, 400 μg [2H4]-cholate (in 0.5% NaHCO in PBS, pH = 
7.4) was intravenously administered at day ten of the two-week periods. 
Subsequently, retro-orbital blood samples (75 μl) were obtained at 12, 24, 36, 48 
and 60 h after injection of [2H4]-cholate in chow-fed lean and db/db mice. A pilot 
study in colesevelam-treated animals indicated that, as expected, turnover of [2H4]-
cholate was markedly increased. Therefore, blood samples were obtained at 12, 
18, 24, 30 and 36 h after administration of [2H4]-cholate in colesevelam-treated 
lean and db/db mice. Plasma was stored at -20°C until analyzed. Feces were 
collected over the 60 h experimental period and, after air-drying, kept at room 
temperature until analysis. After 60 h, mice were anesthetized by intraperitoneal 
injection of Hypnorm (1 ml/kg) and Diazepam (10 mg/kg) and subjected to 
gallbladder cannulation for 30 min. During bile collection, body temperature was 
stabilized using a humidified incubator. Bile was stored at -20°C until analyzed. 






Blood glucose concentrations were measured using EuroFlashTM test strips 
(LifeScan Benelux, Beerse, Belgium). Hepatic lipids were extracted according to 
Bligh & Dyer21. Plasma and liver triglyceride and cholesterol contents were 
determined using commercially available kits (Roche Diagnostics, Mannheim, 
Germany and DiaSys Diagnostic Systems, Holzheim, Germany). Plasma free fatty 
acids were determined using a NEFA-C kit (Waco Chemicals, Neuss, Germany). 
Pooled plasma samples from each group were used for lipoprotein separation by 
fast protein liquid chromatography (FPLC) on a Superose 6 column using an Akta 
Purifier (GE Healthcare, Diegem, Belgium). Triglycerides in each fraction were 
determined. Total bile acids in bile and feces were determined by an enzymatic 
fluorimetric assay22.Liver morphology was assessed by Masson’s trichrome 
staining of parafin embedded material.  
 
GC/MS analysis and mass isotopomer distribution analysis (MIDA) 
Biliary and fecal bile acids were determined by gas chromatography as described 
23. The isotope dilution technique as well as the preparation of plasma samples for 
analysis of bile acids by gas chromatography-mass spectrometry (GC-MS) were 
described in detail by Hulzebos et al23. Fecal neutral sterols were analyzed as 
described24. Labeling of acetyl-CoA pools with orally provided [1-13C]-acetate was 
described by Jung et al25. Cholesterol was extracted from blood spots and 
prepared for GC-MS analysis as described26. Lipids in liver homogenates were 
hydrolyzed in HCl/acetonitril. Fatty acids were extracted in hexane and converted 
to their pentafluorobenzyl (PFB) derivatives. The fatty acid-PFB isotopomer 
patterns (mass fragments C16:0 m/z 255-259, C18:0 m/z 283-287, C18:1 m/z 281-
285) were analyzed using a Agilent 5975 series GC-MS (Agilent Technologies, 
Santa Clara, CA). GC-MS measurements of fatty acids and MIDA analyses were 
performed essentially as described27, 28.  
 
Calculation of de novo synthesis and chain elongation of fatty acids 
Incorporation of [1-13C]-acetate into C16:0 was assumed to be solely the result of 
de novo lipogenesis via the malonyl-CoA-Fas pathway. The M1 and M3 mass 
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isotopomers of C16:0 were used to calculate the acetyl CoA precursor pool and 
fractional synthesis of C16:0 as described28.  
C18:0 is synthesized from chain elongation of pre-existing (chain elongation) and 
de novo synthesized C16:0 (de novo lipogenesis). The M1 mass isotopomer of 
C18:0 represents the sum of these two processes; the M3 mass isotopomer 
results only from chain elongation of de novo synthesized C16:0. We assumed that 
the acetate precursor pool enrichment calculated for C16:0 equalled the precursor 
pool of acetate used to elongate C16:0. C18:0 generated from de novo 
synthesized C16:0 was considered as nonamer of acetate. Therefore, MIDA 
algorithms using M3 of C18:0 and the acetate precursor pool enrichment 
calculated for C16:0 were used to calculate the fractional C18:0 synthesis. 
Subsequently, total M1 mass isotopomer of C18:0 was corrected for the 
contribution of C18:0 derived from de novo synthesized C16:0. Using this 
methodology, we could calculate the contribution of chain elongation of pre-
existing C16:0 to the total fractional C18:0 synthesis.  
C18:1 is synthesized by desaturation of C18:0 by Scd1. Using similar methodology 
to that of C18:0, we could calculate the contribution of chain elongation of pre-
existing C16:0 and de novo synthesized C16:0 to total fractional synthesis of 
C18:1.  
Throughout the manuscript, chain elongation is defined as synthesis of C18:0 or 
C18:1 from pre-existing C16:0; de novo lipogenesis is defined as the synthesis of 
C18:0 or C18:1 from de novo synthesized C16:0.  
 
Calculation of CDCA- and CA-derived bile acids 
The murine bile acid species we quantified in bile and feces using GC-MS include 
cholate, deoxycholate, chenodeoxycholate, α-muricholate, β-muricholate, ω-
muricholate, hyodeoxycholate and ursodeoxycholate. We consider cholate and 
deoxycholate as CA-derived and the others as CDCA-derived bile acids. The 
contribution of deoxycholate to CA-derived bile acids is minor in bile (~5%), 
because the majority of DCA that returns to the liver is reconverted to CA in mice. 
Therefore, the pool size and synthesis rate of cholate as determined in vivo using 





The composition and synthesis of CDCA-derived bile acids were calculated from 
the ratio of CDCA-derived/CA-derived bile acids and the CA-derived pool and 
synthesis as determined by calculations of [2H4]-cholate. The product of the 
CDCA/CA ratio in feces and CA synthesis represents the synthesis of CDCA-
derived bile acids. The product of the CDCA/CA ratio in bile and CA pool size 




Supplemental  Figure 1. Plasma lipoprotein profile of control and colesevelam-treated lean 
and db/db mice. VLDL-TG was reduced in diabetic mice upon treatment. No changes in  
VLDL-TG levels were observed in lean mice. Plasma from 6 animals per group was pooled 




Total RNA was isolated from liver and intestine using TRI-reagent (Sigma, St. 
Louis, MO) according to the manufacturers’ protocol. cDNA was produced as 
described29. Real-time PCR was performed on a 7900HT FAST real-time PCR 
system using FAST PCR master mix and MicroAmp FAST optical 96 well reaction 
plates (Applied Biosystems Europe, Nieuwekerk ad IJssel, The Netherlands). 
Primer and probe sequences have been published before 
(www.labpediatricsrug.nl). PCR results were normalized to 18S (liver) and β-actin 
(intestine).  




All values are represented as mean ± standard deviation. Statistical analysis was 
assessed using the Mann-Whitney-U-test (SPSS 12.0.1 for Windows). P-values 





Effects of colesevelam-treatment on food intake, body weight and plasma 
metabolites in lean and db/db mice  
Lean and db/db mice were treated with the bile acid sequestrant colesevelam for 
two weeks. Food intake was increased in colesevelam-treated lean and db/db 
mice during treatment compared to untreated controls (Table 1). Body weight gain 
was unaffected in colesevelam-treated lean mice but decreased in colesevelam-
treated db/db mice. Blood glucose levels increased in control db/db mice during 
the two-week intervention period but remained stable in colesevelam-treated db/db 
mice. Blood glucose levels remained unchanged upon treatment in lean mice. 
Fasting insulin levels (not shown) were unchanged and decreased, respectively, in 
colesevelam-treated lean and db/db mice. Non-esterified fatty acid (NEFA) and 
VLDL-triglyceride levels (Supplemental Figure 1) were significantly reduced in 
colesevelam-treated db/db mice compared to untreated controls but remained 
unchanged in lean mice.  
 
Biliary bile acid flux and cholate pool size remain unchanged in colesevelam-
treated lean and db/db mice  
Control db/db mice showed increased feces production and a higher fecal bile acid 
output, representing hepatic bile acid synthesis, compared to lean controls (Figure 
1A and B, resp.). As expected, colesevelam-treatment led to massive increases in 
fecal bile acid output (Figure 1B). Untreated lean and db/db mice had similar bile 
flow rates and biliary bile acid output rates (Figure 1C and D, resp.) which 







Table 1. Basal, plasma and liver parameters of lean and db/db mice (control and 
colesevelam-treated). Values are presented as mean ± SD. N=6 animals per group. 




Direct end-products of de novo bile acid synthesis are the primary bile acids 
cholate and chenodeoxycholate. Modifications of these bile acids in liver and 
intestine give rise to differentially structured primary and secondary bile acids, 
respectively. Supplemental Table 1 provides details on biliary and fecal bile acid 
compositions. In short, sequestrant-treatment resulted in a strongly increased 
relative content of fecal deoxycholate in both groups. Cholate remained the major 
biliary bile acid species in both models upon sequestrant-treatment. Next, we 
determined relevant kinetic parameters of cholate23, the major primary bile acid 
species in mice. Untreated db/db mice displayed a larger pool size and a higher 
synthesis rate of cholate compared to untreated lean mice (Figure 2). Importantly, 
cholate pool size remained unchanged upon colesevelam-treatment in both 
models. Synthesis rates of cholate were massively increased upon sequestrant- 























































Figure 1. Effects of colesevelam on fecal and biliary bile acids. Fecal output (A) was 
unchanged in both lean and db/db mice upon colesevelam-treatment. As expected, fecal 
bile acid output (B) of lean and db/db mice was increased upon colesevelam-treatment, 
indicative for higher hepatic bile acid synthesis. Importantly, bile flow (C) and biliary bile acid 
output (D) were unchanged upon colesevelam treatment. Values are presented as mean ± 
SD. N=6 animals per group. Significant differences within or between groups are indicated # 
and *, respectively. 
 
treatment (+375% and +172%, lean and db/db mice, respectively) and completely 
compensated for the increased fecal bile acid loss induced by colesevelam. The 
calculated amount of cholate reabsorbed from intestines of colesevelam-treated 
lean and db/db mice was reduced by about 30% compared to untreated controls 
(Figure 2D). Decreased plasma bile acid levels further reflect a reduced flux of bile 
acids returning to the liver (Figure 2E).  
To gain insight into colesevelam-induced changes in total bile acid pool 
composition and synthesis of bile acids derived from the primary bile acid species 
cholate and chenodeoxycholate, we calculated the amount of cholate- and 
chenodeoxycholate-derived bile acids in the pool as well as their synthesis rates. 
Upon sequestrant-treatment, the total pools of bile acids remained unchanged in 
both models (Figure 3A). Nevertheless, the pool size of chenodeoxycholate-








































































Figure 2. The pool size of cholate is unchanged in lean and db/db mice after a two-week 
colesevelam-treatment. The kinetics of cholate were calculated from the decay of [2H4]-
cholate from plasma (18). Despite substantial fecal bile acid loss (Figure 1B) in 
colesevelam-treated lean and db/db mice, cholate pool size (A) was unchanged in both 
groups. Hence, the fractional turnover rate (FTR) (B) and synthesis rate (C) of cholate were 
massively increased. Both lean and db/db mice had reduced absorption of cholate (D) upon 
treatment with colesevelam. Additionally, total plasma bile acids (E) were reduced in 
colesevelam-treated mice. Reabsorbed cholate is represented as percent of cholate 
secreted in bile. Values are presented as mean ± SD. N=6 animals per group. Significant 
differences within or between groups are indicated # and *, respectively. 
 
 
massively increased, whereas synthesis of chenodeoxycholate-derived bile acids 
remained unchanged in sequestrant-treated mice compared to untreated controls 
(Figure 3B). Corresponding with increased cholate synthesis, hepatic expression 
of Cyp7a1, encoding the first and rate-limiting enzyme in bile acid synthesis, and 











































































































Figure 3. Decreased chenodeoxycholate (CDCA)-derived bile acid pool size and 
synthesis in colesevelam-treated mice. The composition and synthesis of the total bile 
acid pool were calculated from the ratio of CDCA-derived/cholate (CA)-derived bile acids 
and the pool size and synthesis of cholate as determined in vivo using [2H4]-cholate. The 
product of CDCA-derived/CA-derived bile acid ratio in feces and CA synthesis represents 
the synthesis of CDCA-derived bile acids. The product of the CDCA-derived/CA-derived bile 
acid ratio in bile and CA pool size represents the contribution of CDCA-derived bile acids to 
the total bile acid pool size. The total bile acid pool size (A) was unchanged in colesevelam-
treated lean and db/db mice. Synthesis (B) of CA-derived bile acids was massively 
increased whereas synthesis of CDCA-derived bile acids was unaffected. Hepatic 
expression (C) of Cyp7a1, Cyp8b1 and Cyp27a1 were massively increased. Interestingly, 
intestinal expression (D) of the FXR-target gene Fgf15 was undetectable in colesevelam-
treated mice whereas expression of Ibabp (Fabp6), another FXR target gene was 
unchanged. Values are presented as mean ± SD. In panel A-B, * and # indicate significant 
differences in total (CA + CDCA-derived) pool and synthesis. Gene expression levels are 
presented as relative expression normalized to 36B4 (liver) and 18S (intestine). N=6 
animals per group. Significant differences within or between groups are indicated # and *, 









Cyp8b1, encoding the specific enzyme required for cholate synthesis, were 
massively increased. Cyp27a1 directs bile acid synthesis towards CDCA. Although 
expression of Cyp27a1 was increased in colesevelam-treated mice, this was not 
reflected in increased CDCA synthesis (Figure 3C). Despite the fact that bile acid 
reabsorption was not completely abolished, expression levels of the Fxr-target 
gene Fgf15 were undetectable in distal ilea of colesevelam-treated lean and db/db 
mice (Figure 3D).  
Cholesterol synthesis is massively increased in colesevelam-treated lean 
and db/db mice colesevelam-treatment increased fecal cholesterol excretion 
(Figure 4A). Together with a strongly increased synthesis of bile acids this 
translates into an increased turnover of cholesterol. However, this did not result in 
reduced plasma concentrations or hepatic contents of cholesterol (Figure 4B and 
C, respectively). Increased hepatic expression of Hmgr, encoding the rate-
controlling enzyme in cholesterol synthesis, and of Ldlr (Figure 4D) indicated the 
anticipated hepatic compensatory response in cholesterol metabolism after 
colesevelam-treatment. To quantify this, the fraction of newly synthesized 
cholesterol was determined by analysis of the incorporation of [1-13C]-acetate into 
plasma cholesterol. Fractional cholesterol synthesis was indeed robustly increased 
in colesevelam-treated mice (Figure 4E). 
 
Hepatic triglyceride content is increased due to enhanced contribution of 
lipogenesis in colesevelam-treated mice  
Both colesevelam-treated lean and db/db mice had modestly increased (lean 
+50%, db/db +23%) hepatic triglyceride contents compared to untreated controls  
(Table 1). Remarkably, fat accumulated primarily in periportal areas upon bile acid 
sequestration (Figure 5A and B). Increased hepatic expression of key lipogenic 
genes (Srebp1c, Acc1, Fasn and Scd1) (Figure 5C) was highly suggestive of 
enhanced synthesis of fatty acids. Indeed, the total fractions of newly synthesized 
C16:0, C18:0 and C18:1, as determined by incorporation of [1-13C]-acetate 
followed by MIDA analysis, confirmed that synthesis of these major hepatic fatty 
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Figure 4. A massive increase in de novo cholesterol synthesis completely compensates for 
the loss of cholesterol via increased conversion into bile acids and increased fecal loss after 
colesevelam-treatment. Fecal cholesterol output (A) was increased in lean and db/db mice 
upon colesevelam-treatment. Yet, plasma concentrations (B) and hepatic contents (C) of 
cholesterol remained unchanged. Increased hepatic expression levels (D) of Ldlr and Hmgcr, 
key genes involved in hepatic cholesterol metabolism, strongly pointed towards 
compensatory cholesterol synthesis. To assess this, the fraction of newly synthesized 
cholesterol was calculated by means of [1-13C]-acetate incorporation using Mass 
Isotopomer Distribution Analyses (MIDA). The fraction of newly synthesized cholesterol was 
indeed massively increased upon colesevelam-treatment in lean and db/db mice (E). Values 
are presented as mean ± SD. Gene expression levels are presented as relative expression 
normalized to 36B4. N=6 animals per group. Significant differences within or between 














































































































Figure 5. Increased fatty acid synthesis and chain elongation underlie the increased hepatic 
triglyceride content after colesevelam-treatment. Colesevelam-treatment lead to increased 
hepatic fat contents (Table 1) which was mainly periportally defined (A) vs (B), lean control 
vs lean colesevelam respectively. Increased expression of the key lipogenic genes Srebp1c, 
Acc1 (Acaca), Fasn and Scd1 (C) were highly suggestive of enhanced lipogenesis in 
colesevelam-treated mice. The fraction of newly synthesized C16:0 (D) was significantly 
increased in colesevelam-treated lean mice only. The fractions of newly synthesized C18:0 
and C18:1 were significantly increased in lean and db/db mice. Additionally, chain 
elongation (defined as C16:0 + C:2) and desaturation were increased in Colesevelam-
treated lean and db/db mice. Values are presented as mean ± SD. Gene expression levels 
are presented as relative expression normalized to 36B4. N=6 animals per group. 
Significant differences within or between groups are indicated # and *, respectively. In panel 
D-F, * and # indicate significant differences in total (de novo + chain elongated) fraction of 
newly synthesized fatty acids. +; colesevelam-treated. 
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acid species was increased. Additionally, we calculated the contribution of de novo 
synthesis and chain elongation to the total fractional C18:0 and C18:1 synthesis 28. 
The increased total fraction of newly synthesized fatty acids was mainly 
attributable to increased chain elongation in colesevelam-treated lean and db/db 





























Supplental Figure 2. Hepatic expression of Fxr and Fxr-target genes. Hepatic 
expression of Fxr  (Nr1h4) and of the well-defined Fxr-target genes Shp (Nrob2), Ntcp 
(Slc10a1), and Bsep (Abcb11) were unaffected in colesevelam-treated lean mice compared 
to controls. In db/db mice, however, hepatic expression of Shp and Ntcp were reduced and 
increased, respectively, which is indicative of reduced FXR-signaling. Expression of Bsep 
was unchanged on colesevelam HCL-treated db/db mice compared to controls. Gene 
expression levels are represented as relative expression normalized to 18S. N=6 animals 
per group. Significant differences within or between groups are indicated # and *, 
respectively. 
 
Lipogenic gene expression upon sequestrant-treatment is Fxr and Lxrα 
dependent  
Bile acid-mediated changes in expression of one of the major regulators of 
lipogenesis, Srebp1c, have been reported to be regulated by both FXR- and LXRα-
regulated pathways17. Surprisingly, expression levels of well-defined FXR- and 
LXRα-target genes were differentially or not at all affected in colesevelam treated 
lean and db/db mice (Supplemental Figure 2 and 3, resp.). To further address the 
role of hepatic FXR and LXRα in the lipogenic response to bile acid sequestration, 
Fxr-/- and Lxrα-/- mice and wild-type littermates were treated with colesevelam for 
two weeks. The key lipogenic genes Srebp1c, Acc1, Fasn and Scd1 were 



































Supplemental Figure 3. Colesevelam-treatment does not affect hepatic expression of Lxr 
(Nr1h3) and Lxr-target genes. Gene expression levels are presented as relative expression 
normalized to 18S. N=6 animals per group. Significant differences within or between groups 
are indicated # and *, respectively 
 
untreated controls (Figure 6). Lipogenic genes, however, were barely affected in 
sequestrant-treated Fxr-/- and Lxrα-/- mice. These results support earlier 
observations on the regulatory roles of these nuclear receptors in the response to 
bile salt-mediated changes in lipid metabolism 17.  
 
Discussion 
This work provides novel insights in the interrelationship between bile acid and 
lipid metabolism in lean and diabetic db/db mice treated with the bile acid 
sequestrant colesevelam. To the best of our knowledge, this is the first report 
which quantitatively shows that, despite massively induced fecal bile acid loss 
upon sequestrant-treatment, bile acid pool sizes and biliary bile acid secretion 
rates remain unaffected. Additionally, we show that bile acid sequestration induces 
hepatic fatty acid synthesis and elongation. An altered hepatic bile acid gradient 
due to decreased reabsorption but increased de novo synthesis of bile acids likely 
affects specific aspects of hepatic bile acid signaling. The lipogenic response 
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Figure 6. The lipogenic response to colesevelam treatment is dependent on FXR and LXRα 
signaling pathways. Fxr-/- and Lxrα-/- mice and their wild-type littermates were treated with 
colesevelam for two weeks. Wild-type mice had increased hepatic expression of the 
lipogenic genes Srebp1c, Acc1, Fasn and Scd1 upon colesevelam-treatment. On the 
contrary, these effects were abolished in livers of Fxr-/- and Lxrα-/- mice. Values are 
presented as mean ± SD. Gene expression levels are presented as relative expression 
normalized to 36B4. N=4 animals per group. Significant differences within or between 
groups are indicated # and *, respectively. 
 
appears to be dependent on FXR- and LXRα-signaling as was evident from 
studies in the respective knockout mice.  
Knowledge of possible disturbances in bile acid metabolism in type 2 diabetic 
humans and animal models is very limited 3. For the first time, to our knowledge, 
we report data on kinetic alterations of bile acid metabolism in diabetic db/db mice 
and show that db/db mice have an increased pool size and synthesis rate of bile 
acids compared to lean controls. As suggested for db/db mice 15 and liver-specific 
insulin receptor knockout (LIRKO) mice 30, disturbed hepatic insulin signaling may 
directly contribute to changes in bile acid synthesis. Indeed, insulin was shown to 
reduce plasma bile acids in type 1 diabetic rats 31 possibly via FOXO1-mediated 
regulation of Cyp7a1 32. Further studies beyond the scope of this work, are needed 
to further unravel underlying mechanisms of disturbed bile acid metabolism in type 





Db/db mice responded favorably to sequestrant-treatment: blood glucose levels 
stabilized while NEFA and VLDL-TG levels decreased. These parameters were 
unchanged in lean mice. Importantly, the pool size of the primary bile acid species 
cholate as well as the total pool size of bile acids remained unchanged in 
sequestrant-treated lean and db/db mice. Remarkably, only the synthesis of 
cholate was massively increased: synthesis of chenodeoxycholate-derived bile 
acids was not affected at all. In humans, an increased cholate-to-
chenodeoxycholate ratio would result in a more hydrophilic bile acid pool which 
has been associated with decreased susceptibility for gallstone disease 33. 
Colesevelam-treatment might therefore be beneficial for prevention of gallstone 
formation in type 2 diabetic humans who have an increased prevalence of 
gallstones34. Bile acid reabsorption was reduced by 30% in both models. Although 
bile acid reabsorption was not fully impaired, Fgf15 expression levels were not 
detectable in ilea of sequestrant-treated wild-type mice. Possibly, bile acid 
sequestration decreases the cellular content of bile acids below a certain threshold 
value necessary to activate FXR in enterocytes as observed in an in vivo study in 
rabbits35.  
Interestingly, hepatic triglyceride contents of colesevelam-treated lean and 
db/db mice were enhanced which appeared to be mediated by an increased de 
novo synthesis of hepatic fatty acids and chain elongation. In contrast to our data, 
other studies addressing the effects of bile acid sequestration on lipid metabolism 
showed that bile acid sequestration prevented triglyceride accumulation in the liver 
36, 37. It should be realized that those studies were performed in high fat diet-fed 
mice in which the beneficial effects of bile acid sequestration are likely partly 
attributable to sequestrant-induced malabsorption of lipids. In addition, strain-
specific responses to sequestrant-treatment cannot be ruled out.  
At a molecular level, the interrelationship between bile acid and lipid 
metabolism is generally accepted to be mediated by FXR. Nevertheless, data to 
explain the exact mechanisms of this relationship are still very inconsistent. 
Pharmacological activation of FXR has been shown to reduce FFA levels in 
insulin-resistant rodents15, 38. Absence of FXR signaling in Fxr-/- mice leads to 
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increased VLDL-TG levels in plasma of these mice 39 suggestive of a role for Fxr in 
control of VLDL assembly.  
Colesevelam-treatment induced hepatic expression levels of the lipogenic gene 
Srebp1c in lean and db/db mice. Hepatic expression levels of the lipogenic gene 
Srebp1c were reduced in Fxr-/- mice compared to controls 39,40. Conversely, FXR 
activation was also shown to repress the expression of Srebp1c in a pathway 
involving SHP 17, 40. Expression levels of the FXR-target gene Shp were unaffected 
and decreased in colesevelam-treated lean and db/db mice, respectively. These 
results are suggestive of SHP-independent regulation of Srebp1c upon 
sequestrant-treatment. Supportive of SHP-independent regulation of lipogenic 
gene expression by FXR was the observation that FXR regulates the transcription 
of the lipogenic gene Fasn through direct binding to the Fasn promoter 41. Since 
expression levels of well-known FXR-target genes were differentially affected in 
lean and db/db mice, we studied the role of FXR in the lipogenic response of 
sequestrant-treatment in Fxr-/- mice and found that in contrast to wild-type mice 
littermates, lipogenic gene expression levels were barely affected. Srebp1c, is 
strongly regulated by the oxysterol receptor LXRα 42. Increased synthesis of 
cholesterol, as occurs in sequestrant-treated mice, could possibly lead to 
increased hepatic levels of oxysterols and, hence, activation of LXRα. Expression 
levels of established LXRα-target genes, however, were unaffected in sequestrant-
treated lean and db/db mice, suggestive of unchanged LXRα signaling. Yet, 
investigation in sequestrant-treated Lxrα-/- mice revealed that lipogenic gene 
expression was not increased in these mice compared to untreated wild-type 
littermates. Our results from colesevelam treated Fxr-/- and Lxrα-/- mice confirm 
earlier findings that FXR and LXRα are both involved in regulation of bile acid-
mediated changes in lipogenic pathways 17. The exact molecular mechanisms via 
which these nuclear receptors signal regulate the lipogenic response to bile acid 
sequestration exceed the scope of this report.  
At a physiological level, bile acid-mediated signaling pathways are dependent 
on the concentration of bile acids in the liver acinus. We speculate that the concept 
of metabolic zonation 43 might add to the understanding of the observed hepatic 





display different metabolic activities than those lining the central vein, e.g., bile 
acid and fat synthesis are pericentrally localized processes whereas cholesterol 
synthesis is mainly carried out by portal hepatocytes 43. As we show in the current 
report, the amount of bile acid molecules reabsorbed in ilea of colesevelam-treated 
mice was decreased by ~30% with a subsequent reduction in plasma bile acid 
levels and, hence, reduced bile acid signaling in periportal hepatocytes. Newly 
synthesized bile acids, which accommodate a much larger fraction of the bile acid 
pool of colesevelam-treated mice compared to controls, are primarily secreted by 
pericentrally localized cells and possibly exert differential signaling functions. 
Selective periportal fat accumulation and differentially affected expression levels of 
hepatic Fxr-target genes support this hypothesis. Additionally, it was shown that 
Cyp7a1, which is exclusively expressed in pericentral hepatocytes 44, translocates 
to a larger area of the liver lobulus with more involvement of periportally localized 
cells in sequestrant-treated rats 45. It should be stressed that this hypothesis 
requires dedicated investigation.  
In conclusion, we show that colesevelam-treatment increases lipogenesis and 
chain elongation in mice which, at least at the level of gene expression, is 
dependent on FXR and LXRα. A shift from reabsorption to de novo synthesis as 
the source of biliary bile acids affects the sinusoidal gradient of bile acids 46. This 
shift modifies the regulation of genes and proteins involved in bile acid synthesis 
and bile acid-mediated regulation of metabolism and possibly underlies the 
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glucose levels in db/db mice by increasing 
its metabolic clearance rate  
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Aims/hypothesis   Bile acid sequestrants (BAS) reduce plasma glucose levels in 
type II diabetics and in murine models of diabetes but the mechanism herein is 
unknown.  We hypothesized that sequestrant-induced changes in hepatic glucose 
metabolism would underlie reduced plasma glucose levels. Therefore, in vivo 
glucose metabolism was assessed in db/db mice on and off BAS using tracer 
methodology.   
Methods  Lean and diabetic db/db mice were treated with 2% (wt/wt in diet) 
Colesevelam HCl (BAS) for 2 weeks. Parameters of in vivo glucose metabolism 
were assessed by infusing [U-13C]-glucose, [2-13C]-glycerol, [1-2H]-galactose and 
paracetamol for 6 hours, followed by mass isotopomer distribution analysis, and 
related to metabolic parameters as well as gene expression patterns. 
Results   Compared to lean mice, db/db mice displayed an almost 3-fold lower 
metabolic clearance rate of glucose (p=0.0001), a a3-fold increased glucokinase 
flux (p=0.001) and a a2-fold increased total hepatic glucose production rate 
(p<0.001). BAS treatment increased glucose metabolic clearance rate by a37% but 
had no effects on glucokinase flux nor total hepatic or endogenous glucose 
production. Strikingly, BAS-treated db/db mice displayed reduced long-chain 
acylcarnitine content in skeletal muscle (p=0.032) but not in liver (p=0.189). 
Unexpectedly, BAS treatment increased hepatic FGF21 mRNA expression 2-fold 
in lean mice (p=0.030) and 3-fold in db/db mice (p=0.002). 
Conclusions/interpretation   BAS induced plasma glucose lowering in db/db 
mice by increasing metabolic clearance rate of glucose in peripheral tissues, which 
coincided with  decreased skeletal muscle long-chain acylcarnitine content. BAS-












Type 2 diabetes is a major health problem worldwide 1. The predominant features 
of type 2 diabetes entail increased fasting blood glucose levels, increased plasma 
triglycerides and LDL-cholesterol levels, as well as disturbed peripheral glucose 
utilization 2-4.  The use of bile acid sequestrants (BAS) for lowering of LDL-
cholesterol levels is well-established 5-7. More recently, Colesevelam HCl, a BAS, 
has been indicated by the FDA to improve glycemic control in patients with type 2 
diabetes 8-10. So far, however, the actual changes in hepatic and/or peripheral 
glucose metabolism upon BAS supplementation are not understood. 
Bile acids are synthesized from cholesterol in the liver. Upon secretion into 
bile, bile acids function to emulsify fats in the small intestine. Most of the secreted 
biliary bile acids are reabsorbed in the ileum (enterohepatic circulation).  
Sequestrants interfere with the enterohepatic circulation of bile acids by binding 
them in the intestine, thereby inhibiting their reabsorption and promoting their fecal 
loss.  As a consequence, the liver increases bile acid synthesis and subsequently 
cholesterol uptake from the circulation thereby reducing LDL-cholesterol levels 11, 
12. 
To date, there is a lack of understanding how BAS reduce plasma glucose 
levels. However, a large body of research suggests that bile acids modulate 
hepatic glucose metabolism via signaling pathways mediated by the nuclear 
receptor Fxr in diabetes 13-19.  Fxr is expressed in the liver, intestine, adrenal gland 
and kidney 20, and it acts to inhibit de novo bile acid synthesis when activated by 
bile acids  in the liver 21. Paradoxically, both agents that inhibit de novo bile acid 
synthesis, such as bile acids themselves and synthetic Fxr ligands 14, 22, as well as 
agents that increase de novo bile acid synthesis such as BAS, were shown to 
reduce plasma glucose levels in diabetic mice 23, 24. Thus, the cause of bile acid-
mediated changes in blood glucose levels remains elusive. 
We therefore questioned whether BAS-induced changes in hepatic 
carbohydrate fluxes are responsible for the observed reduction in plasma glucose 
levels in db/db mice. To test this, we treated healthy lean mice and obese, diabetic 
db/db mice with Colesevelam HCl. Applying an in vivo infusion protocol of stable 
CHAPTER 3  
70 
 
isotopes followed by mass isotopomer distribution analysis (MIDA), we first 
characterized specific disruptions of whole body glucose turnover and hepatic 
glucose metabolism in db/db mice. We then tested the hypothesis that BAS 
restores disrupted hepatic glucose fluxes thereby mediating the previously 
observed reduction in blood glucose levels in diabetic mice.  In view of the strong 
interaction between glucose and fatty acid metabolism, we additionally tested the 
effect of BAS on levels of lipids and intermediates of fatty acid metabolism in liver 
and muscle.  
 
METHODS and MATERIALS 
 
Animals and diets  
Ten week old male lean C57BL/6 and obese, diabetic db/db mice on a C57BL/6 
background (B6.Cg-m +/+ Leprdb/J) were purchased from Charles River 
Laboratories (L'Arbresle, France and Brussels, Belgium, respectively).  Mice were 
housed in a temperature controlled (21°C) room with a dark-light cycle of 12 h 
each. For all animal experiments the principles of laboratory animal care (NIH 
publication no. 85–23, revised 1985) were followed. The Ethics Committee for 
Animal Experiments of the University Groningen, the Netherlands, approved 
experimental procedures.   
One week after arrival at the animal facility, 8 db/db (db) and 6 lean (L) 
mice were put on a diet containing standard laboratory chow (RMH-B; Arie Blok, 
Woerden, The Netherlands) supplemented with 2% (wt/wt) Colesevelam HCl 
(Daiichi Sankyo, Inc., Parsippany, NJ, USA) for 2 weeks.  Another 8 db/db and 6 
lean mice remained on standard laboratory chow.  Body weights and food intake 
were recorded every other day. One week into the diets, mice were fitted with a 
permanent catheter in the right atrium via the jugular vein, as described previously 
25. Mice were allowed to recover from surgery for 6 days.  
 
Materials  
The following isotopes were used: [2-13]-C glycerol (99% 13C atom percent excess), 
[1-2H]-galactose (98% 2H atom percent excess) (Isotec, Miamisburg, Ohio, USA), 
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[U-13C]-glucose (99% 13C atom percent) (Cambridge Isotope Laboratories, 
Andover, Mass., USA). All reagents and chemicals used were reagent pro analysis 
grade. Blood spots and urine were collected on Schleicher and Schuell No. 2992 
filter paper (Schleicher and Schuells, ‘s Hertogenbosch, The Netherlands).  
Infusates were freshly prepared and sterilized at the day before the experiment. 
 
Animal Experiments   
The infusion experiment was performed in conscious mice, as described 
previously 25. Mice were fasted for 4 hours (03:00-08:00 am) and then housed in 
metabolic cages to allow frequent collection of urine and blood spots on filter paper. 
Mice were infused with a sterile solution containing [U-13 C]-glucose (13.9 μmol/ml), 
[2-13C]-glycerol (160 μmol/ml), [1-2H]-galactose (33 μmol/ml) and paracetamol 
(1.0mg/ml) at a rate of 0.6 ml/h. Before and during the experiment, small blood 
samples were obtained via tail bleeding to allow for the determination of plasma 
glucose. Blood was immediately centrifuged and stored at -20°C until analysis. 
Blood spots were collected on filter paper before the start of the infusion and 
hourly afterwards until 6 h after the start of the infusion. Blood spots were air dried 
and stored at room temperature until analysis.  Hourly urine samples were 
collected on filter paper, air dried and stored at room temperature until analysis. At 
the end of the experiment, animals were anesthetized with isoflurane and a small 
blood sample was collected via orbital puncture for the determination of insulin. 
Mice were allowed to recover and five days after the infusion experiment. 
Mice were then fasted for 7 hours (03:00-10:00h) and terminated by heart puncture 
under isoflurane anesthesia.  A large blood sample was collected in heparin-
containing tubes, immediately centrifuged and stored at -20 °C until analysis.  Liver 
was excised, weighed, snap frozen and stored at -80 °C until further analysis.  
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Measurement and Analysis of Mass Isotopologue Distribution Analysis by 
GC-MS  
Analytical procedures for extraction of glucose in bloodspots and paracetamol-
glucuronide from urine filter paper strips and derivatization of the extracted 
compounds and GC-MS measurements of derivatives were all performed 
according to Van Dijk et al 26, 27.  The measured fractional distribution was 
corrected for natural abundance of 13C by multiple linear regression as described 
by Lee et al. 28 to obtain the excess mole fraction of mass isotopologues due to 
incorporation and dilution of infused labeled compounds, i.e., [2-13C]-glycerol, [U-
13C]-glucose and [1-2H]-galactose.  This distribution was used in mass 
isotopologues distribution analysis (MIDA) algorithms of isotope incorporation and 
dilution according to Hellerstein et al.29 as described by Van Dijk et al.26, 27.  
 
Determination of metabolite concentrations 
Commercially available kits were used to determine plasma levels of insulin 
(Mercodia, Uppsala, Sweden), triglycerides, total cholesterol, free cholesterol and 
NEFA (Wako Chemicals, Neuss, Germany),  
Plasma HOMA-index was calculated multiplying the blood glucose levels by the 
plasma insulin levels at 6h of MIDA infusion and dividing the product by 61.64, 
which was the HOMA-reference factor derived from the product of the average 
blood glucose level and plasma insulin level of lean control mice of this experiment. 
Hepatic glycogen and glucose-6-phosphate content were determined as previously 
described 25.  Hepatic lipids were determined in liver homogenates by 
commercially available kits for triglycerides and total cholesterol (Wako Chemicals, 
Neuss, Germany) after lipid extraction as described by Bligh and Dyer 30. Plasma 
acylcarnitines were determined according to the method of Chase et al 31 as 
described by Derks et al.32.  Profiles of long-chain acylcarnitines (C16:0, C16:1, 
C18:0, C18:1 and C18:2) in muscle and liver homogenates (15% (w/v) in PBS) 








Total RNA was isolated from liver using TRI-reagent (Sigma, St. Louis, MO) 
according to the manufacturers’ protocol. cDNA was produced as described by 
Plösch and coworkers 34. Real-time PCR was performed on a 7900HT FAST real-
time PCR system using FAST PCR master mix and MicroAmp FAST optical 96 
well reaction plates (Applied Biosystems Europe, Nieuwerkerk ad IJssel, The 
Netherlands). Primer and probe sequences have been deposited at the 
RTprimerDB 35. PCR results were normalized to 18S-rRNA abundance. 
 
Statistics  
All values are represented as mean ± standard deviation. Statistical significance 
was assessed using the Mann-Whitney-U-test (SPSS 12.0.1 for Windows). P-
values were corrected for multiple comparison errors. Statistical significance was 





Bile acid sequestration reduced plasma glucose levels in db/db mice.   
Previously, our laboratory has shown that Colesevelam HCl treatment lowers 
plasma glucose concentrations in db/db mice compared to untreated counterparts 
24.  To confirm these findings, basal parameters related to glucose metabolism 
were determined in lean and db/db mice treated with the bile acid sequestrant 
(BAS) for two weeks. As expected, BAS-treatment lowered blood glucose levels of 
diabetic mice (Table 1).  No effects of BAS on body weight, liver weight or liver 
weight / body weight ratio were observed (Table 1). Plasma insulin concentrations 
were decreased (a30%) and the HOMA-index was improved in sequestrant-treated 
diabetic mice compared to untreated counterparts. Moreover, we observed a more 
than 50% reduction in plasma 3-hydroxybutyrate levels and a non-significant 
decrease in plasma NEFA levels (Table 1). Consistent with our previous 
observations 24, liver triglyceride contents were increased in sequestrant-treated 
lean and db/db mice compared to controls (Table 1). 




Table 1. 7h fasted parameters (unless otherwise stated) in lean mice (L), lean mice 
supplemented with BAS (L BAS), db/db (db) and db/db mice supplemented with BAS (db 
BAS). Data are shown as means ± SD; *p<0.05 vs. same genotype, †p<0.05 vs. lean same 
condition 
 
                                                                 L                 L BAS                db               db BAS 
 
Body weight (g)                               23.9 ± 1.1       24.9 ± 0.9        37.9 ± 3.2†     39.7 ± 3.5† 
 
Liver weight (g)                              1.14 ± 0.08     1.19 ± 0.09      1.74 ± 0.24†   1.93 ± 0.27† 
 
Liver weight / Body weight (%)        4.7 ± 0.2         4.7 ± 0.2          4.7 ± 0.6          4.9 ± 0.7 
 
Plasma Parameters 
4h fasted blood glucose                  8.3 ± 0.6         8.8 ± 0.9         27.7 ± 4.4†     19.3 ± 4.8†* 
(mmol/L)   
 
Blood glucose at end of MIDA        9.2 ± 0.5         9.7 ± 1.0         32.7 ± 3.9†     23.1 ± 3.9†* 
infusion (mmol/L) 
 
Plasma insulin at end of MIDA       6.7 ± 1.8         7.5 ± 1.6         66.6 ± 23.3†   48.0 ± 28.4† 
infusion (mU/L) 
 
HOMA Index                                   1.0 ± 0.3         1.2 ± 0.3        34.8 ± 10.1†    16.9 ± 6.7†* 
 
NEFA (μmol/L)                              300 ± 109        393 ± 92         697 ± 149†      555 ± 149 
 
Lactate (mmol/L)                            8.4 ± 1.1          8.3 ± 1.3         6.8 ± 1.5          8.6 ± 1.8 
 
3-Hydroxybutyrate (mmol/L)          0.3 ± 0.2          0.3 ± 0.2          1.5 ± 1.0†       0.7 ± 0.3† 
 
Triglycerides (mmol/L)                   0.7 ± 0.2          0.5 ± 0.1*        1.0 ± 0.1          0.7 ± 0.1 * 
 
Total cholesterol (mmol/L)             2.3 ± 0.3         2.3 ± 0.2          2.8 ± 0.1 †       3.2 ± 0.4†* 
 
Liver Parameters 
Triglycerides (μmol/g liver)              16 ± 6             31 ± 14*           44 ± 11†          59 ± 21† 
 
Glycogen (μmol/g liver)                   62 ± 45           47 ± 30          175 ± 21†         216 ± 37† 
 




Bile acid sequestration increased metabolic clearance of glucose without 
affecting hepatic glucose production.   
BAS promotes specific changes in hepatic cholesterol and bile acid synthesis 24. 
To gain insight in hepatic glucose metabolism upon BAS-treatment, in vivo glucose 
metabolism was studied in lean and db/db mice after 2 weeks of BAS treatment. 
First, whole body and hepatic glucose metabolism in db/db mice was characterized. 
In db/db mice, plasma glucose concentrations were almost 3 times higher than in 
lean mice (9.2 ± 0.5, 32.7 ± 3.9 mmol/l, lean vs. db/db, Table 1). The rate of uptake 
of plasma glucose by peripheral tissues was only slightly but significantly higher in 
db/db mice compared to lean mice (93.1. ± 13.1 vs. 117.0 ±  14.6 ml.kg-1.min-1, 
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lean vs. db/db, Table 2).  Consequently, the metabolic clearance rate of plasma 
glucose was lower in db/db mice (9.9 ± 1.3 vs. 3.6 ± 0.7 ml.kg-1.min-1, lean vs. 
db/db, Table 2). Diabetic mice had significantly higher hepatic glycogen contents 
compared to lean mice while, surprisingly,  hepatic glucose-6-phosphate contents 
was decreased in the db/db genotype (Table 1).  A strongly increased hepatic 
glucose cycling brought about by a massively increased glucokinase flux was 
observed in db/db compared to lean mice (47 ± 5 vs. 150 ± 58 umol.kg-1.min-1, lean 
vs. db/db, Table 2).  However, since hepatic clearance of glucose by glucokinase, 
as derived by dividing blood glucose from the glucokinase flux, was not 
significantly different from hepatic glucose clearance in lean mice (5.1  r  0.7 
ml.kg-1.min-1 vs. 4.6 r 0.7 ml.kg-1.min-1, lean vs. db/db mice), the observed 
increase in glucose cycling was most likely driven by the extreme hyperglycemia in 
db/db mice. In db/db mice, de novo synthesis of glucose-6-phosphate was 
significantly decreased when compared to lean mice (86 ± 6 umol.kg-1.min-1 vs. 74 
± 11 umol.kg-1.min-1, lean vs. db/db, p<0.05, Table 2). Endogenous glucose 
production (excluding glucose cycling) was slightly higher (87 ± 13 vs. 115 ± 14 
umol.kg-1.min-1, lean vs. db/db, p<0.05, Table 2) whereas total glucose output 
(including glucose cycling) was massively higher in db/db compared to lean mice 
(118 ± 17 umol/kg-1.min-1 vs. 244 ± 54. umol/kg-1.min-1 lean and db/db mice, 
respectively (Table 2).  
BAS treatment had differential effects on whole body glucose metabolism 
in lean and db/db mice. Irrespective of the decreased plasma glucose 
concentration, BAS treatment had no effect on the flux through glucokinase in 
livers of db/db mice. As a consequence, hepatic clearance of glucose by 
glucokinase was significantly increased in db/db  compared to lean mice, from 5.6 
± 0.4 ml.kg-1.min-1 in lean mice to 8.1 ± 0.7 ml.kg-1.min-1 in db/db mice (p<0.05).  
Since the glucokinase flux remained high, glucose cycling remained higher in 
treated db/db mice when compared to treated lean mice. In treated db/db mice the 
rate of endogenous glucose production did not change and the rate of total hepatic 
glucose output tended to increase, albeit non-significantly (Table 2). Although BAS 
was not effective to reduce rates of hepatic glucose consumption or production, we 
did observe a decrease of de novo glucose-6-phosphate synthesis in treated db/db  
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Table 2. In vivo parameters of hepatic glucose metabolism during the last 3 hours of the 
infusion experiment in lean mice (L), lean mice supplemented with BAS (L BAS), db/db mice 
(db) and db/db mice supplemented with BAS (db BAS). The middle panel of the table shows 
the contributions of de novo glucose-6-phosphate synthesis to glucose and of glycogen to 
glucose to the endogenous glucose production rate. The middle panel shows the 
contributions of the endogenous glucose production rate and the glucose cycling rate to the 
total hepatic glucose production rate which equals the flux rate through glucose-6-
phosphatase. The lower panel shows the flux rates through glucokinase and the rate of 
glucose-6-phosphate de novo synthesis. Each value represents the mean ± SD; *p<0.05 vs. 
same genotype untreated; †p<0.05 vs. L same condition 
 
          
  L LBAS db db BAS 
Rate of glucose disposal 
(μmol/kg/min) 93 ± 13 107 ± 9.2 117 ± 13† 119 ± 8† 
Metabolic clearance rate 
(ml/kg/min) 9.9 ± 1.3 10.7 ± 0.6 3.6 ± 0.7† 5.3 ± 0.3†* 
  
Contributions to endogenous glucose 
production rate (μmol/kg/min) 
De novo glucose-6-
phosphate synthesis to 
glucose 60 ± 7 64 ± 8 66 ± 6 56 ± 8* 
Glycogen to glucose 27 ± 6 37 ± 5* 49 ± 8† 61 ± 6†* 
Endogenous glucose 
production rate 87 ± 13 101 ± 9 115 ± 14† 117 ± 6† 
  
Contributions to hepatic glucose production 
rate (μmol/kg/min) 
Endogenous glucose 
production rate 87 ± 13 101 ± 9 115 ± 14† 117 ± 6† 
Glucose cycling rate 31 ± 4 38 ± 3 129 ± 53† 156 ± 53† 
Total hepatic glucose 
production rate 118 ± 17 139 ± 17 244 ± 54† 273 ± 58† 
  Flux rates (μmol/kg/min) 
Glucokinase 47 ± 5 56 ± 7 150 ± 58† 184 ± 54† 
Glucose-6-Phosphate 
de novo synthesis 86 ± 6 87 ± 9 74 ± 11 61 ± 7†* 
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mice (87 ± 9 μmol/kg-1.min-1  vs. 61 ± 7 μmol/kg-1.min-1, lean vs. db/db mice, 
p<0.05, Table 2). This accounted for the decreased contribution of newly 
synthesized glucose-6-phosphate towards plasma glucose (Table 2). Since the 
flux through glucokinase and glucose cycling remained invariantly high, these 
decreases of de novo glucose-6-phosphate synthesis and newly synthesized 
glucose-6-phosphate partitioning towards glucose did not translate into a 
decreased total glucose output in db/db mice. Importantly, BAS treatment 
significantly increased peripheral metabolic clearance of glucose in db/db mice 
(a37%; Table 2) without affecting whole body glucose disposal (Table 2). Improved 
plasma glucose concentrations in BAS-treated db/db mice are therefore mainly 
attributed to  increased  peripheral glucose clearance. 
To assess whether changes in hepatic glucose metabolism were in 
parallel with changes in gene expression patterns, expression levels of genes 
involved in hepatic glucose metabolism in untreated lean and db/db mice were 
compared. Compared to lean mice, in db/db mice expression levels of glucose 
transporter 2, glucokinase and glucose-6-phosphate hydrolase were increased, 
whereas no difference was observed in the expression of the gene encoding 
phospho-enol-pyruvate carboxykinase (Figure 1A, B, C and D). Furthermore, 
expression of the glycolytic enzyme pyruvate kinase was not differentially 
expressed in lean and db/db mice (Figure 1E). Additionally, expression levels of 
these genes were measured in both models following BAS-treatment. BAS 
treatment had differential effects on expression of genes involved in hepatic 
glucose metabolism. In lean mice, expression of glucose transporter 2 and 
glucokinase was increased upon BAS treatment whereas expression levels 
remained high in db/db mice. Quite surprisingly, expression of the glycolytic 
enzyme pyruvate kinase was strongly increased upon treatment in db/db mice 
whereas expression levels remained unaffected in lean mice upon treatment. 
(Figure 1E).   In addition, hepatic gene expression levels of fibroblast growth factor 
21  (FGF21), which has lately gained attention for its remarkable in vivo actions on 
glucose metabolism, were measured 36.  Surprisingly, expression levels of FGF21 
were 2-fold increased in treated lean and 3- fold increased in treated db/db mice 
compared to untreated counterparts (Figure 1F).   
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Figure 1.  Hepatic mRNA expression levels of genes involved in hepatic glucose 
metabolism in lean mice (L, n=5), lean mice supplemented with BAS (L BAS, n=6), db/db 
mice (db, n=8) and db/db mice supplemented with BAS (db BAS, n=8) for glucose 
transporter 2 (A), glucokinase (B), glucose-6-phosphate hydrolase (C), phospho-enol 
pyruvate carboxykinase (D), pyruvate kinase (E) and fibroblast growth factor 21 (F). 
Expression of genes was normalized to 18S-rRNA. 18S-rRNA levels were similar in livers of 
all animals.Data are mean ± SD; *p<0.05 vs. same genotype untreated; †p<0.05 vs. L same 
condition 
 
Bile acid sequestration reduced long-chain acylcarnitine content in muscle 
and plasma in db/db mice.   
Skeletal muscle is the major site of both glucose and fatty acid uptake and 
oxidation 4. It is known that under circumstances of high glucose concentrations  
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Figure.2. Effect of BAS on hepatic long-chain acylcarnitines content (Sum of C16:0, C16:1, 
C18:0, C18:1 and C18:2) (A), skeletal muscle long-chain acylcarnitines content (B), skeletal 
muscle saturated long-chain acylcarnitines content (C) and plasma acylcarnitine 
concentration (D) in lean mice (L, (n=5), lean mice supplemented with BAS (L BAS, n=4), 
db/db mice (db, n=5) and db/db  mice supplemented with BAS (db BAS, n=5).  Data are 
mean ± SD; † p<0.05 vs. L same condition; * p<0.05 vs. same genotype untreated  
 
muscle favors glucose uptake and oxidation over fatty acid uptake and oxidation 4, 
while accumulating excess fatty acids, in particular saturated free fatty acid 
species like stearate and palmitate 37, 38. Recently, it has been shown that 
excessive fatty acid oxidation in diabetic mice results in inefficient oxidation 39. 
Concomitantly, high intracellular concentrations of long-chain acylcarnitines, 
markers of inefficient mitochondrial fatty acid oxidation, were measured. High 
concentrations of these intermediates can impair the switch to carbohydrate 
oxidation, a marker of “metabolic flexibility”. To study whether BAS affected fatty 
acid metabolism, long-chain acylcarnitine contents in liver and skeletal muscle 
were measured. In db/db mice, both skeletal and liver long-chain acylcarnitines 
were strongly increased compared to lean mice (Figure 2).  BAS treatment had no 
effect on hepatic long-chain acylcarnitine content in db/db mice (Figure 2A). In 
contrast, in skeletal muscle of db/db mice a strong reduction of long-chain 
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acylcarnitine content was observed which almost reached the level of untreated 
lean mice (Figure 2B). Specifically saturated long-chain acylcarnitine species of 
palmitic (C16:0) and stearic acid (C18:0) were affected (Fig. 2C).  Apparently, 
increased metabolic clearance of glucose by peripheral tissue is paralleled by 
changes in long-chain acylcarnitine content of muscle indicative of increased 




The leptin receptor deficient db/db mouse is a widely utilized mouse model of type 
2 diabetes as it displays several of the features of human type 2 diabetes at 12 
weeks of age 40. However, no characterization describing disturbances of in vivo 
hepatic glucose metabolism in this mouse model is available.  Here, we first show 
that leptin receptor deficiency results in a variety of alterations of in vivo hepatic 
glucose metabolism, the most prominent perturbations being the massively 
increased glucokinase flux and glucose cycling in db/db mice. Secondly, we tested 
whether the bile acid sequestrant Colesevelam (BAS) induces its reported blood 
glucose-lowering actions 23, 24 by specific alterations of in vivo hepatic glucose 
metabolism. Our results, however, demonstrate that BAS treatment increased 
metabolic clearance of glucose by peripheral tissue without affecting hepatic 
glucose production. Unexpectedly, we observed a three-fold induction of hepatic 
FGF21 gene expression and a decrease in skeletal muscle long-chain 
acylcarnitine content in treated db/db mice. We speculate this lowering in skeletal 
muscle long-chain acylcarnitines to be indicative of an improved skeletal muscle 
insulin sensitivity and glucose uptake.  Increased hepatic FGF21 gene expression 
might provide a novel role for FGF21 as modulator of peripheral glucose 
metabolism upon BAS.  
A major and novel observation of this study concerns the disturbances in 
in vivo hepatic glucose metabolism in db/db mice. Most strikingly, glucokinase flux 
was drastically increased in db/db mice compared to lean mice. Irrespective the 
dramatic increase of the HOMA index in db/db compared to lean mice, the 
metabolic clearance of glucose by the liver was essentially not affected. Moreover, 
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a similar ineffectiveness of insulin to modulate hepatic glucose metabolism was 
apparent from the data on de novo synthesis of glucose-6-phosphate: biosynthesis 
of glucose-6-phosphate was only slightly decreased (~20%) in db/db compared to 
lean mice. Moreover, fluxes through glucokinase and de novo glucose-6-
phosphate synthesis were insensitive towards changes in insulin concentration.  
Secondly, we studied whole body glucose metabolism. We found that the 
metabolic clearance rate of glucose by peripheral organs was a3-fold lower in 
db/db mice at blood glucose concentrations more than 3 times higher and plasma 
insulin concentrations a7.5 times higher than those of lean mice. It is of interest to 
compare the hepatic clearance of glucose by glucokinase with values obtained for 
peripheral glucose clearance in db/db mice.  In db/db mice, peripheral clearance of 
glucose was strongly reduced, whereas hepatic clearance of glucose by 
glucokinase was hardly affected compared to lean mice.  Furthermore, the rate of 
gluconeogenesis was hardly affected by the prevailing high glucose and insulin 
concentrations in db/db mice. Similar observations were made previously by us in 
ob/ob mice 25.  It clearly indicates that the increase in blood glucose concentration 
in both db/db and ob/ob mice is driven by an impaired uptake and metabolism of 
glucose in peripheral organs rather than by increased hepatic glucose production. 
Treatment with BAS has been shown to reduce plasma glucose levels in 
type 2 diabetic humans 41, 42 and rodents 23, 24.  We tested whether the glucose-
lowering actions of BAS in db/db mice were due to improvement of disturbed 
hepatic glucose metabolism. Plasma glucose concentration and de novo glucose-
6-phosphate synthesis decreased upon BAS treatment in db/db mice. Furthermore, 
insulin concentration tended to decrease, albeit not significantly, when compared 
to untreated db/db mice.  The glucokinase flux as well as the glucose cycling rate, 
however, remained invariantly high. Thus, changes in liver glucose metabolism do 
not mediate the glucose-lowering effect of BAS.  
Intriguingly, we also observed an increase in hepatic triglyceride content in 
BAS treated db/db mice, likely due to induction of lipogenesis 24, which is often 
associated with impaired insulin sensitivity and potentially may have counteracted 
a BAS induced improvement of hepatic insulin sensitivity. However, the 
relationship between insulin sensitivity and hepatic triglyceride levels is not 
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straightforward and fatty liver does not necessarily result in increased insulin 
resistance. For example, fatty liver induced by an LXR-agonist resulted in 
improved whole body insulin sensitivity, lowered blood glucose levels and 
increased metabolic glucose clearance in ob/ob mice while massively increasing 
hepatic triglyceride levels 43. Moreover, adding treatment of healthy mice with an 
LXR-agonist induced hepatic steatosis while not affecting blood glucose levels, 
whole-body insulin sensitivity nor metabolic clearance rate 43.  
BAS improved peripheral glucose clearance in db/db mice. Interestingly, 
long-chain acylcarnitine content in db/db skeletal muscle, specifically long-chain 
acylcarnitines of palmitic and stearic acid, decreased upon BAS treatment. 
Acylcarnitines are by-products of mitochondrial fatty acid oxidation and are formed 
upon acyl transfer from acyl-CoA to carnitine.  Composition and content of 
acylcarnitines can reflect both high and low rates of mitochondrial fatty acid 
oxidation. In inborn errors of mitochondrial fatty acid oxidation, in which fatty acid 
oxidation is impaired, acylcarnitines typically accumulate in tissues and plasma. 
Additionally, it has been shown that excessive fatty acid oxidation in diabetic mice 
results in inefficient oxidation. Increased content of long-chain acylcarnitines in 
skeletal muscle of db/db mice compared to lean mice could therefore be indicative 
of impaired oxidation of long-chain fatty acids in skeletal muscle mitochondria 39. 
This results in metabolical inflexibility, i.e., the switch to glucose oxidation cannot 
be made and insulin is unable to stimulate glucose oxidation 44. BAS treatment 
resulted in a clear-cut decrease of long-chain acylcarnitine content of skeletal 
muscle in db/db mice only, nearly to the level that was observed in lean mice. This 
is suggestive of a more efficient mitochondrial fatty acid oxidation. Concomitantly, 
a higher metabolic clearance rate of glucose was observed, indicative of an 
increased ability of the mitochondria to switch to carbohydrate oxidation and 
indicative of an improved insulin sensitivity.  
We also observed an increased ileal expression of glucagon-like-peptide-1 
upon BAS treatment (data not shown), which has been associated with an 
improved insulin sensitivity 45. Concomitantly, BAS induced a slight malabsorption 
of dietary fatty acids in lean and db/db mice (data not shown), indicative of an 
increased amount o fatty acids passing through the distal parts of the intestine 
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upon BAS treatment.  Fatty acids can induce GLP-1 by stimulation of L-cells in the 
ileum 46. Indeed, very recent work by Shang et al showed that 8 week dietary 
addition of BAS in insulin-resistant, diet-induced obese rats led to an increased 
Glp-1 release during an oral glucose tolerance test while plasma glucose and 
insulin concentrations decreased compared to untreated insulin-resistant diet-
induced obese rats 47.  
The question arises how BAS treatment, which interrupts the 
enterohepatic circulation of bile acids, can exert its beneficial effects in peripheral 
tissues. We observed that BAS induced a 2-fold increase in hepatic FGF21 gene 
expression in lean and 3-fold increase in db/db mice. Overexpression of FGF21 in 
livers of db/db or ob/ob mice or administration of recombinant FGF21 to db/db or 
ob/ob mice or to diabetic Zucker rats have been shown to have beneficial effects 
on insulin sensitivity and glucose clearance 36, 48, 49.  In this respect, FGF21 might 
provide a link to communicate changes in liver metabolism to peripheral tissues to 
allow for metabolic adaptation. How FGF21 exactly brings about these changes 
remains, however, elusive at the moment.  
In conclusion, this study is the first to characterize hepatic glucose fluxes 
in db/db mice.  Glucokinase flux and rates of hepatic glucose output were 
massively increased in these mice compared to lean mice. Additionally, db/db mice 
had lower metabolic clearance rates of glucose by peripheral tissues compared to 
lean mice. Decreased plasma glucose levels upon BAS treatment were mainly 
attributable to increased metabolic clearance of glucose by peripheral tissues: 
hepatic glucose output remained unaffected. Interestingly, skeletal muscle long-
chain acylcarnitine content was decreased in BAS-treated db/db mice. Increased 
hepatic FGF21 gene expression levels might play a crucial role in modulating 
peripheral glucose handling upon BAS-treatment. This hypothesis, however, 
requires further investigation. 
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Exercise enhances whole-body     
cholesterol turnover in mice 
M. Meissner, R. Havinga, R. Boverhof, I. Kema,  A. K. Groen, F. 
Kuipers 
Med Sci Sports Exerc. 2010, 42(8):1460-8 





Purpose Regular exercise reduces cardiovascular risk in humans by 
reducing cholesterol levels but underlying mechanisms have not been fully 
explored. Exercise might provoke changes in cholesterol and bile acid metabolism 
and thereby reduce cardiovascular risk. We examined whether voluntary wheel 
running in mice modulates cholesterol and bile acid metabolism.  
Methods Male mice (10 wk old) were randomly assigned to have access to 
a voluntary running wheel for 2 wks (RUN) or remained sedentary (SED). Running 
wheel activity was recorded daily.  In a first experiment, fecal sterol outputs, fecal 
bile acid profiles, plasma parameters and expression levels of genes involved in 
cholesterol and bile acid metabolism were determined. In a second experiment, 
bile flow, biliary bile acid profile and biliary secretion rates of cholesterol, 
phopsholipids and bile acids were determined.  
Results RUN ran an average of 10 km per day and displayed lower plasma 
cholesterol compared to SED (p=0.030). Fecal bile acid loss was induced by ~30% 
in running mice compared to SED (p=0.001). A ~30% increase in fecal cholesterol 
output in RUN (p=0.014) was consistent with changes in parameters of cholesterol 
absorption, like reduced plasma plant sterol / cholesterol ratio (p=0.044) and 
decreased jejunal expression of Npc1l1 (p=0.013). Supportive of an increased 
cholesterol synthesis to compensate for fecal sterol loss were increased hepatic 
mRNA levels of Hmgcr (p=0.006) and an increased plasma lathosterol/cholesterol 
ratio (p=0.001) in RUN.  
Conclusion  Voluntary wheel running increased cholesterol turnover in healthy 
mice due to an increased fecal bile acid excretion and a decreased intestinal 
cholesterol absorption. Enhanced cholesterol turnover may contribute to the 
established reduction of cardiovascular risk induced by regular exercise.  
 




Exercise is known as a preventative and therapeutic for cardiovascular diseases 1 
but exactly how exercise exerts its beneficial actions on cardiovascular risk is 
largely unknown.  One of the major hallmarks in exercise-induced risk reduction 
observed in human studies is an improvement in plasma lipid levels 2, 3. 
Specifically, high density lipoprotein levels increase with exercise and 
concomitantly total cholesterol, low-density lipoprotein cholesterol and triglycerides 
decrease 2, 3.  Yet, the mechanisms behind such exercise-induced improvements 
in plasma lipids have not been defined. An enhanced transport of peripheral 
cholesterol towards the liver for subsequent secretion as free cholesterol or bile 
acids into bile and eventual excretion into feces has been suggested 4, 5. In fact this 
pathway, known as the reverse cholesterol transport (RCT), constitutes the major 
elimination route for excess cholesterol from the body 6. HDL is considered to be 
the carrier of cholesterol in the RCT pathway. To date, the effects of exercise on 
this pathway are poorly understood 4, 5.  However, if exercise enhances RCT this 
should be reflected in an enhanced turnover of cholesterol and, possibly, 
modulations in bile acid metabolism. 
Excess cholesterol can be removed from the body either as such or after 
conversion into bile acids. The liver secretes free cholesterol into bile, which is 
eventually released into the intestine where it mixes with dietary cholesterol. 
Fractional absorption of cholesterol in humans shows a range between 30-70%. 
While in mice values of 30-50% are reported 7. Bile acids are synthesized from 
cholesterol exclusively in the liver and expelled into the intestinal lumen after 
ingestion of a meal. Bile acids are important molecules for the emulsification and 
reabsorption of fats in the intestine 8.  The majority of bile acids are reabsorbed 
from the terminal ileum, transported back to the liver for resecretion into bile 
(enterohepatic circulation). The fraction of bile acids that escapes reabsorption is 
lost in feces and constitutes an important part of cholesterol turnover, since fecal 
bile acid loss is compensated for by de novo synthesis from cholesterol to maintain 
the bile acid pool size 9, 10.  This means that pertubations provoking an increased 
fecal bile acid loss also provoke an increased hepatic de novo bile acid synthesis. 
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Indeed, past limited work indicates that exercise potentially modulates 
cholesterol and bile acid metabolism 11-13.  Early studies on female rats showed 
that six weeks of voluntary wheel running promoted an increased biliary bile acid, 
cholesterol and phospholipid secretion 12 and either increased or had no effect on 
bile flow 12, 13.  Moreover, a recent study in mice showed that 12 weeks of forced 
treadmill exercise prevents gallstone formation in gallstone-prone mice 11. 
Gallstone disease is characterized by an abnormally high biliary cholesterol-to-bile 
acid and phospholipid ratio 8.   
However, these limited data do not provide a clear understanding of the 
effects of exercise on bile acid and cholesterol turnover in rodents. Therefore the 
purpose of this study was to clarify whether exercise modulates cholesterol and 
bile acid turnover in mice. If exercise indeed has such actions, this would offer 
novel insight in mechanisms contributing to the beneficial effects of exercise on 
cardiovascular diseases.  
 
METHODS AND MATERIALS 
 
All experiments were approved by the Animal Care and Use Committee of the 
University of Groningen, The Netherlands.  The University of Groningen is 
accredited by AAALAC (Association for Assessment and Accreditation of 
Laboratory Animal Care) International and follows the Public Health Service Policy 
for the Care and Use of Laboratory Animals. Animal care was provided in 
accordance with the procedures outlined in the Guide for the Care and Use of 
Laboratory Animals (Guide for the Care and Use of Laboratory Animals. In: 
Council NR, ed. Washington (DC): National Academy Press 1996) and the study 
was in adherence to ACSM animal care standards.   
 
Animals and voluntary cage-wheel exercise  
Ten week old male C57BL/6 mice were purchased from Charles River 
Laboratories (L'Arbresle, France).  Upon arrival at the animal facility, mice were 
singly housed in a cage (47 x 26 x 14.5 cm3) in a temperature-controlled room with 
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a 12:12 light-dark cycle.  Throughout the study mice had access to standard 
commercial pelleted laboratory chow (RMH-B, Hope Farms bv Woerden, the 
Netherlands) and water ad libitum. At 11 weeks of age, mice were randomly 
selected to either voluntary cage wheel running (RUN) or to remain sedentary 
(SED).  The voluntary running wheel set-up utilized has previously been described 
14. Briefly, the cage of RUN mice was equipped with a hamster-sized metal cage 
wheel with a diameter of 11 cm which was fitted with a cycle computer containing a 
digital magnetic counter (Art NO.: K-13-TL SET-P3-NL, Xiron, Netherlands). Each 
morning total distances ran, total times ran, average and maximum daily speeds 
were recorded. Twice a week, mice were weighed and food intake was recorded. 
Exposing mice to a voluntary running wheel for 2 weeks has previously been 
shown to result in cardiac and skeletal muscle adaptations consistent with those of 
endurance exercise 14. Moreover, the voluntary cage wheel set-up provides an 
anti-stress intervention 15 compared to force exercise interventions which have 
been found to cause chronic stress-like changes in the hypothalamic–pituitary–
adrenal axis 16. 
 
Experimental procedures  
There were two primary experiments examining the effect of voluntary cage wheel 
running on cholesterol and bile acid metabolism: one on fecal, plasma, hepatic and 
intestinal parameters, and the other on biliary parameters.  The endpoint of both 
experiments was reached after 2 weeks of RUN or SED, at 13 weeks of age. 
 
Experiment 1: Determination of plasma, fecal, hepatic and intestinal 
parameters of cholesterol and bile acid metabolism  
In experiment 1, RUN (n=8) and SED (n=6) mice were sacrificed by heart puncture 
under isoflurane anesthesia from 06:30-08:30 h. Plasma was stored at -20°C until 
analysis. The liver was quickly removed, weighed and snap-frozen in liquid 
nitrogen. The small intestine was excised, flushed with ice cold (4°C) PBS, divided 
into three sections of equal lengths and subsequently snap-frozen in liquid 
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nitrogen. Both liver and intestine were stored at -80ºC for later biochemical 
analysis and RNA isolation.  
 
Plasma and liver lipid analysis  
Plasma was collected by centrifugation of blood samples obtained via heart 
puncture. Plasma total cholesterol, free cholesterol and triglyceride levels were 
measured by standard enzymatic methods using commercially available assay kits 
(Roche Diagnostics, Mannheim, Germany and DiaSys Diagnostic Systems, 
Holzheim, Germany). Hepatic lipids were determined after extraction according to 
Bligh and Dyer 17 using the same commercially available kits as for plasma lipids. 
We analyzed plasma plant sterols and lathosterol levels relative to plasma 
cholesterol levels as makers of intestinal cholesterol absorption (plant sterols) and 
cholesterol synthesis (lathosterol). The plasma plant sterol (campesterol + 
sitosterol) / cholesterol ratio is often utilized as a marker for intestinal cholesterol 
absorption as it correlates very well with rates of fractional intestinal cholesterol 
absorption 18. The plasma lathosterol / cholesterol ratio is a marker of cholesterol 
synthesis 18, because lathosterol is a precursor of the cholesterol biosynthetic 
pathway. Plasma plant sterol (campesterol and sitosterol) and lathosterol 
concentrations were determined by gas chromatography, as described by Windler 
et al.19. Pooled plasma samples from each group were used for lipoprotein 
separation by fast protein liquid chromatography on a Superose 6 column using 
Akta Purifier (GE Healthcare, Diegem, Belgium). 
 
 
Fecal Parameters  
Forty-eight-hour feces productions were collected before running wheel exposure 
and at 2 weeks of running wheel exposure. Feces were dried, weighed and 
homogenized to a powder. Aliquots of fecal powder were used for analysis of total 
bile acids by an enzymatic fluorimetric assay 20. Neutral sterols and bile acid 
profiles were determined according to Arca et al. 21 and Setchell et al. 22, 
respectively.  
 




Supplemental Table 1: Progression in Running Wheel Activity. Values are means ± SD for 
RUN (n=8) over the two week running wheel intervention 
  DAY 1 Day 7 Day 14 
Running Wheel 
Activity       
Average daily 
distance (km) 5.35 ±  1.7 7.88 ± 1,7 10.2 ± 2.2 
Maximum Speed 
(km×h-1) 2.83 ±  0.6 2.94 ± 0.23 3.1 ±  0.16 
Average speed 
(km×h-1) 0.87 ±  0.10 1.34 ±  0.14 1.78 ± 0.18 
Average daily time 
ran (h:min) 6:05 ±  1:32 5:54 ± 0:55 5:46 ± 0:52 
 
RNA isolation and PCR procedures  
Total RNA was isolated from liver and intestine using TRI-reagent (Sigma, St. 
Louis, MO) according to the manufacturers’ protocol. cDNA was produced as 
described by Plösch and coworkers 23. Real-time PCR was performed on a 
7900HT FAST real-time PCR system using FAST PCR master mix and MicroAmp 
FAST optical 96-well reaction plates (Applied Biosystems Europe, Nieuwekerk ad 
IJssel, The Netherlands). Primer and probe sequences have been deposited at the 
RTprimerDB 24. PCR results were normalized to β-actin. 
 
 
Experiment 2: Determination of biliary parameters of cholesterol and bile 
acid metabolism  
Another eight RUN and five SED mice underwent a gallbladder cannulation for 
collection of bile at 13 weeks of age 23. Briefly, mice were anaesthetized by 
intraperitoneal injection with Hypnorm ® (1 ml∙kg-1) and diazepam (10 mg∙kg-1). 
During the 30-min bile collection period, mice were placed in a humidified 
incubator to ensure maintenance of body temperature. Bile flow was determined 
gravimetrically, assuming a density of 1g∙ml-1 for bile. Bile was stored at -20°C until 
analysis. Total biliary bile acids were determined by an enzymatic fluorimetric 
assay 20.  Levels of biliary cholesterol and phospholipids were measured as 
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described by Kuipers et al. 25. Biliary bile acid composition was determined as 
described by Hulzebos et al. 26. 
 
Statistics   
Statistical analysis was assessed using the Mann-Whitney-U-Test (SPSS 12.0.1 
for Windows). All data are expressed as means r  SD. A P-value of <0.05 was 
accepted as statistically significant. 
 
Table 1. Biometrical parameters and running wheel data. Values are means ± SD at two 





Basal parameters upon two weeks of voluntary wheel exercise 
Exposing 11-week old chow fed C57BL/6 mice to a voluntary running wheel for two 
weeks did not affect body weight, liver weight, body weight / liver weight ratio nor 
intestinal length compared to sedentary mice (Table 1). Mice exposed to a running 
wheel averaged a daily distance of a10 km (Table 1) and were progressively 
running at a greater average speed and for a longer time and distance during the 2 
week running wheel exposure (Supplement Table 1).  
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Running mice consumed a30% more food than sedentary mice did (Table 1). 
Running mice had decreased total and free plasma cholesterol levels compared to 
sedentary controls (Table 2), but plasma lipoprotein profiles for cholesterol or 
triglycerides were not different between running and sedentary mice 
(Supplemental Figure 1). Hepatic total and free cholesterol store were not affected 
by the running intervention (Table 2).  It seems that there is a small, albeit not 
significant, effect of running in decreasing hepatic esterified cholesterol content 
coinciding with a decrease in hepatic mRNA expression levels of Acat2 
(Supplemental Figure 1), the major cholesterol esterifying enzyme. In addition, 
running mice displayed approximately 20% lower hepatic triglyceride content 
compared to sedentary controls (Table 2).  









































Voluntary wheel exercise increased fecal neutral sterol and bile acid output   
To determine whether 2 weeks of voluntary running wheel exercise alters 
cholesterol and bile acid metabolism in healthy chow-fed mice, we first assessed 
fecal parameters of cholesterol and bile acid metabolism. For this study, feces was  
Supplemental Figure 1. Plasma 
lipoprotein profiles showing distribution of 
cholesterol (A) and triglycerides (B) in 
pooled plasma of SED (n=6) and RUN 
(n=8). Lipoproteins in plasma pools were 
separated by fast protein liquid 
chromatography (FPLC) on a Superose 6 
column; and (C)  Hepatic mRNA 
expression levels of Acat2 in SED (n=6) 
and RUN (n=8). *p<0.05 vs. SED 




Table 2. Plasma and liver lipids. Values are means ± SD. at two weeks of running for SED 
(n=6) and RUN (n=8); *p<0.05 vs. SED, **p<0.01 vs. SED 
       
 
collected during the last 48 hrs of the intervention in running and control mice to 
determine the fecal neutral sterol and bile acid output, as well as the fecal bile acid 
profile.  We found that running mice had a  significantly increased fecal production, 
fecal neutral sterol and fecal bile output (all by a30%) compared to sedentary 
controls (Figures 1A-C), while no differences  in any of these parameters was 
observed between RUN and SED before the intervention (data not shown).. 
Secondly, as shown in Table 3A, running mice had an increased fecal 
deoxycholate output compared to control mice. Deoxycholate is a secondary bile 
acid species which is formed from cholate in the intestine.  The increasein fecal 
deoxycholate output in runners was paralleled by a non-significant decrease in 
fecal cholate output (p=0.053). Thus, the total cholate output, which is the sum of 
cholate and deoxycholate, remained unaltered (Table 3A). Since under steady 
state conditions fecal bile acid loss equals hepatic synthesis rate, these results 
imply that running wheel activity accelerates the conversion of cholesterol to bile 
acids in the liver. 
 
Voluntary running wheel exercise increases biliary bile acid secretion   
Observing this running-induced increase in fecal bile acid excretion, we next asked  




Figure 1. Fecal parameters for SED (n=6) and RUN (n=8) after two weeks of running: A. 
Daily feces production, B. Daily fecal bile acid output, C. Daily fecal neutral sterol output.  
*p<0.05 vs. SED, **p<.0.01 vs. SED, ***p<0.001 vs. SED 
 
whether this increased loss was reflected in changes in biliary parameters.  Thus, 
we subjected another set of mice of both groups to gallbladder cannulations for the 
collection of hepatic bile to examine the effect of voluntary running on bile flow, 
biliary bile acid, cholesterol and phospholipid secretion.  We found a trend for a 
higher bile flow in running mice (Figure 2A). Then, as shown in Figure 2B, running 
mice had an increased biliary total bile acid secretion (Figure 2B) and also an 
increased absolute biliary bile acid concentration (27.78 ± 2.31 and 33.40 ± 4.52 
mmol∙L-1, control and running mice respectively, p=0.042). However, secretion 
rates of biliary cholesterol and phospholipids were not affected by 2 weeks of 
voluntary wheel running (Figure 
2C and D).  Next, running increased the biliary total cholate-derived bile acid 
output because of an increase in biliary cholate output while biliary deoxycholate 
remained unchanged (Table 3B). This increase in total cholates was reflected in an 
increased biliary cholate / chenodeoxycholate ratio upon running. Thus, the 
running-induced increase in fecal bile acid loss was paralleled by changes in biliary 
bile acid parameters. 
We found that the running-induced fecal bile acid loss coincided with changes of 
some genes, but not others, implicated in bile acid transport in liver and intestine. 
For example, no changes were observed in ileal mRNA expression levels of Asbt 
(Slc10a2), which functions in active absorption of bile acids from the intestinal 
lumen 
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into the ileal enterocytes (Figure 3A) nor Fgf15 (Figure 3B), which is induced by 
bile acids in the ileum and represses bile acid synthesis via signaling mechanisms. 
Running mice displayed lower intestinal mRNA expressions of Ostα (Figure 3C) 
and Ostβ (Figure 3D), which act together in basolateral efflux of bile acids from the 
ileum into the portal blood. Moreover, the hepatic mRNA expression levels of Ntcp 
(Slc10a1) (Figure 3E), a basolateral bile acid transporter acting to clear bile acids 
from the portal blood into the hepatocyte, was also decreased in running mice. On 










































































Figure 2.  Biliary Parameters for SED (n=5) and RUN (n=8) after 2 weeks of running: A. Bile 
flow, B. Biliary bile acid output. C.Biliary cholesterol output. D. Biliary phospholipid output; 
*p<0.05 vs. SED 
 
acting to transport bile acids from the hepatocyte into the bile, were not affected 
through the running intervention. 
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Voluntary running wheel exercise decreases cholesterol absorption and 
increases cholesterol synthesis  
An increased neutral sterol loss is suggestive of a decreased reabsorption and an 
increased synthesis to compromise the consequences of the loss. We therefore 
questioned whether the increased fecal bile acid and neutral sterol loss was 
reflected by changes in markers of cholesterol absorption and synthesis. Indeed, 
the jejunal mRNA expression of Npc1l1, a protein required for intestinal cholesterol 
absorption 27, was decreased in running mice (Figure  4A), while the jejunal mRNA 
expressions of the ATP-binding cassette transporters Abcg5 and Abcg8, two 
proteins implicated in control of cholesterol absorption 28 29 were unchanged 
(Figure 4B and C). Similarly to the reduced Npc1l1 mRNA expression, the plasma 
total plant sterol / cholesterol ratio, a marker of cholesterol absorption, was  
 
Table 3. Fecal and biliary bile acid composition as percentage of total bile acids. Values are 
means ± SD at two weeks of running for SED (n=5) and RUN (n=8); CDCA = 
chenodeoxycholate, *p<0.05 vs. SED 
               
Percentages of Total Bile Acids SED RUN 
(A) Fecal bile acid profile     
Cholate 31.1 ± 16.8 14.2 ± 2.9 
Deoxycholate 29.4 ± 6.6 42.7 ± 5.1* 
   Total Cholate-derived bile acids 60.5 ± 10.3 56.9 ± 4.7 
Chenodeoxycholate 1.6 ± 0.9 0.7 ± 0.6 
ß-muricholic acid 6.3 ± 1.3 5.6± 1.6 
w-muricholic acid 27.7 ± 9.6 32.3 ± 3.8 
 a-muricholic acid 3.9 ± 0.5 4.6 ± 0.4* 
   Total CDCA-derived bile acids 39.5 ± 10.3 43.2 ± 4.7 
(B) Biliary bile acid profile     
Cholate 51.3 ± 2.3 57.6 ± 5.3* 
Deoxycholate 4.1 ± 1.0 2.9 ± 0.8 
   Total Cholate-derived bile acids 55.4 ± 2.7 60.5 ± 5.7* 
Chenodeoxycholate 2.6 ± 0.6 1.9 ± 0.8 
ß-muricholic acid 23.3 ± 4.2 22.1 ± 4.6 
w-muricholic acid 12.9 ± 2.6 11.1 ± 2.4 
 a-muricholic acid 5.8 ± 0.6 4.5 ± 0.5 
   Total CDCA-derived bile acids 44.6 ± 2.7 39.5 ± 5.7 
Cholates / Chenodeoxycholates 1.3 ± 0.1 1.6 ± 0.4* 
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decreased in running mice (Figure 4E), thus indicating a decreased cholesterol 
absorption in runners.  In addition, we also observed changes in markers of 
cholesterol synthesis indicative of an increased cholesterol synthesis upon 
running. This is shown first in the running- induced increase in hepatic mRNA 
expression levels of Hmgcr, a gene that encodes the rate-controlling enzyme in 
cholesterol synthesis (Figure 5A), and second in the a 60% increase in the plasma 
lathosterol / cholesterol ratio in running mice (Figure  5B), supportive of an 





This study was designed to assess whether voluntary wheel running modulates 
cholesterol and bile acid metabolism in healthy mice.  The experiments presented 
here show that running modulates a variety of parameters of cholesterol and bile 
acid metabolism in mice and that these modulations result in an increased 
cholesterol turnover due to a decreased intestinal cholesterol and bile acid 
absorption. This has been demonstrated in three ways.  First, the finding that 
running mice increased their fecal neutral sterol and bile acid output is consistent 
with a variety of parameters reflective of a decreased cholesterol absorption, the 
decreased plasma total plant  
sterol / cholesterol ratio (Figure  4E), which correlates with the rate of cholesterol 
absorption 18 and the decreased jejunal expression of Npc1l1 (Figure  4A), which is 
a protein required for intestinal cholesterol absorption.  Second, the present data 
indicate that the running-induced fecal neutral sterol loss translated into an 
increased cholesterol synthesis (Figure 5A and B), representing a physiological 
response to an enhanced cholesterol loss. Third, the increase in fecal bile acid 
output upon running demonstrates an increased de novo bile acid synthesis, which 
contributes to cholesterol turnover. 
Our observations of a running-induced increase in fecal production 30, 
fecal neutral sterol and bile acid output 31 on one hand confirm some of the limited 
previous work on humans 30-32 but contradict others showing that four months of 
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training decreased the total fecal neutral sterols excretion in men 32, and that the 
total fecal bile acid secretion in male distance runners was lower due to an 
increased fecal production 30. The relevance of these findings is, however, difficult 
to evaluate because all previous studies were restricted to middle aged male long 
distance runners 30-32, were not controlled for dietary intake, age 30-32 or 
 
 
       

















































































Figure 3. Quantitative RT-qPCR of RNA from intestinal (A through D) and hepatic (E and F) 
bile acid transporters and signaling molecules in SED (n=6) and RUN (n=8) after two weeks 
of running. A. Ileal apical sodium dependent bile acid transporter, Asbt / Slc10a2; B. Ileal 
fibroblast growth factor 15, Fgf15; C and D. Ileal organic solute transporter alpha, Ostα (C) 
and beta, Ostβ (D); (E) Hepatic sodium-dependent taurocholic cotransporting polypeptide, 
Ntcp / Slc10a1 and (F) Hepatic bile acid export pump, Bsep / Abcb11; *P<0.05 vs. SED 
        








































































endurance-training 30, 31, while the present investigation concerns a controlled 
study of previously sedentary but healthy mice having at libitum but monitored 
access to standard laboratory chow and were exposed to a voluntary running 
wheel for 2 weeks. 
In our study the loss of bile acids is specific for deoxycholate, a secondary 
bile acid (Table 3 A). Deoxycholate is formed by conversion of cholate, a primary 
bile acid, by intestinal flora 33.  This increase in fecal deoxycholate is probably due 
to a decreased bile acid reabsorption in the terminal ileum, thus allowing increased 
Figure 4. Parameters of cholesterol 
absorption in SED (n=6) and RUN (n=8) 
mice after two weeks of running. Jejunal 
mRNA expression levels of: A. Niemann-
Pick disease, type C1, gene like 1, 
Npc1l1; B. ATP-binding cassette 
transporter g5, Abcg5; C. ATP-binding 
cassette transporter g8, ABcg8;  and D. 
Plasma Total Plant Sterol / Cholesterol 
Ratio; *p<0.05 vs. SED 
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conversion by intestinal microbiota but also possibly by running-induced alterations 
in intestinal microbiota leading to an increased production of deoxycholate. 
Intriguingly, it has recently been shown that male rats exposed to a voluntary 
wheel running wheel for 5 weeks displayed markedly changed composition of 
cecal microbiota 34.  However, how exactly voluntary wheel running acts in 
provoking the specific increase in deoxycholate excretion in mice and what role the 
role of intestinal microbiota is herein was not the scope of this study but deserves 
future investigation. 
 In addition to intestine-modulated changes in fecal bile acid composition, 
voluntary wheel running affects the intestine further by decreasing jejunal mRNA 
expression of Npc1l1, a protein critical for intestinal cholesterol absorption 27.  
Similarly, we found a running-induced decrease in jejunal acetyl-CoA:cholesterol 
acetyltransferase 2 (Acat2) mRNA expression levels (Figure  4D).  After 
cholesterol is taken up via Npc1l1 from the intestinal lumen to the enterocyte, it is 
esterified by Acat2 for proper chylomicron formation.  The effect of voluntary 
running on decreasing intestinal cholesterol absorption was specific for the uptake 
transporter Npc1l1, as we show here that running did not affect mRNA levels of the 
cholesterol efflux transporters Abcg5 and Abcg8 in the intestine. Abcg 5 and 
Abcg8 function as a heterodimer and are responsible for sterol efflux from the 
enterocytes into the lumen, whereas Npc1l1 is involved in sterol entry from the 
lumen into the enterocyte 35. In support of a decreased cholesterol absorption 
despite no effects on Abcg5/8 expression, a previous study showed that reductions 
in cholesterol absorption correlated with decreased Npc1l1 mRNA expression 
while Abcg5/8 mRNA expression remained unchanged 36.   
Next, our study indicates in two ways that the exercise-induced 
malabsorption of sterols is compensated by an increased hepatic cholesterol 
synthesis. First, running mice had an increased hepatic mRNA expression level of 
Hmgcr, the rate-limiting enzyme of cholesterol synthesis. And second, running 
mice had an increased plasma lathosterol / cholesterol ratio.  Lathosterol is a 
precursor of cholesterol synthesis, and an increased lathosterol / cholesterol ratio 
is indicative of an increased cholesterol synthesis 18.  However, our present results 
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on young, healthy mice are in discrepancy with previous reports 37, 38. The 
inconsistent and limited information that is available regarding the effects of 
exercise on cholesterol synthesis and absorption is largely restricted to plasma 
markers of cholesterol synthesis and absorption 37, 38. These few previous 

































Figure 5. Parameters of cholesterol metabolism in SED (n=6) and RUN (n=8) mice after two 
weeks of running. A. Hepatic mRNA expression of 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase, Hmgcr as a marker of cholesterol synthesis B. Plasma lathosterol / cholesterol 
ratio as a marker of cholesterol; *p<0.05 vs. SED, **p<.0.01 vs. SED 
 
lathosterol / cholesterol 38, or only increases in plasma plant sterols / cholesterol 37 
or no effect on markers of cholesterol synthesis or absorption at all 38.  These 
discrepancies in markers of cholesterol absorption and synthesis between our 
study and the previous works might be explained by differences in populations 
studied and exercise utilized. For example, the previous works are limited to 
humans with lipoprotein abnormalities exercising three times a week for eight 
weeks or six months 37, 38 while we utilized healthy mice that exercised every day 
for 2 weeks.  
Although our results indicate that voluntary wheel running increases bile acid 
synthesis, a surprising finding was that expression of the main genes involved in 
bile acid synthesis, Cyp7a1 and Cyp27a1 (Supplemental Fig 2 A and B), were not 
affected by the intervention. Genes involved in bile acid synthesis follow a 
circadian rhythm 39 . For this reason, we asked whether the time for termination 
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and tissue collection originally chosen did not allow for an observation of 
differences in gene expression levels. However, we did not observe the anticipated 
running-induced increase in genes involved in bile acid synthesis when terminating 
another cohort of running mice and controls between 18:30 and 20:00 hours (12 
hours later than all other mice described in this study) (Supplemental Fig. 2 C and 
D). Thus, within this study the increase in bile acid synthesis upon voluntary wheel 
running as demonstrated by fecal bile acid loss did not result in an upregulation of 
mRNA expression levels of key genes involved in bile acid synthesis, specifically 
Cyp7a1. Possibly a small decrease in reabsorbed intestinal bile acids is sufficient 
to repress the inhibitory signaling on Cyp7a1 without affecting mRNA expression 
levels in the voluntary wheel running intervention. In support of this, previous 
investigations on bile acid synthesis have shown that modulations of bile acid 


























































Supplemental Figure 2.  Quantitative RT-qPCR of liver RNA from SED (n=6) and RUN 
(n=8) mice terminated between 06:30-08:00 h (A and B) and 18:30-20:00 h. (C and D) for  
Cholesterol-7a-hydroxylase; Cyp7a1 (A and C) and  Sterol-27a-hydroxylase; Cyp27a1 (B 
and D) 




In conclusion, the results presented here collectively show that voluntary wheel 
running in healthy chow-fed mice enhanced cholesterol turnover. The running-
induced enhanced cholesterol turnover was reflected in a decreased intestinal 
cholesterol and bile acid absorption leading to a subsequent increase in 
cholesterol synthesis and alterations in bile acid metabolism. Herein, this work 
offers novel findings on the mechanisms contributing to the beneficial effects of 
exercise on cardiovascular diseases. 
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       CHAPTER 5 
Voluntary exercise increases cholesterol 
efflux but not macrophage reverse 
cholesterol transport in vivo in mice 
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Physical exercise beneficially impacts on the plasma lipoprotein profile as well as 
on the incidence of cardiovascular events and is therefore recommended in 
primary and secondary prevention strategies against atherosclerotic cardiovascular 
disease. However, the underlying mechanisms of the protective effect of exercise 
remain largely unknown. Therefore, the present study tested the hypothesis that 
voluntary exercise in mice impacts on cholesterol efflux and in vivo reverse 
cholesterol transport (RCT). After two weeks of voluntary wheel running (average 
10.1 ± 1.4 km/day) plasma triglycerides were lower (p<0.05), while otherwise lipid 
and lipoprotein levels did not change. Macrophage cholesterol efflux towards 
plasma was significantly increased in running (n=8) compared to sedentary (n=6) 
mice (14.93 ± 1.40 vs. 12.33 ± 2.60%, p<0.05). In addition, fecal excretion of bile 
acids (3.86 ± 0.50 vs. 2.90 ± 0.51 nmol/d, p=0.001) and neutral sterols (2.75 ± 0.43 
vs. 1.94 ± 0.22 nmol/d, p<0.01) was significantly higher in running mice. However, 
RCT from macrophages to feces remained essentially unchanged in running mice 
compared with sedentary controls (bile acids: 3.2 ± 1.0 vs. 2.9 ± 1.1 % of injected 
dose, n.s.; neutral sterols: 1.4 ± 0.7 vs. 1.1 ± 0.5 % injected dose, n.s.). Judged by 
the plasma lathosterol to cholesterol ratio, endogenous cholesterol synthesis was 
increased in exercising mice (0.15 ± 0.03 vs. 0.11 ± 0.02, p<0.05), while the 
hepatic mRNA expression of key transporters for biliary cholesterol (Abcg5/g8, Sr-
bI) as well as bile acid (Abcb11) and phospholipd (Abcb4) excretion did not change. 
These data indicate that the beneficial effects of exercise on cardiovascular health 
include increased cholesterol efflux, but do not extend to other components of RCT. 
The increased fecal cholesterol excretion observed in running mice is likely 
explained by higher endogenous cholesterol synthesis, however, it does not reflect 
increased RCT in the face of unchanged expression of key transporters for biliary 
sterol secretion. 
 




Complications of atherosclerotic cardiovascular disease (CVD) represent a major 
cause of morbidity and mortality in developed societies 1. Physical exercise is 
associated with a reduced risk for coronary events and is therefore recommended 
for primary as well as secondary prevention strategies 2, 3. As one potential 
beneficial effect physical exercise has been shown to improve the plasma 
lipoprotein profile towards a less atherogenic phenotype 4, 5. In addition, exercise in 
humans increases the capacity of plasma to promote cholesterol efflux from RAW-
264.7 mouse macrophages in vitro6. However, the impact of exercise on in vivo 
macrophage-to-feces reverse cholesterol transport (RCT) has not been addressed. 
Therefore, the present study assessed the impact of voluntary exercise in mice on 
cholesterol efflux and in vivo RCT. 
 
MATERIALS AND METHODS 
 
Animals  
Male C57BL/6 mice from Charles River (L'Arbresle, France) were kept in rooms 
with alternating 12-hour periods of light (from 7:00 a.m. to 7:00 p.m.) and dark (from 
7:00 p.m. to 7:00 a.m.), with ad libitum access to water and mouse chow diet (Arie 
Blok, Woerden, The Netherlands). Animal experiments were performed in 
accordance with national laws and were approved by the responsible ethics 
committee of the University of Groningen. 
 
Voluntary cage wheel running experiments  
Twelve week old mice were individually housed in cages either equipped with an 
11 cm steel running wheel continuously present in the cage (running group, n=8) or 
not (sedentary control group, n=6) 7. Distance covered and time of running were 
recorded daily during the two week experimental period with a digital cycling 







Cholesterol efflux and in vivo RCT  
Thioglycollate-elicited mouse peritoneal macrophages were harvested and cultured 
essentially as described 8. Macrophages were loaded for 24h with 50 μg/ml 
acetylated LDL and 3 μCi/ml 3H-cholesterol (Perkin Elmer, Boston, MA, USA) and 
equilibrated for 18h in RPMI 1640 medium containing 1% penicillin/streptomycin 
and 2% bovine serum albumin (Sigma, St. Louis, MO, USA). For in vitro 
cholesterol efflux experiments, cells were incubated for 24h with 1% of respective 
plasma samples (performed in triplicates). Efflux was determined as the 
percentage of label in the supernatant related to the total amount of label within 
medium and cells 9. For in vivo RCT two million labeled macrophages were 
injected intraperitoneally, blood samples were taken at 6, 24 and 48h, feces 
collected for 48h, and after 48h livers were harvested (sacrifice by heart puncture 
under isoflurane anesthesia) and stored at -80°C until further analysis as 
previously published 9. Plasma counts were assessed directly by liquid scintillation 
counting (Packard 1600CA Tri-Carb, Packard, Meriden, CT, USA). Counts within 
liver were determined following solubilization of the tissue (Solvable, Packard, 
Meriden, CT, USA) exactly as reported 10. Fecal samples were dried, weighed and 
thoroughly ground. Aliquots were separated into bile acid and neutral sterol 
fractions as previously published 11. Counts recovered from respective aliquots 
were related to the total amount of feces produced over 48h. All obtained counts 
were expressed relative to the administered tracer dose. 
 
Plasma lipid and lipoprotein analysis  
Plasma total cholesterol and triglycerides were measured enzymatically (Wako 
Pure Chemical Industries, Neuss, Germany). To determine plasma HDL 
cholesterol levels, apoB-containing lipoproteins were precipitated using 0.36% 
phosphotungstic acid (Sigma) and cholesterol content in the supernatant was 
determined as described above. Pooled plasma samples from mice of the same 
experimental group were subjected to fast protein liquid chromatography (FPLC) 
gel filtration using a Superose 6 column (GE Healthcare, Uppsala, Sweden) as 
described 11. Sample separation took place at a flow of 0.5 ml/minand were 
collected in 500 μl fractions. Individual fractions were assayed for cholesterol 
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concentrations as described above. Plasma lathosterol levels relative to plasma 
cholesterol levels were measured by gas chromatography as described 12. 
 
Liver lipid analysis  
Liver lipids were extracted following the general procedure of Bligh and Dyer and 
were determined enzymatically using commercially available reagents (Wako Pure 
Chemical Industries, Neuss, Germany) 13. 
 
 
           
 
Analysis of gene expression by real-time quantitative PCR  
Total RNA from mouse livers was isolated using Tri-Reagent (Sigma), and real-
time quantitative PCR was carried out on an ABI-Prism 7700 (Applied Biosystems, 
Foster City, CA, USA) sequence detector with the default settings 14. PCR primers 
and fluorogenic probes were designed with the Primer Express Software (Applied 
Biosystems). mRNA expression levels were calculated relative to the average of 
the housekeeping gene cyclophilin and further normalized to the relative 
expression levels of the respective controls. 
Figure 1.  FPLC cholesterol 
profiles in sedentary (SED) and 
exercising mice (RUN). Pooled 
plasma samples were subjected to 
gel filtration using a superose 6 
column and cholesterol levels 
within each fraction were 
determined as described in 





Statistical analysis  
Statistical analysis was carried out using the Statistical Package for the Social 
Sciences (SPSS, Inc., Chicago, IL, USA). Values are expressed as means r SD. 
Student´s t test was used to assess statistical differences between groups. 





Voluntary exercise decreases hepatic cholesterol content, while plasma 
cholesterol levels remain unchanged  
Exercising mice ran almost exclusively during the dark cycle, on average 356±52 
min/d thereby covering a distance of 10.2±2.2 km (average speed: 1.78±0.18 
km/h). Plasma triglycerides were lower (p<0.05), while phospholipids, total, non-
HDL and HDL 
 
Table 1. Plasma and liver lipids. Values are means r SD in sedentary (SED n=6) and mice 
exposed to a voluntary wheel (RUN, n=7) at 2 weeks of voluntary wheel running exercise. * 
p<0.05 vs. sedentary mice 
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cholesterol (Table 1) and apoA-I (Western blot, data not shown) remained 
unchanged in response to exercise. FPLC analysis revealed a small decrease in 
the HDL and VLDL/LDL cholesterol peaks of running mice (Figure 1). Running 
increased liver weight by 12% (p<0.01, Table 1), while hepatic cholesterol and 
triglyceride contents were decreased by 14% (p<0.05) and 42% (p<0.001), 
respectively. 
 
Cholesterol efflux from macrophage foam cells towards plasma of running 
mice is increased  
Although plasma total cholesterol levels did not change and HDL cholesterol levels  
tended to be lower in running mice, in vitro cholesterol efflux towards plasma of the 
running mice was significantly increased (p<0.001, Figure 2). This effect was 
consistent independent of the blood sampling time from these mice, either directly 
after (a.m.) or before (p.m.) the running period.  
 
                                            
Figure 2: In vitro cholesterol efflux from macrophage foam cells towards plasma from 
sedentary (SED) and exercising mice (RUN). Efflux experiments were performed using 
primary mouse peritoneal macrophages and 1% plasma from the respective mice as 
detailed in materials and methods. Running wheels were continuously present in the cage, 
however, running activity occurred almost exclusively at night during the dark cycle. In order 
to determine, if changes in cholesterol efflux might be short-term effects occuring directly 
after the running period, plasma from mice bled in the morning immediately after running 
(AM) and bled directly before the dark cycle after rest during the day (PM) was compared 
separately. Data are given as means ± SD; n=6 each for SED AM and PM; n=9 for RUN 





Macrophage-to-feces RCT is unchanged in exercising mice  
Next, in vivo RCT experiments were performed. 3H-cholesterol originating from 
macrophages was unchanged in plasma comparing running with sedentary mice 
as were counts within liver (Figure 3). Daily feces production (871±97 vs. 616±54 
mg/d, p<0.001) and mass fecal excretion of bile acids (3.86±0.50 vs. 2.90±0.51 
nmol/d, 
 
Table 2. Hepatic gene expression levels. mRNA expression levels were determined by real-
time quantitative PCR in livers of C57BL/6 mice in sedentary (SED, n=6) and mice exposed 
to a voluntary running wheel (RUN, n=7)  after 2 weeks of voluntary wheel running exercise 
compared. Results are normalized to the expression of the housekeeping gene cyclophilin 
and are expressed relative to the respective controls. Data are given as means ± SD. 
                       
 
p=0.001) and neutral sterols (2.70±0.25 vs. 1.90±0.39 nmol/d, p<0.01) were 
increased in the running group. However, fecal excretion of 3H-cholesterol tracer 
originating from macrophages, reflecting completed RCT, remained unchanged 
both within neutral sterols and bile acids (Figure 3). In support of these 
physiological data, also the mRNA expression of several transporters critical for 
the biliary secretion of cholesterol (Abcg5/g8, Sr-bI), bile acids (Abcb11) and 
phospholipids (Abcb4) remained unchanged (Table 2). The plasma 
lathosterol/cholesterol ratio as a measure of endogenous cholesterol synthesis 
was significantly higher in the running mice (Figure 4) indicating that the increased 
amount of fecal sterols secreted in this group is rather originating from increased 




The results of this study demonstrate that voluntary exercise in mice increases the 
efflux capacity of plasma despite a tendency towards decreased plasma HDL 
cholesterol levels, but does not alter macrophage-to-feces RCT. To the best of our  
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Figure 3: In vivo reverse cholesterol transport in sedentary (SED) and exercising (RUN) 
mice. At the end of the 2-week experimental period exercising mice (n=8) and sedentary 
controls (n=6) were injected intraperitoneally with 3H-cholesterol-labeled and acLDL-loaded 
primary mouse peritoneal macrophages and tracer appearance was followed for 48h as 
detailed in materials and methods. (A) Time course of tracer appearance in plasma, (B) 
tracer recovery within liver at the 48h time point, (C) tracer level within fecal bile acids (BA) 
after 48h, (D) tracer recovery within fecal neutral sterols (NS) after 48h. Data are expressed 
as percentage of the injected tracer dose and are given as means ± SD.  
 
 
knowledge this is the first study investigating a potential impact of exercise on in 
vivo RCT. While the beneficial effects of exercise on cardiovascular health have 
long been noted and exercise has been implemented in the recommendations for 
primary as well as secondary prevention strategies 3, the precise underlying 
mechanism for exercise decreasing CVD risk has not been fully elucidated thus far. 
It has been noted that aerobic capacity training decreases markers of inflammation 
and oxidative stress as well as blood pressure levels over time 3, 15, 16, while acute 
endurance exercise such as marathon running is associated with increased 
oxidative stress and a pro-inflammatory response 17, 18. As a further beneficial 
effect of exercise in humans increased plasma HDL cholesterol levels and an 




efflux from macrophage foam cells in vitro has been noted 6. These results have 
been related to an increased plasma level of preβ-HDL particles in  
 
                               
Figure 4: Effect of two week voluntary wheel running on the plasma lathosterol / cholesterol 
ratio as marker of endogenous cholesterol synthesis in exercising mice (RUN, n=8) and 
sedentary controls (SED, n=6). Plasma cholesterol and lathosterol levels were determined 
by gas chromatography as detailed in materials and methods. Data are given as means ± 
SD 
 
trained individuals 19, 20. Our study confirmed the efflux data in a mouse model of 
voluntary endurance exercise, while in contrast to the human situation plasma HDL 
cholesterol levels rather had a tendency to be lower in exercising mice. The 
increase in cholesterol efflux in vitro was not reflected by altered plasma counts in 
the in vivo RCT experiment, likely since these represent the net balance between 
efflux and removal from the plasma compartment. Interestingly, feces production 
was increased in exercising mice, which also mirrors the human situation 21. In 
addition, fecal mass secretion of bile acids and neutral sterols was significantly 
elevated in response to exercise, which in our interpretation reflects increased 
endogenous hepatic cholesterol synthesis. In humans one study reported a non-
significant 63% increase in endogenous cholesterol synthesis using the deuterium 
incorporation method 22, while another study detected no difference in plasma 
lathosterol levels in response to exercise training 23. Since RCT in humans differs 
in several aspects from mice (e.g. by the expression of CETP), studies on the 
impact of exercise on RCT in humans will be interesting to perform, once an 
integrated experimental system for these types of studies becomes available.  
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   CHAPTER 6  
Voluntary wheel running decreases 
atherosclerosis development and 
increases sterol excretion in 
hypercholesterolemic mice  
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ABSTRACT     
 
Objective: Regular physical activity decreases the risk for atherosclerosis but 
underlying mechanisms are not fully understood. We questioned whether 
voluntary wheel running provokes specific modulations in cholesterol turnover 
that translate into a decreased atherosclerotic burden in hypercholesterolemic 
mice. 
Methods: Male LDLR-deficient mice (8 wk old) had either access to a voluntary 
running wheel for 12 weeks (RUN) or remained sedentary (CONTROL). Both 
groups were fed a western-type/high cholesterol diet. Running activity and food 
intake were recorded.  At 12 weeks of intervention, feces, bile and plasma were 
collected to determine fecal, biliary and plasma parameters of cholesterol 
metabolism and plasma cytokines. Atherosclerotic lesion size was determined 
in the aortic root. 
Results:  RUN weighed less (~13%) while food consumption was increased by 
17% (p=0.004). Plasma cholesterol levels were decreased by 12% (p=0.035) 
and plasma levels of pro-atherogenic lipoproteins decreased in RUN compared 
to CONTROL. Running modulated cholesterol catabolism by enhancing 
cholesterol turnover: RUN displayed an increased biliary bile acid secretion 
(68%, p=0.007) and increased fecal bile acid (93%, p=0.009) and neutral 
sterols (33%, p=0.002) outputs compared to CONTROL indicating that reverse 
cholesterol transport was increased in RUN.  Importantly, aortic lesion size was 
decreased by 43.6% in RUN (p=0.033). 
Conclusion: Voluntary wheel running reduces atherosclerotic burden in 
hypercholesterolemic mice.  An increased cholesterol turnover, specifically its 
conversion into bile acids, may underlie the beneficial effect of voluntary 










Atherosclerosis is a complex vascular disease, which is characterized by major 
abnormalities in systemic factors, such as circulating lipids and lipoproteins, 
and concomitant inflammation of the vascular wall. 
It has long been known that exercise is a deterrent of atherosclerosis. 
Numerous clinical and experimental studies report on the beneficial effects of 
physical activity on atherosclerosis1-7 and various effects of physical activity on 
different processes involved in the pathogenesis and progression of 
atherosclerosis have been reported.  For example, it has been shown that 
physical activity improves the antioxidant system4, 6, plaque composition as well 
as plaque stability3, 7 and favorably modulates the inflammatory response 1. 
However, despite these recent efforts it remains unclear how exactly physical 
activity decreases the atherosclerotic process.  We hypothesize that the 
enterohepatic system, which plays a critical role in several aspects of 
cholesterol metabolism, may be of great relevance herein.  
Increasing cholesterol excretion into feces as neutral sterols or bile 
acids represents an efficient strategy in the amelioration of atherosclerosis, as it 
improves the pro-atherogenic state by modulating lipid content in plasma 8, 9. 
The liver secretes free cholesterol into bile, which is released into the intestine 
upon ingestion of a meal.  In the small intestine, biliary cholesterol mixes with 
dietary cholesterol and is partially reabsorbed. The remainder is lost in the 
feces within the neutral sterol fraction.  Bile acids are synthesized from 
cholesterol exclusively in the liver and enter the intestinal lumen after a meal. 
Bile acids are important for the emulsification and absorption of dietary fats in 
the intestine 10.  About 95% of the bile acids are reabsorbed from the terminal 
ileum, transported back to the liver for re-secretion into bile (enterohepatic 
circulation). The fraction of bile acids that escapes reabsorption is lost in feces 
and constitutes an important part of cholesterol turnover, since fecal bile acid 
loss is compensated for by de novo synthesis from cholesterol to maintain the 
bile acid pool size11.  Under steady state conditions, fecal bile acid loss equals 
hepatic de novo bile acid synthesis. 
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We have recently shown that exposing healthy chow-fed mice to a 
voluntary running wheel for two weeks enhanced fecal neutral sterol and bile 
acid excretion with specific changes in biliary, plasma and intestinal parameters 
contributing to an increased cholesterol turnover upon running 12. To our 
knowledge, no previous studies have examined the effects of exercise on 
cholesterol and bile acid metabolism in a hypercholesterolemic mouse model. 
Thus, the purpose of this study was to investigate whether the recently 
observed effects of voluntary running wheel exercise on whole body cholesterol 
turnover in healthy chow-fed mice 12 extend to the hypercholesterolemic LDLR-
deficient mouse model.  We hypothesized that voluntary wheel running 
beneficially modulates cholesterol and bile acid metabolism in 




MATERIALS AND METHODS 
 
All experiments were approved by the Animal Care and Use Committee of the 
University of Groningen, The Netherlands. The University of Groningen is 
accredited by AAALAC (Association for Assessment and Accreditation of 
Laboratory Animal Care) International and follows the Public Health Service 
Policy for the Care and Use of Laboratory Animals. Animal care was provided 
in accordance with the procedures outlined in the Guide for the Care and Use 
of Laboratory Animals. 
 
Animals and voluntary cage-wheel exercise 
Sixteen 5-week-old male LDLR deficient (B6.129S7-LDLRtm1Her/J) mice were 
purchased from Jackson Laboratories (The Jackson Laboratory, Bar Harbor, 
ME, USA). Upon arrival, mice were singly housed in a cage (47 x 26 x 14.5 cm) 
in a temperature-controlled room with a 12:12h light-dark cycle and had access 
to standard commercial pelleted laboratory chow (RMH-B, ABDiets, Woerden, 
The Netherlands). At 8 weeks of age, mice were switched to a western-type 
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diet (0.25% cholesterol, 16% fat, Purified Western Diet, 4021.06, ABDiets, 
Woerden, The Netherlands) and were randomly selected to either voluntary 
cage wheel running (RUN, n=10) or to remain sedentary (CONTROL, n=7) for 
12 weeks. Throughout the study, mice had ad libitum access to food and water. 
The voluntary running wheel set-up has been described previously12. Twice a 
week, mice were weighed and food intake was recorded. Two mice in the 
running group were excluded from all analyses because they showed no 
activity on the running wheel. 
 
Experimental procedures 
Fecal, plasma, biliary, hepatic and intestinal parameters were collected at the 
endpoint of the experiment after 12 weeks of RUN or CONTROL, i.e., at 20 
weeks of age. 
 
Fecal Parameters 
Forty-eight hour feces were collected before and at 12 weeks running wheel 
exposure. Feces were dried, weighed and homogenized to a powder. Aliquots 
of fecal powder were used for analysis of total bile acids by an enzymatic 
fluorimetric assay 13. Neutral sterols were determined according to Setchell et 
al. 14.  
 
Determination of biliary parameters of cholesterol and bile acid 
metabolism 
After 12 weeks of CONTROL or RUN, all mice underwent gallbladder 
cannulation for continuous collection of bile 15. Briefly, mice were anaesthetized 
by intraperitoneal injection with Hypnorm ® (1 ml∙kg-1) and diazepam 
(10mg∙kg-1). During the 30min bile collection period, mice were placed in a 
humidified incubator to ensure maintenance of body temperature. Bile flow was 
determined gravimetrically, assuming a density of 1g∙ml-1 for bile. Bile was 
stored at -20°C until analysis. Total biliary bile acids were determined by an 
enzymatic fluorimetric assay16. Biliary cholesterol and phospholipids levels 
were measured as described by Kuipers 17.  
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Determination of plasma markers of cholesterol metabolism 
 Immediately after bile collection, blood was drawn via the orbital sinus. Plasma 
was collected by centrifugation and stored at -20°C until analyzed. Plasma total 
cholesterol, free cholesterol and triglyceride levels were measured by standard 
enzymatic methods using commercially available assay kits (Roche 
Diagnostics, Mannheim, Germany and DiaSys Diagnostic Systems, Holzheim, 
Germany). Plasma pro-and anti-inflammatory makers were analyzed using 
BD™ Cytometric Bead Array (CBA) Mouse Inflammation Kit (BD Biosciences, 
San Diego, CA). Utilizing gaschromatography, as described by Windler et al.18, 
we analyzed plasma plant sterols (campesterol and sitosterol) relative to 
plasma cholesterol levels as marker of intestinal cholesterol absorption in 
pooled plasma samples of each group. Pooled plasma samples from each 
group were used for lipoprotein separation by fast protein liquid 
chromatography (FPLC) on a Superose 6 column using an Akta Purifier (GE 
Healthcare, Diegem, Belgium). 
 
Tissue Collection 
Mice were opened immediately after blood collection. the heart was slowly 
perfused with PBS at physiological pressure. Then, the liver was excised, 
weighed and snap frozen in liquid nitrogen. The small intestine was excised, 
flushed with ice cold PBS (4°C) and divided into three sections of equal lengths 
and subsequently snap-frozen in liquid nitrogen. Lastly, the thoracic aorta was 
excised and epididymidal fat pads were removed and weighed. Thoracic aorta, 
liver and intestine were stored at -80ºC for later analysis. Hearts were flushed 
with PBS to remove the excess of blood before fixation in formaldehyde 1% 
(Formal-Fixx, Thermo Electron Corporation, Pittsburgh, Pa.) for 24 hours, cut in 
an angle eventually revealing the aortic sinus and stored at –80°C embedded in 
OCT (Tissue-Tek O.C.T., Sakura, Zoeterwoude, the Netherlands). 
 
Determination of atherosclerotic lesion size and aortic cholesterol 
content Frozen sections from the aortic sinus were prepared according to 
Paigen et al 19. Surface lesion area was measured after Oil Red O staining by 
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computer-assisted image quantification with Leica QWin software (Leica 
Microsystems, Wetzlar, Germany). Images were captured with a Leica DFC 
420 video camera. At least 5 sections per mouse were examined for each 
staining. Due to technical difficulties, we were able to analyze atherosclerotic 
lesion size in 4 of 8 running mice and 4 of 7 sedentary mice.  
 
    
 
Supplemental Figure 1. Voluntary running wheel activity during the 12 week running 
wheel exposure: A. Average distance ran per day (km/h) and B: Average time ran per 
day (h/day) in RUN (n=7). Data was statistically analyzed comparing 2 and 12 weeks 
utilizing the Wilcoxon signes-rank test. Data are expressed as means ± SD; *p<0.05 2 
weeks vs. 12 weeks 
 
Determination of hepatic lipids 
 Hepatic lipids were determined after extraction according to Bligh and Dyer 20 
and redisolving in Triton-2%H2O using the same kits as for plasma lipids. 
Phospholipids were determined in all tissues according to Böttcher et al 21. 
 
RNA isolation and PCR procedures 
Total RNA was isolated from liver and intestine using TRI-reagent (Sigma, St. 
Louis, MO) according to the manufacturers’ protocol. cDNA was produced as 
described by Plösch et.al. 15. Real-time PCR was performed on a 7900HT 
FAST real-time PCR system using FAST PCR master mix and MicroAmp FAST 
optical 96 well reaction plates (Applied Biosystems Europe, Nieuwekerk ad 
IJssel, The Netherlands). Primer and probe sequences have been published 
before (www.labpediatricsrug.nl). PCR results were normalized to β-actin.  




Statistical analysis was performed using the Mann-Whitney-U test (SPSS 
12.0.1 for Windows). All data are expressed as means r SD. P-values of <0.05 





Running wheel activity and morphometric parameters   
Mice exposed to a voluntary running wheel progressively ran less during the 12 
week running wheel intervention. While a daily average running distance of ~10 
km and average running duration of ~6.5 hours was observed at the start of the 
experiment, it dropped to ~5.5 km/day and ~4.0 hours at the end of the 
experiment (Supplemental Figure 1).  Despite a 17% increase in food intake 
compared to control mice, running mice displayed a ~13% lower bodyweight 
and ~73% lower epididymidal white adipose tissue weight at 12 weeks of 
running (Table 1). Liver weight, body weight / liver weight ratio and small 
intestinal length were not different between running and control mice (Table 1).  
 
Table 1. Biometrical data. Values represent mean ±  SD at 12 weeks of running in 
CONTROL (n=7) and RUN (n=7); *P<0.05 vs. CONTROL 
 
         
Effect of voluntary wheel running on atherosclerotic lesion size and 
inflammatory markers   
First, we investigated whether 12 weeks of voluntary wheel running beneficially 
affected lesion size area in atherosclerosis-prone LDLR-deficient mice. Indeed, 
  CONTROL RUN 
Body weight (g) 29.6 ± 2.3 25.9 ± 1.0* 
Liver weight (g) 1.35 ± 0.14 1.23 ± 0.05 
Liver weight / body weight (%) 4.6 ± 0.7 4.7 ± 0.2 
Small intestine length (cm) 33.3 ± 1.8 31.5 ± 1.8 
Epididymal white adipose weight 
(g) 0.85 ± 0.25 0.23 ± 0.1* 
Food Intake (g/day) 3.4 ± 0.4 4.0 ± 0.14* 
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quantification of atherosclerotic lesion areas in aortic sinus showed a 43.6% 
reduction in running mice (Figure 1A-C). Because inflammation plays an 
important role in the pathogenesis of atherosclerosis, we also assessed the 
effect of running on plasma levels of inflammatory markers.  Interestingly, 
voluntary wheel running had no effect on plasma levels of inflammatory 
markers (Supplemental Figure 2).   
                                                   
       
                             
Figure 1. Voluntary wheel running reduces atherosclerotic lesions size development. 
Representative morphological section of aortic arch stained with Oil Red Oil of 
CONTROL (A) and RUN (B); (C) Quantification of lesion size in aortic sinus of Control 
(n=4) and RUN (n=4) at 12 weeks of running. *p<0.05 vs. CONTROL 
 
Voluntary wheel running beneficially affects plasma lipoprotein profile  
Elevated lipid levels are key factors in the development of atherosclerosis. 
Running mice displayed a small but significant reduction in plasma levels of 
total cholesterol, esterified cholesterol and triglycerides (Table 2).  Importantly, 
we found improved plasma lipoprotein profiles with reduced levels of VLDL-and  
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Supplemental Figure 2. Voluntary wheel running has no effects on pro- and anti-
inflammatory cytokines. Plasma cytokines in CONTROL(n=7) and RUN (n=7). Pro-
inflammatory cytokines: Tumor necrosis factor alpha (TNFa ), interferon gamma (IFNy), 
monocyte chemotactic protein 1 (MCP1), interleukin 6 (IL-6) and anti-inflammatory 
cytokine interleukin 10 (IL-10). Data represent means ± SD 
 
LDL-sized lipoproteins in running compared to control mice (Supplemental 
Figure 3A and B). Paralleling these running-induced improvements in 
lipoprotein profiles, we not only found a reduction in hepatic expression of 
microsomal triglyceride transfer protein, indicative of a decreased hepatic 
production of VLDL, but also observed an increased hepatic lipoprotein lipase 
expression (Table 3), indicative of an increased lipoprotein clearance.  More 
beneficial effects of running were observed on hepatic lipid storage. First, 
control mice displayed substantial hepatic triglyceride stores, which were 
reduced by almost half in running mice (Table 2).  Second, running resulted in a 
significantly lower hepatic storage of cholesterol, paralleled by a running-
induced decrease in Hmgcr, the rate-limiting enzyme in cholesterol 
biosynthesis. Hepatic contents of cholesterol esters tended to be reduced in 
running mice with a lower expression of Acat2, an enzyme required for 
cholesterol esterification (Table 3).  Moreover, the beneficial changes in hepatic 
lipid content were paralleled by decreased expression levels of key lipogenic 
genes Fasn and Scd1 (Table 3).  Collectively, these data show that running 
provokes favorable changes in plasma and liver lipid metabolism. 
 
Voluntary wheel running increased fecal sterol output 
Next, we assessed whether the running-induced beneficial changes in plasma 
and liver lipid metabolism were accompanied by changes in cholesterol and bile 
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Table 2. Plasma and liver lipids. Values represent mean ±  SD at 12 weeks of running in 
CONTROL (n=7) and RUN (n=7); *p<0.05 vs. CONTROL 
         
  CONTROL RUN 
Plasma Lipids 
(mmol/L)     
Total Cholesterol  27.7 ±  1.5 23.6±  2.5* 
Free Cholesterol  8.80 ±  1.4 7.65 ±  0.7 
Cholesterol Esters  18.9 ±  0.9 15.9 ±  1.8* 
Triglycerides  8.52 ±  1.54 6.59 ±  0.8* 
Liver Lipids (nmol/mg liver)   
Triglycerides  78  ±  2 41 ±  10* 
Total Cholesterol  16.3 ± 2.0 13.1 ±  1.3* 
Free Cholesterol  5.5 ± 0.9 4.7 ± 0.3 
Cholesterol Esters  10.9 ± 1.7 8.4 ± 1.1 





Supplemental Figure 3. Voluntary wheel running improves the lipoprotein profile. 
Plasma lipoprotein profiles showing distribution of cholesterol (A) and triglycerides (B) in 
pooled plasma of CONTROL (n=7) and RUN (n=8). Lipoproteins in plasma pools were 
separated by fast protein liquid chromatography (FPLC) on a Superose 6 column  
 
 
acid metabolism. First, we assessed fecal parameters of cholesterol and bile 
acid metabolism and feces were collected quantitatively from all mice during 
the last 48 hours of the experiment.  Hypercholesterolemic running mice had 
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significantly increased feces production (+19%, data not shown) as well as 
fecal neutral sterol (+33%) and fecal bile acid output rates (+93%) compared to 
sedentary controls (Table 4). No differences in any of these parameters were 
observed before the running wheel intervention (data not shown).  Next, we 
investigated whether voluntary wheel running increased fecal neutral sterol 
output by modulating cholesterol absorption.  Running had no effect on the 
plasma plant sterol/cholesterol ratio (Supplemental Figure 4A), a marker of 
cholesterol absorption. No effect of voluntary wheel running was found on 
jejunal Npc1l1 mRNA expression (Supplemental Figure 4B), while, intriguingly, 
the expression of the ATP-cassette binding transporters g5 and g8 
(Supplemental Figure 4C and D), which are known to promote efflux of 
cholesterol and plant sterols from the enterocyte back into the intestinal lumen 
for elimination into feces, was increased.  
 
Voluntary wheel running increases bile flow and biliary bile acid secretion   
To evaluate whether physical activity modulates biliary parameters under 
hypercholesterolemia, mice were subjected to gallbladder canulations for 
collection of hepatic bile at 12 weeks of running. Indeed, running mice had a 
22.6% increased bile  
flow (P=0.011), a 67.5% increase in biliary bile acid secretion and a trend 
towards increased biliary cholesterol secretion (P=0.179), while no differences 
in the rate of biliary phospholipid secretion was found (Table 4).  Moreover, no 
differences in the expression levels of important genes involved in cholesterol 
efflux from the hepatocyte towards the plasma (Table 3) were observed. Our 
data suggest that voluntary wheel running increases cholesterol turnover to 
promote its fecal excretion as cholesterol and bile acids, indicating increased 











In the present study, we tested the hypothesis that voluntary wheel running 
ameliorates atherosclerosis possibly by modulating cholesterol metabolism.  By 
using hypercholesterolemic LDLR-deficient mice on a western-type diet, we 
were able to show for the first time that voluntary wheel running provokes 
specific changes in cholesterol metabolism, particularly by promoting its 
conversion into bile acids likely contributing to reduced plasma lipid levels, and 
that these alterations coincide with a reduction in atherosclerosis.   
First, we show running-induced increases in fecal neutral sterol and 
bile acid excretion.  The fecal bile acid loss in running mice is massive and 
reflective of an increased de novo bile acid synthesis.  Second, we found that 
the increased fecal bile acid loss was paralleled by specific changes in biliary 
parameters consistent with an increased cholesterol turnover. Specifically, 
running mice had a higher bile flow, an increased biliary bile acid secretion and 
a trend towards an increased biliary cholesterol secretion.  Third, hepatic 
cholesterol content was reduced in running mice, indicating cholesterol turnover 
over storage. 
To the best of our knowledge, this is the first study showing that 
voluntary exercise is equally efficient as forced exercise in reducing 
atherosclerotic lesion size development in hypercholesterolemic mice.  While 
we show here a 43.6% reduction in atherosclerotic lesion size upon voluntary 
wheel running, previous studies in LDLR-deficient mice undergoing forced 
exercise, like treadmill running or swimming, reported a reduction by ~40% 4, 22.  
Additionally, reductions of atherosclerotic lesion size of ~54% to ~30% have 
been observed in another hypercholesterolemic mouse model, the ApoE-
deficient mouse, when forced to swim for different durations 5, 6, 23.  In contrast, 
voluntary wheel running did not result in reductions of atherosclerosis in ApoE-
deficient mice with preexisting lesions, however, a reduction in pro-
inflammatory markers was reported 1. No literature is available describing the 
effects of exercise (forced or voluntary) on plasma pro-inflammatory markers in 
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Table 3.  Hepatic genes involved in lipid metabolism. Hepatic mRNA expression levels 
of lipoprotein lipase (Lpl), microsomal triglyceride transfer protein (Mttp),  3-hydroxy-3-
methyl-glutaryl-CoA reductase (Hmgcr), acetyltransferase 2 (Acat2), ATP-binding 
cassette transporter 1 (Abca1),  ATP-binding cassette transporter g5 (Abcg5), ATP-
binding cassette transporter 8 (Abcg8),    fatty acid synthase (Fasn), stearoyl-CoA 
desaturase-1 (Scd1) , Values are  relative to ß-actin and represent mean ±  SD in 
Control (n=6) and RUN (n=6)             
 
  CONTROL RUN P-value 
Cholesterol Metabolism     
Clearance       
Lpl 1.0 ± 0.2 1.6 ± 0.1* 0.006 
Production       
Mttp 1.0 ± 0.3 0.7 ± 0.2* 0.029 
Hmgcr 1.0 ± 0.3 0.6 ± 0.1* 0.020 
Acat2 1.0 ± 0.2 0.7 ± 0.1* 0.024 
Efflux       
Abca1 1.0 ± 0.3 1.1 ± 0.3 0.061 
Abcg5 1.0 ± 0.2 0.9 ± 0.2 0.426 
Abcg8 1.0 ± 0.1 1.0 ± 0.1 0.420 
Fat Metabolism       
Fasn 1.0 ±  0.2 0.7 ±  0.1* 0.048 
Scd1 1.0 ±  0.3 0.6 ±  0.1* 0.029 
 
atherosclerosis development in mice.  We show here that voluntary wheel 
running reduced atherosclerosis independent of pro-and anti-inflammatory 
markers.  The mechanisms behind the beneficial effects of exercise on 
atherosclerosis are not yet understood. Being a major physiological process for 
the body to clear excess cholesterol, the fecal excretion of cholesterol as 
neutral sterol or bile acid plays a critical role in the maintenance of whole-body 
cholesterol homeostasis. Increasing cholesterol excretion into feces as neutral 
sterol or bile acid is long known as an efficient strategy in the amelioration of 
atherosclerosis, as it improves the pro-atherogenic state by reducing lipid 
content in plasma 8, 9. Furthermore, it has been demonstrated that patients with 
coronary artery disease have a reduced fecal excretion of bile acids 24.  
Strikingly, there is a complete lack of studies describing the effects of physical 
activity on the enterohepatic metabolism of cholesterol in hypercholesterolemic  
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Table 4. Fecal and biliary sterol parameters. Values represent mean ± SD at 12 weeks 
of running for CONTROL (n=7) and RUN (n=7); *p<0.05 vs. CONTROL 
 
  CONTROL RUN 
Fecal outputs (μmol/24h/100gBW)     
Neutral sterols 48 ±  6 64 ±  4* 
Bile acids 5.3 ±  1.6 10.2 ±  3.1* 
Dietary cholesterol balance 35 ± 6 41 ± 3 
Biliary secretions (μmol/24h/100gBW)   
Cholesterol 0.9 ±  0.4 1.6 ±  0.8 
Bile acids 249 ±  49 417 ±  134* 
Phospholipids 25.4 ±  2.9 29.4 ±  12.6 
Bile flow (μl/min/100gBW) 4.3 ± 0,7 5.2 ± 0.7* 
 
 
mice. Our observations of running-induced increases in fecal neutral sterol and 
bile acid outputs confirm our earlier results in chow-fed mice running for 2 
weeks. It is, however, noteworthy that the effects are more striking in 
hypercholesterolemic mice running for 12 weeks.  For example, while we found 
a ~30% increase in both fecal neutral sterol and bile acid outputs in chow-fed  
mice upon 2 weeks running, we report here a similar increase in fecal neutral 
sterol loss in 12 week running hypercholesterolemic mice (~33%) yet because 
the diet already contained 0,25% the amount of extra cholesterol excreted by 
running is massive. In addition there was a strong increase in  fecal bile acid 
secretion (~93%) compared to 30% in control mice. This increase in fecal bile 
acid excretion in running mice is remarkable and reflects an increase in de 
novo bile acid synthesis.  Consistent  
with our previous study 12 in chow-fed mice, we did not observe changes in any 
of the major genes involved in bile acid synthesis in running mice (data not 
shown) 12. Thus, within this and our previous study, the increase in bile acid 
synthesis upon voluntary wheel running as demonstrated by fecal bile acid loss 
did not result in an upregulation of key genes involved in bile acid synthesis, 
such as Cyp7a1 and Cyp8b1 indicating that regulation via the nuclear receptor 
FXR and its downstream target FGF15 is not operational here.  Increases in de 
novo bile acid synthesis without concomitant increases in any of the major bile 
acid genes have also been reported by others25, 26 and are most likely induced 
by posttranscriptional mechanisms.  It is speculative, therefore, that physical 
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activity enhances bile acid synthesis by metabolic mechanisms. For example, 
physical activity increased dietary fatty acid absorption (data not shown).  
During physical activity, energy is depleted in energy expending tissues, such 
as skeletal muscle. Thus, a high demand to recover this expended energy 
manifests in these tissues.  In this regard, physical activity might, hypothetically, 
increase bile acid synthesis to increase the capacity for micelle formation, 
thereby fatty acid absorption and thus energy delivery to energy expending 
tissues.   
Paralleling our observations of fecal bile acid excretion, running 
appears to induce more drastic effects on biliary parameters in 
hypercholesterolemic mice than in chow-fed healthy mice.  Compared to control 
mice, the increase in biliary bile acid secretion was ~20% in healthy chow-fed 
mice running for 2 weeks 12. Furthermore, we report here an increase in bile 
flow, which was not observed in running chow-fed mice, but has been 
previously reported in exercising rats 27.  
Next, it is intriguing that the livers of running mice display ~20% less 
cholesterol stores and ~45% less triglyceride stores than control mice do. 
Control LDLR-deficient mice on a western-type diet display hepatic triglyceride 
and cholesterol contents more than 2.5 times that of chow-fed wildtype mice 12.  
Yet, despite their increased food intake, running mice had significantly reduced 
hepatic cholesterol and triglyceride stores demonstrating an enhanced turnover 
rather than their storage.  No data are available describing the effects of 
exercise, either forced or voluntary, on hepatic lipids in hypercholesterolemic 
mouse models.  Yet, limited data show that high fat and low fat-fed wildtype 
mice displayed reduced hepatic triglycerides levels after treadmill exercise 
training 28 and that swim training reduced hepatic fatty acid synthesis in 
C57BL/6J mice 29.  Moreover, we previously found reduced hepatic triglyceride 
content and a trend towards reduced hepatic cholesterol content in chow-fed 
mice running for 2 weeks 12.. Collectively these observations demonstrate 
favorable effects of physical activity on hepatic lipid storage.   

















































































            
Supplemental Figure 4. Parameters of cholesterol absorption after 12 weeks of running. 
A. Plasma total plant sterol / plasma cholesterol ratio in CONTROL (n=5) and RUN 
(n=5); Jejunal mRNA expression levels of: B. Niemann-Pick C1 Like 1, Npc1l1; C. ATP-
binding cassette transporter g5, Abcg5; and D. ATP-binding cassette transporter g8, 
Abcg8 in CONTROL (n=7) and RUN (n=7). *p<0.05 vs.  CONTROL 
 
 
We have previously reported indications for impaired cholesterol 
absorption in chow-fed C57BL/6J mice exposed to a voluntary running wheel 
as the jejunal expression levels of a crucial protein in cholesterol absorption, 
Npc1l1,  and the plasma plant sterol / cholesterol ratio were decreased in 
running mice 12.  In contrast, we did not observe an effect on jejunal Npc1l1 
expression nor on the plasma plant sterol / cholesterol ratio here.  In contrast, 
we show a running-induced increased expression of jejunal Abcg5/8 the 
heterodimer cholesterol efflux transporter implicated in the excretion of 
cholesterol from the intestine 30. Thus, running appears to differentially affect 
parameters of cholesterol absorption under low dietary cholesterol, normo-
cholesterolemic versus high dietary cholesterol, hypercholesterolemic 
conditions.  It is also possible that the previously observed running-induced 
decreases in expression of Npc1l1 upon 2 weeks of running might underlie 
CHAPTER 6                                              
144 
 
transient adaptations in the intestine, which could be modulated further during 
longer periods of running.  
Noteworthy is that we also found improvements in plasma cholesterol 
levels and plasma lipoprotein profile and thereby reduced atherosclerotic lesion 
formation in running mice. Similar small improvements in plasma cholesterol 
levels have previously been reported in swimming4 and treadmill-running22 
LDLR-deficient mice and may underlie at least part of the antiatherosclerotic 
effect. 
Intriguing is the running-induced improvements in plasma lipoprotein 
profiles, showing a marked reduction in the apoB-containing lipoprotein 
particles VLDL and IDL/LDL. Decreased LDL and VLDL levels have been 
reported for physically active men 31, however, no such descriptions are 
available in hypercholesterolemic mice.  Furthermore, the improved plasma 
lipoprotein profiles parallel the running-induced increase in hepatic lipoprotein 
lipase expression levels and the running-induced decrease in hepatic 
microsomal transfer protein, suggesting an increased lipoprotein clearance and 
decreased production, respectively. However, what exactly the role of running 
in lipoprotein clearance and reduced production is and how this relates to the 
human situation remains to be explored in future studies.   
Altogether, the present study shows that voluntary wheel running is a 
feasible means to decrease atherosclerotic burden in hypercholesterolemic 
mice and that an enhanced turnover of cholesterol into bile acids might be the 
underlying mechanism herein. 
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       CHAPTER 7 
Beneficial effects of bile acid 
sequestration and voluntary wheel 
running on cholesterol turnover and 
atherosclerosis in hypercholesterolemic 
mice 
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Introduction Bile acid sequestrants (BAS) are cholesterol-lowering agents that 
have been demonstrated to decrease incidence in cardiovascular events and 
regression of atherosclerotic plaque formation in clinical trials.  However, little is 
known about the effect of BAS on atherosclerotic lesion formation. Recently, we 
showed that voluntary running wheel activity (RUN) decreases atherosclerotic 
lesion size in hypercholesterolemic mice. Lifestyle and pharmacological strategies 
are often co-prescribed, thus we questioned the effect of BAS treatment alone and 
in combination with RUN on cholesterol metabolism, heart function and 
atherosclerotic lesion size in hypercholesterolemic mice. 
Methods Male Ldlr-deficient mice remained either sedentary (CONTROL), 
were treated with 2% (wt/wt in diet) Colesevelam HCl (BAS), had access to a 
voluntary running wheel (RUN), or were exposed to BAS and  RUN (BAS RUN). 
All groups were fed a high cholesterol diet for 12 weeks.. At 12 weeks of 
intervention, feces, bile and plasma were collected to determine fecal, biliary and 
plasma parameters of cholesterol metabolism. Atherosclerotic lesion size was 
determined in the aortic arch and heart function by echocardiography. 
Results  BAS RUN ran more than RUN (6.4 ± 1.4 vs. 3.5 ± 1.0 km/day, 
p<0.05).  BAS and BAS RUN displayed a3-fold reductions in plasma cholesterol 
levels (p<0.001), a2.5-fold increases in fecal neutral sterol (p<0.001) and bile acid 
(p=0.01) outputs, decreases in biliary secretions of cholesterol (~6-fold, p<0.0001), 
bile acids and phospholipids (both ~2-fold, p<0.001) vs. CONTROL while no 
effects were observed in RUN. Compared to CONTROL, atherosclerotic lesion 
size decreased by 78% in both BAS and BAS RUN, (p<0.0001).  
Conclusion  BAS reduce atherosclerosis in Ldlr-deficient mice, coinciding with 
a switch from cholesterol accumulation to cholesterol loss. RUN slightly modulated 
atherosclerotic lesion formation but the combination of BAS and RUN had no clear 
additive effects in this respect.  





Atherosclerosis is a complex vascular disease, which is initiated by abnormalities 
in systemic parameters, such as elevated circulating lipid and lipoprotein levels, 
leading to inflammation of the vascular wall. Cholesterol has a central role in the 
pathogenesis of atherosclerosis, excess cholesterol in vascular macrophages 
leads to formation of atherosclerotic plaques. Strategies that increase the fecal 
cholesterol excretion as neutral sterols or bile acids, i.e., accelerated whole body 
cholesterol turnover, improve the pro-atherogenic state by modulating plasma lipid 
content and thus represent efficient strategies in the amelioration of 
atherosclerosis.   
Fecal excretion of cholesterol as bile acids quantitatively represents a 
major route of cholesterol removal from the body. Bile acids are synthesized from 
cholesterol exclusively in the liver and enter the intestinal lumen after a meal. Bile 
acids are important for the emulsification and absorption of dietary fats in the 
intestine 1.  .About 95% of the bile acids is reabsorbed from the terminal ileum, 
transported back to the liver for resecretion into bile (enterohepatic circulation). 
However, the fraction of bile acids that escapes reabsorption is lost in feces and 
constitutes an important part of cholesterol turnover, since fecal bile acid loss is 
compensated for by de novo synthesis from cholesterol to maintain the bile acid 
pool size 2-4.  In addition to their role in lipid uptake, bile acids have emerged as 
important metabolic regulators of glucose, lipid and energy metabolism 5, which 
are all implicated in the pathogenesis of atherosclerosis. 
Physical activity has long been known as a beneficial strategy for cardiovascular 
risk reduction 6-15. We have recently shown that voluntary wheel running enhances 
cholesterol turnover into bile acids in healthy chow-fed mice 16 as well as in 
hypercholesterolemic atherosclerotic mice  (Chapter 6). Furthermore, the running 
induced increase in fecal bile acid secretion coincided with a reduction in 
atherosclerotic lesion size development in hypercholesterolemic running mice 
(Chapter 6), demonstrating that physical activity beneficially modulates 
atherosclerosis by enhancing cholesterol turnover in mice.  However, despite the 




cardiovascular diseases, regular physical activity programs are frequently reported 
to be underutilized, adherence to these programs proofs poor or engagement in 
physical activity is not frequent enough 17, 18.  Moreover, physical activity will not 
result in adequate improvements in individuals presenting with more aggressive 
cardiovascular derangements.  In these situations, pharmacological intervention 
becomes necessary and is prescribed either alone or in combination with physical 
activity.   
Bile acid sequestrants (BAS) have long been utilized for improving 
hypercholesterolemia 19.  Moreover, like physical activity, BAS induce an enhanced 
cholesterol turnover.  BAS are positively charged indigestible resins. In the 
intestinal lumen they bind to negatively charged bile acids forming non-absorbable 
complexes, thus increasing fecal bile acid excretion which subsequently stimulates 
the liver to convert cholesterol into bile acids. A compensatory increase in hepatic 
LDL receptor activity subsequently clears LDL cholesterol from the circulation, 
thereby reducing LDL cholesterol levels 19, 20.   Additionally, human studies have 
shown that colestipol and cholestyramine, two older generation BAS 19, induced 
reductions in total and LDL cholesterol that were not only accompanied by 
reductions in relative coronary heart disease death 21 but also by increased 
regression and decreased progression in coronary artery lesion 22-26. Colesevelam 
HCL is a more recent BAS that was specifically engineered for more specificity 19. 
However, its effects on atherosclerosis development have not been reported so far. 
Thus, the aim of this study was to evaluate the effects of BAS-induced 
disruption of bile acid metabolism on parameters of cholesterol metabolism, 
atherosclerosis development and parameters of heart function in 
hypercholesterolemic mice.  Pharmacological intervention and lifestyle changes 
are often co-prescribed in cardiovascular disease risk management. Therefore, we 
also investigated whether a combination treatment of BAS and voluntary wheel 
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MATERIALS AND METHODS  
 
All experiments were approved by the Animal Care and Use Committee of the 
University of Groningen, The Netherlands. The University of Groningen is 
accredited by AAALAC (Association for Assessment and Accreditation of 
Laboratory Animal Care) International and follows the Public Health Service Policy 
for the Care and Use of Laboratory Animals. Animal care was provided in 
accordance with the procedures outlined in the Guide for the Care and Use of 
Laboratory Animals. 
 
Animals, voluntary cage-wheel exercise and BAS treatment 
Seventy-four 5 week old male LDLR deficient ((B6.129S7-Ldlrtm1Her/J) mice were 
purchased from Jackson Laboratory (Bar Harbor, ME, USA). Upon arrival, mice 
were singly housed in a cage (47 x 26 x 14.5 cm) in a temperature-controlled room 
with a 12:12 light-dark cycle and had ad libitum access to standard commercial 
pelleted laboratory chow (RMH-B, ABDiets, Woerden, the Netherlands) and water. 
At 8 weeks of age, all mice were switched to a western diet (0.25% cholesterol, 
16% fat, Purified Western Diet, 4021.06, ABDiets, Woerden, The Netherlands) and 
randomly selected to either of the following treatment groups: Sedentary on 
western-type diet only (CONTROL, n=17), BAS-treatment (BAS, n=17), western-
type diet exposed to a voluntary running wheel (RUN, n=20) and BAS exposed to 
a voluntary running wheel (BAS RUN, n=20). All treatments lasted for 12 weeks. 
BAS-treated mice were fed the western diet supplemented with 2% (wt/wt) 
Colesevelam HCL (Daiichi Sankyo, Inc., Parsippany, NJ, USA). Throughout the 
study, mice had ad libitum access to food and water.  
The voluntary running wheel set-up utilized has previously been described 
27. Briefly, the cage of RUN mice was equipped with a hamster-sized metal cage 
wheel with a diameter of 11 cm which was fitted with a cycle computer containing a 
digital magnetic counter (Art NO.: K-13-TL SET-P3-NL, Xiron, Netherlands). Each 
morning, total distances ran was recorded. Once a week, mice were weighed and 
food intake was recorded. Exposing mice to a voluntary running wheel for two 




adaptations consistent with those of endurance exercise 27. Six mice that had 
access to a voluntary running wheel were excluded from all analyses because they 
showed no activity on the running wheel. 
 
Experimental procedures 
To examine the effect of BAS treatment and the combination of BAS and voluntary 
wheel running on cholesterol and bile acid metabolism fecal, plasma, biliary, 
hepatic and intestinal parameters were collected at the endpoint of the experiment 
after 12 weeks of CONTROL, RUN, BAS and BAS RUN i.e.,  at 20 weeks of age. 
 
Heart Function 
Mice were subjected to transthoracal echocardiography as described 28. Mice were 
anaesthetized with 2% isoflurane and body temperature was maintained by placing 
the mouse on a heating pad (Harvard apparatus). We used a Vivid 7 machine (GE 
Healthcare, Diegem, Belgium) equipped with special rodent software and a 14 
MHz transducer. Cardiac dimensions were measured using parasternal short-axis 
view and M-mode tracings to determine end-diastolic and end-systolic LV internal 
diameter, posterior wall thickness (LVPW), and interventricular septal thickness 
(IVS). Left ventricular mass was calculated as described 29: LVmass = 1.05 
([LVIDd + LVPWd + IVSd]3—[LVIDd]3) gram. The cardiac output was calculated by 
measuring the left ventricular outflow tract (LVOT) diameter and measuring a PW 
doppler signal over the LVOT (using the formula: LVOT radius2 x π (3.14) LVOT 
VTI x Heart rate). 
 
Fecal Parameters 
Forty-eight hour feces productions were collected at 4 weeks and 12 weeks of 
treatments and food intake was monitored. Feces were dried, weighed and 
homogenized to a powder. Aliquots of fecal powder were used for analysis of total 
bile acids by an enzymatic fluorimetric assay 30. Neutral sterols were determined 
according to Setchell et al. 31.  Dietary cholesterol balance was calculated from the 
difference of dietary intake and fecal excretion. 
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Determination of biliary parameters of cholesterol and bile acid metabolism 
After 12 weeks of interventions, 8 mice of all groups underwent a gallbladder 
cannulation for collection of bile 32. Briefly, mice were anaesthetized by 
intraperitoneal injection with Hypnorm ® (1 ml∙kg-1) and diazepam (10mg∙kg-1). 
During the 30 min bile collection period, mice were placed in a humidified incubator 
to ensure maintenance of body temperature. Bile flow was determined 
gravimetrically, assuming a density of 1g∙ml-1 for bile. Bile was stored at -20°C 
until analysis. Total biliary bile acids were determined by an enzymatic fluorimetric 
assay33. Biliary cholesterol and phospholipids levels were measured as described 
by Kuipers 34.  
 
Determination of plasma markers of cholesterol metabolism 
Immediately after the bile collection, blood was collected via the abdominal aorta. 
Plasma was collected by centrifugation and stored at -20°C until analyzed. Plasma 
total cholesterol, free cholesterol and triglyceride levels were measured by 
standard enzymatic methods using commercially available assay kits (Roche 
Diagnostics, Mannheim, Germany and DiaSys Diagnostic Systems, Holzheim, 
Germany). We analyzed plasma plants sterols relative to plasma cholesterol levels 
as marker of intestinal cholesterol absorption in pooled plasma samples of each 
group. Plasma plant sterol (campesterol and sitosterol) concentrations were 
determined by gas chromatography, as described by Windler et al.35. Pooled 
plasma samples from each group were used for lipoprotein separation by fast 
protein liquid chromatography (FPLC) on a Superose 6 column using an Akta 
Purifier (GE Healthcare, Diegem, Belgium). 
 
Tissue Collection 
Mice were opened immediately after blood collection. After dissecting the vena 
cava, a syringe containing PBS was inserted at the apex of the heart for cleaning. 
Subsequently the liver was excised, weighed and snap frozen in liquid nitrogen. 
The small intestine was excised, flushed with ice cold PBS (4°C) and divided into 
three sections of equal lengths and subsequently snap-frozen in liquid nitrogen. 




isolation. After collection of all organs the heart was flushed with 1% formalin fix, 
excised and stored in 1% formalin for no longer than 24 hours. Then hearts were 
cut in an angle eventually revealing the aortic sinus, embedded in Tissue Tec 
(Sakura Finetek Europe B.V., Zoeterwoude, NL) and stored in -80ºC. 
 
Determination of atherosclerotic lesion size. 
Frozen sections from the aortic sinus were prepared according to Paigen et al 36. 
Surface lesion area was measured after Oil Red O staining by computer-assisted 
image quantification with Leica QWin software (Leica Microsystems, Wetzlar, 
Germany). Images were captured with a Leica DFC 420 video camera. At least 5 
sections per mouse were examined for each staining. 
 
   
Determination of hepatic lipids 
 Hepatic lipids were determined after extraction according to Bligh and Dyer 37 
using the same kits as for plasma lipids. Phospholipids were determined in all 
tissues according to Böttcher et al38. 
 
RNA isolation and PCR procedures 
Total RNA was isolated from liver and intestine using TRI-reagent (Sigma, St. 
Louis, MO) according to the manufacturers’ protocol. cDNA was produced as 
described by Plösch and coworkers 32. Real-time PCR was performed on a 
7900HT FAST real-time PCR system using FAST PCR master mix and MicroAmp 
FAST optical 96 well reaction plates (Applied Biosystems Europe, Nieuwekerk ad 
Figure 1. Voluntary running wheel 
activity during the 12 week running 
wheel exposure in western-type 
diet fed mice (RUN) and BAS-
treated mice (BAS RUN). Data was 
statistically analyzed comparing 
each week to week 1 separately 
utilizing the Wilcoxon signed-rank-
test. Data are expressed as means 
± SD, *p<0.05 vs. 1 week 
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IJssel, The Netherlands). Primer and probe sequences have been published 
before (www.labpediatricsrug.nl). PCR results were normalized to β-actin for liver 
and to cyclophyllin and 36B4 for intestine.  
 
Statistics 
Multiple group comparisons were done by the Kruskal-Wallis H test, followed by 
Posthoc Conover test, using Bright Stat software 39 unless stated otherwise.  All 
data are expressed as means r SD. A P-value of <0.05 was accepted as 
statistically significant. 
 
Table 1. Biometrical data. Values represent mean ±  SD at 12 weeks of running in 
CONTROL, RUN, BAS and BAS RUN, (n=8 for each group), *p<0.05 vs. CONTROL, 
†p<0.05 vs. BAS 
          
  CONTROL RUN BAS BAS RUN 
Body weight (g) 30.2 ± 3.1 28.6 ± 0.9 26.0 ±  0.6 * 26.1 ±  1.0 * 
Liver weight (g) 1.43 ± 0.14 1.36 ± 0.10 1.26 ±  0.05* 1.3 ±  0.08 
Liver  / body weight (%) 4.7 ± 0.1 4.8 ± 0.3 4.8 ±  0.1 4.9 ±  0.3 





Effect of BAS treatment on morphometric parameters and running wheel 
activity 
Despite an increased food intake compared to control mice, BAS-treated running 
and sedentary mice both displayed a ~14% decrease in body weight that was 
paralleled by a decrease in liver weights in BAS mice, thus resulting in absence of 
a net effect on the liver-to-body weight ratio (Table 1).  All mice exposed to a 
voluntary running wheel progressively ran less during the 12 week running wheel 
intervention. While a daily average running distance of ~10 km was observed at 
the beginning of the experiment, it dropped to 6.4 km/day in BAS-treated mice and 
even to 3.5 km/day in non-BAS-treated running mice (Figure 1).  Furthermore, we 




compared to BAS-treated mice starting at 11 weeks of running wheel exposure 
(Figure 1).   
 
                 
 
                      
Figure 2. BAS treatment reduces atherosclerotic lesion size. (A) Representative 
morphological sections of aortic sinus stained with Oil  Red Oil of CONTROL, RUN, BAS 
and BAS RUN mice, (B) Quantification of lesion size in aortic sinus of CONTROL (n=9), 
RUN (n=9), BAS (n=10) and BAS RUN (n=7) mice at 12 weeks of intervention. *p<0.05 vs. 
CONTROL 
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BAS treatment decreases atherosclerotic lesion size development in LDLR-
deficient mice 
First, we investigated whether 12 weeks of BAS treatment was beneficial in 
reducing atherosclerotic lesion size development in atherosclerosis-prone LDLR-
deficient mice and whether a combination with voluntary running wheel exercise 
would have additional effects. Indeed, quantification of atherosclerotic lesion size 
in aortic sinus showed a 78% reduction in BAS-treated mice compared to control 
mice (Figure 2). The combination treatment of BAS and voluntary wheel exercise 
yielded no additional effects on reducing atherosclerotic lesion size.  Running mice 
not treated with BAS, showed a 23% reduction in atherosclerotic lesion size 
compared to control mice. Atherosclerosis can over time lead to hemodynamic 
impairments in the heart and thus lead to acute myocardial events. Impairments in 
cardiac function have previously been reported for 36-week old LDLR-deficient 
mice fed a western diet 40, 41. Thus, we evaluated whether the BAS mediated 
reduction in atherosclerotic lesion size would impact on cardiac function in the 20-
week old LDLR-deficient mice of this study.  However, no differences were 
observed in left ventricular mass, percent of fractional shortening, heart rate or 
cardiac output upon BAS and combination treatment (Table 2). 
 
Table 2. Cardiac function.  Values represent mean ±  SD at 12 weeks of running in 
CONTROL, RUN, BAS and BAS RUN, (n=8 for each group), *p<0.05 vs. CONTROL, 
†p<0.05 vs. BAS;  LV = left ventricular mass 
          
  CONTROL RUN BAS BAS RUN 
LV mass (mg) 95.2 ± 16.5 96.3 ± 24.7 88.4 ±  17.2 86.1 ±  15.4 
% Fractional Shortening 43 ± 4 43 ± 3 45 ±  4 47 ±  5 
Heart Rate (beats per 
min) 443 ± 49 415 ± 56 395 ±  41 417 ±  26 
Cardiac Output (ml/min) 31.7 ± 4.7 28.5 ±  5.0 29.4 ± 4.9 28.5 ± 5.8 
 
 
BAS  treatment beneficially affects lipid metabolism in LDLR-deficient mice 
Elevated lipid levels are key in the development of atherosclerosis. Thus, we 
evaluated the effect of BAS treatment alone and in combination with voluntary 




hepatic parameters involved in lipoprotein and lipid metabolism. BAS treated mice 
displayed significant reductions in plasma levels of total cholesterol (2.8-fold), 
esterified cholesterol (2.5-fold), free cholesterol (3.7-fold) and triglycerides (3.9-
fold) compared to control mice (Table 3), while no additional improvements were 
observed in the combination treatment.  Importantly, we found improved plasma 
lipoprotein profiles with reduced levels of VLDL- and LDL-sized lipoproteins in all 
BAS treated mice compared to control mice (Figure 3).  
Further beneficial effects of BAS treatment were observed on hepatic lipid storage. 
BAS treated mice displayed 1.8-fold reductions in hepatic triglyceride stores 
compared to control mice (Table 3), which was paralleled by a 40% reduction in 
hepatic expression of the lipogenic gene Srebp1c (Table 4). The combination 
treatment of BAS and voluntary wheel running led to further reductions in hepatic 
triglyceride stores and hepatic Srebp1c levels compared to BAS treatment alone.  
Moreover, all BAS treated mice displayed reductions in hepatic total cholesterol 
(2.2-fold), free cholesterol (1.5-fold) and esterified cholesterol contents (3.8-fold) 
compared to control mice.  Despite the BAS-induced decrease in hepatic 
cholesterol stores, we found increased hepatic levels of Hmgcr (4.3-fold induction),  
 
Table 3. Plasma and liver lipids. Values represent mean ±  SD at 12 weeks of running in 
CONTROL, RUN, BAS and BAS RUN, (n=8 for each group), *p<0.05 vs. CONTROL, 
†p<0.05 vs. BAS 
          
  CONTROL RUN BAS BAS RUN 
Plasma Lipids 
(mM)         
Total cholesterol 30.4±  3.4 30.2 ±  4.3 10.7 ±  1.2* 12.5 ±  3.0* 
Free \cholesterol 10.8 ±  1.0 10.8 ±  1.5 2.9 ±  0.6* 3.8 ±  1.4* 
Cholesterol esters 19.6 ±  2.4 19.4 ±  2.9 7.8 ±  0.7* 8.7 ±  1.7* 
Triglycerides  11.9 ±  1.3 10.9 ±  1.3 3.0 ±  0.5* 3.3 ±  1.2* 
Liver Lipids 
(nmol/mg liver)         
Triglycerides  40.6  ±  7.7 23.3 ±  5.5* 23.4 ± 3.4* 13.6 ± 1.2 *† 
Total cholesterol  18.0 ± 3.3 21.1 ±  4.0 8.2 ± 0.8 * 8.1 ±  0.8 * 
Free cholesterol 8.2 ± 0.7 8.2 ± 0.7 5.6 ±  0.4 * 5.8 ±  0.3 * 
Cholesterol esters  10.0 ± 3.1 13.0 ± 3.4 2,6 ±  0.5 * 2.3 ±  0.5 * 
Phospholipids 26.7 ± 1.3 28.2 ± 1.3* 26.1 ±  3.1 27.1 ±  1.3 
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Effects of BAS treatment on sterol metabolism 
which encodes the rate-limiting enzyme in cholesterol biosynthesis, and Srebp2 (2-
fold induction), a protein implicated in control of cholesterol synthesis upon cellular 
cholesterol depletion, in BAS-treated mice (Table 4). Collectively, these data show 
that BAS provokes favorable changes in lipid metabolism. 
Next, we assessed whether the BAS-induced beneficial changes in 
atherosclerotic lesion size and the improvements in plasma and hepatic lipid levels 
were accompanied by BAS-induced modulation of cholesterol and bile acid 
metabolism. 
 
Figure 3. FPLC separation of plasma lipoproteins of CONTROL, RUN, BAS and BAS RUN. 
Plasma of 8 mice per group was pooled and separated by fast protein liquid 
chromotography (FLPC) on a Superose 6 column. Cholesterol (A) and triglyceride (B) 
content was measured in each fraction. VLDL = very low density lipoprotein, LDL = low 
densitiy lipoprotein and HDL = high density lipoprotein 
. 
 
BAS treatment increased fecal sterol output in LDLR-deficient mice 
We first assessed fecal parameters of cholesterol and bile acid metabolism at 12 
weeks of the intervention.  BAS-treated mice had significantly higher neutral sterol 
and bile acid excretions (2.3-fold and  4.2-fold, respectively; Table 5).  As fecal bile 
acid excretion is reflective of de novo synthesis, BAS treated mice displayed an 
increased de novo bile acid synthesis.  This was paralleled by a BAS-induced 
increase in hepatic expression of genes encoding bile acid synthesizing proteins 




fibroblast growth factor 15 (Fgf15), a gene which acts to inhibit bile acid synthesis 
(Table 5). 
 
BAS treatment promotes a negative cholesterol balance 
Because accumulation of excess cholesterol in vascular macrophages leads to the 
formation of atherosclerotic plaques, we then calculated the whole body 
cholesterol balances.  The difference between dietary cholesterol intake and fecal 
cholesterol excretion was positive in non-BAS treated mice, (Table 5) 
demonstrating cholesterol accumulation in the body. However, the cholesterol 
balance was markedly decreased and became negative in BAS treated mice, even 
more in BAS-only treated mice than in mice receiving the combination treatment, 
showing that BAS treated mice excreted their accumulated cholesterol and when 
in a new steady state compensated by an increase in de novo synthesis (Table 5).  
 
BAS treatment decreased biliary sterol secretions 
Subsequently, we assessed biliary parameters. Mice were subjected to gallbladder 
cannulation for collection of hepatic bile at 12 weeks of interventions. BAS-treated 
mice had a 11% decreased bile flow, and major reductions in biliary secretions of 
cholesterol (73% decreased, Table 5), bile acids (55% decreased, Table 5) and 
phospholipids  (50% decreased, data not shown) compared to control mice.  The 
BAS-induced decrease in biliary cholesterol secretion was paralleled by a 
decrease in hepatic ATP-binding cassette transporter protein g5 and a slight, albeit 
not significant, reduction in g8 (Table 5), which both act to transport cholesterol 
across the canalicular membrane into the bile. BAS had no effect on hepatic Bsep 
(Abcb11) expression, which acts to transport bile acids across the canalicular 
membrane (Table 5).  The combination treatment did not result in differential or 
stronger effects on fecal and biliary parameters than BAS treatment alone.   
 
BAS treatment decreased bile acid reabsorption  
From the fecal and biliary data we calculated other parameters of in vivo bile acid 
and cholesterol turnover. We found the daily reabsorption of bile acids dramatically 
decreased upon BAS treatment (96 r 1 % in CONTROL vs. 50 r 25% in BAS and 





Table 4. Hepatic and intestinal genes of cholesterol and bile acid metabolism.  
Hepatic and intestinal mRNA expression levels for sterol-responsive-binding-protein 1c 
(Srepb1c),3-hydroxy-3-methyl-glutaryl-CoA reductase (Hmgcr), sterol-responsive- binding 
protein 2 (Srebp2), ATP-binding cassette transporter g5 (Abcg5) and g8 (Abcg8), 
cholesterol 7 alpha- hydroxylase (Cyp7a1), sterol 12-alpha-hydroxylase (Cyp8b1), sterol 27-
hydroxylase (Cyp27), bile salt export pump (Bsep), ATP-binding cassette transporter 
ABCA1 (Abca1),apical sodium dependent bile aicd transporter (Asbt), ileal bile acid binding 
protein (Ibabp), fibroblast growth factor 15 (Fgf15)  in CONTROL (n=8), RUN (n=8), BAS 
(n=8) and BAS RUN (n=8); Hepatic values are relative to β-actin, Intestinal values are 
relative to cyclophyllin and 36B4 all values represent mean ± SD, *p<0.05 vs. CONTROL, 
†p<-0.05 vs. BAS 
          
  CONTROL RUN BAS BAS RUN 
Liver         
Lipogenessis         
Srebp1c 1.0 ±  0.2 0.7 ±  0.2* 0.6 ± 0.1* 0.5 ±  0.1*† 
Cholesterol Synthesis       
Hmgcr 1.0 ±  0.3 0.6 ±  0.2* 4.3 ±  1.0* 5.0 ±  1.0* 
Srebp2 1.0 ±  0.1 0.9 ±  0.2 2.0 ±  0.3* 1.9 ±  0.2* 
Cholesterol Excretion       
Abcg5 1.0 ± 0.2 0.9 ± 0.2 0.8 ± 0.1* 0.7 ± 0.2* 
Abcg8 1.0 ± 0.2 1.0 ± 0.3 0.9 ± 0.3 0.8 ± 0.2 
Bile Acid Metabolism       
Cyp7a1 1.0 ± 0.6 0.7 ± 0.4 3.8 ± 1.6* 5.3 ± 2.0* 
Cyp8b1 1.0 ± 0.2 0.8 ± 0.2 2.1 ± 0.4* 2.1 ± 0.3* 
Cyp27 1.0 ± 0.2 0.9 ± 0.2 1.3 ± 0.2* 1.3 ± 0.2* 
Bsep 1.0 ± 0.1 1.0 ± 0.2 1.2 ± 0.2 1.2 ± 0.1* 
Intestine         
Cholesterol Metabolism       
Jejunal Abcg5 1.0 ± 0.2 1.3 ± 0.2 0.7 ± 0.1* 0.7 ± 0.2* 
Jejunal Abcg8 1.0 ± 0.3 1.3 ± 0.2 0.6 ± 0.1* 0.6 ± 0.2* 
Jejunal Abca1 1.0 ± 0.2 0.8 ± 0.2 0.3 ± 0.1* 0.3 ± 0.1* 
Bile Acid Metabolism       
Ileal Asbt 1.0 ± 0.4 1.0 ± 0.4 2.6 ± 0.9* 2.3 ± 0.4* 
Ileal Ibabp 1.0 ± 0.3 1.1 ± 0.2 0.6 ± 0.1* 0.6 ± 0.1* 
Ileal Fgf15 1.0 ± 0.5 1.8 ± 0.9 0.02 ± 0.01* 0.02 ± 0.02* 
 
41 r 30% in BAS RUN).  Despite the decreased bile acid reabsorption, ileal 
expression of the apical sodium dependent bile acid transporter (Asbt, Slc10a2), 
was induced more than 2-fold in BAS-treated mice, however, expression of ileal 




facilitates intracellular bile acid transport in the ileocyte, was decreased with BAS 
treatment (Table 4).  
 
BAS treatment increased cholesterol secretion from non-biliary compartment 
As the fecal cholesterol loss was by far higher than the sum of biliary and dietary 
cholesterol input upon BAS treatment, we calculated by how much a non-
hepatobiliary cholesterol excretion could account for this massive BAS-induced 
cholesterol loss. We have previously determined the fractional cholesterol 
absorption to be 38.3 ± 11% in LDLR-deficient mice fed the western-type diet for 
12 weeks (unpublished data) and thus used this value for non-BAS treated mice. 
We were not able to assess cholesterol absorption upon BAS treatment. Yet, In 
light of the by ~6-fold decreased plasma plant sterol / cholesterol ratio (Table 5) 
upon BAS treatment, the rate of cholesterol absorption must have decreased 
considerably. We therefore calculated the non-hepatobiliary cholesterol excretion 
for BAS treated mice using a cholesterol absorption of 0. This would also yield the 
lowest possible non-hepatobiliary cholesterol excretion and thus prevent 
overestimation. The calculated non-hepatobiliary cholesterol excretion values were 
more than ~2.3-fold higher in BAS-treated mice, suggesting that this non-
hepatobiliary route of cholesterol excretion is enhanced under BAS.  Jejunal 
expressions of ATP-cassette binding transporters g5 and g8 and Abca1, proteins 
known to promote cholesterol transport from the enterocyte back into the intestinal 
lumen for elimination into feces, were, however, decreased in BAS-treated mice 




In the present study, we describe the effects of disrupting the enterohepatic 
circulation of bile acids by Colesevelam HCL, a new generation bile acid 
sequestrant (BAS) in an established mouse model of atherosclerosis. Since 
lifestyle interventions, such as physical activity, are often co-prescribed to 
pharmacological intervention, we furthermore evaluated whether a combination 
treatment of BAS and voluntary wheel running would yield additional benefits over  
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Table 5. Parameters of cholesterol and bile acid metabolism. 
This table represents measured and calculated values of fluxes involved in the 
enterohepatic system and  parameters of cholesterol metabolism.  Values for bile acid 
synthesis were assumed to equal the measured values for  bile acids excreted via the feces.  
Daily bile acid reabsorption was calculated by the difference in measured bile acids 
secreted in the bile and feces. Dietary cholesterol balance was calculated by the difference 
between dietary cholesterol intake and fecal cholesterol excretion. Fractional cholesterol 
absorption in non-BAS-treated mice was set to 38%, a value determined by us previously 
utilizing the dual isotope dilution technique in LDLR-deficient mice fed the western diet for 
12 weeks (unpublished data). Fractional cholesterol absorption was set to 0% for BAS-
treated mice taking into account the decrease in plasma plant sterols / cholesterol ratio 
which is indicative of a decreased cholesterol absorption and taking account that lower 
values of absorption give lower non-hepatobiliary cholesterol excretion values; thus non-
hepatobiliary cholesterol excretion values calculated represent the lowest possible values 
and thus might be underestimated for the BAS-treated groups. Non-hepatobiliary 
cholesterol excretion was calculated by the difference between  the sum of fecal and 
absorbed cholesterol and the sum of dietary and biliary cholesterol Values represent mean 
±  SD at 12 weeks of interventions for CONTROL (n=6), RUN (n=8), BAS (n=8) and  BAS 
RUN (n=8); *p<0.05 vs. CONTROL 
 
 
  Control RUN BAS BAS RUN 
Bile flow 
(ul/min/100gBW) 5.47 ±  0.90 
6.00 ±  
0.49 4.86 ±  0.62* 5.12 ±  0.82 
Bile Acids (μmol/day/100gBW) 
Bile  210 ± 22 250 ± 105 94 ± 37* 106 ± 37* 
Feces  9 ± 2 12 ± 4 40 ± 4* 53 ± 14* 
Synthesis  9 ± 2 12 ± 4 40 ± 4* 53 ± 14* 
Reabsorption  201 ± 22 238 ± 106 55 ± 39* 53 ± 51* 
Absorption (%) 96 ± 1 94 ± 4 50 ± 25* 41 ± 30* 
Feces (%) 4 ± 1 6 ± 4 50 ± 25* 59 ± 30* 
Cholesterol (μmol/day/100gBW) 
Dietary intake  83 ± 4 97 ± 8* 135 ± 7* 156 ± 14* 
Bile  2.5 ± 0.2 1.9 ± 0.8 0.4 ± 0.4* 0.7 ± 0.6* 
Dietary cholesterol 
balance   21 ±  6 17 ±  5  -36 ±  10*  -22 ±  14* 
Feces  62 ± 8 79 ± 8 171 ± 12* 178 ± 19* 
Absorption  38 ±  11 38 ±  11 0 ±  0* 0 ±  0* 
Non-hepatobiliary 
cholesterol excretion 16 ±  10 19 ±  6 36 ±  7* 22 ±  15* 
Plasma plant sterol/ cholesterol (μmol/mmol) 







BAS treatment alone. We were able to show, for the first time, that treatment with 
Colesevelam HCL indeed provokes specific changes in cholesterol metabolism, 
specifically switching from a positive to a negative cholesterol balance and 
increasing cholesterol removal via non-hepatobiliary route.  These favourable 
BAS-induced modulations translated into improved plasma as well as liver lipid 
metabolism and ultimately into a dramatic (78%) reduction in atherosclerotic lesion 
size development in western-type diet fed, hypercholesterolemic LDLR deficient 
mice. Moreover, we show that a combination treatment of BAS and physical 
activity had no additional benefits herein. Physical exercise alone modestly 
reduced lesion size (23%). Surprisingly, heart function was normal in all groups 
studied. 
Our data clearly show that under severe hypercholesterolemia as in LDLR-
deficiency, BAS treatment is much more effective in decreasing atherosclerotic 
lesion size development than voluntary wheel running alone, which is in line with 
the degree of metabolic changes induced by either intervention.  Intriguingly, 
running mice not treated with BAS ran ~2-times less than running mice treated with 
BAS during the last two weeks of the experiment. To our surprise, they also ran 
significantly less than LDLR deficient mice fed a western-type diet in a previous 
study (Chapter 6). In fact, as running activity of these mice was decreased by half 
in this experiment compared to our previous one, the improvements in 
atherosclerotic lesion size development were also decreased by a similar 
magnitude (44% reduction in atherosclerotic lesion upon running compared to 
control mice in our previous study to a 23% reduction in this study).  In fact 
calculating the area under the curve for the average distance ran per day for every  
one of the 12 weeks and plotting this against lesion size for running mice of this 
and the previous experiment, we found a significant correlation between area 
under the curve and lesion size (Spearman r= -0.63, P=0.044). A dose-response 
relationship between amount of physical activity and cardiovascular risk reduction 
has previously been observed 42, 43 and the decrease in physical activity in running 
only mice observed here is most likely the underlying factor for the discrepancy in 
findings between this and the previous study.  Moreover, this discrepancy in 
physical activity and cardiovascular risk reduction between our previous study and 
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the present investigation parallels pitfalls of human physical activity intervention 
programs when compliance is often too low to result in adequate cardiovascular 
risk reduction 18, 44, 45 and pharmacological interventions are called upon for 
efficient treatment. 
Our data support the notion that BAS provide an attractive strategy in 
treating lipid disorders and associated diseases, as monotherapy or as add-on 
therapy in patients that are intolerant to statins or respond inadequately to statins. 
Due to their cholesterol-lowering properties, it has been long appreciated that BAS 
reduce cardiovascular risk, including a reduced incidence of acute myocardial 
events 26.  Additionally, clinical trials have revealed that cholesteryramine and 
colestipol, two older generation BAS, increased regression and decreased 
progression in coronary artery lesion as determined by angiography 22-26. We 
demonstrate here, for the first time, that Colesevelam HCL, a more recent and 
specifically engineered BAS with better side effect profile and efficacy over time 19, 
substantially reduces atherosclerotic lesion size in hypercholesterolemic mice. 
Thus, the results of the present study warrant the evaluation of Colesevelam HCL 
on atherosclerotic lesion size reduction in human trials.   
The differences in lesion size between groups did, in contrast to our 
expectations, not associate with differences in cardiac function in any group of the 
LDLR-deficient mice. All echocardiographic parameters were comparable to 
previously published reference values for C57BL/6J and CD1 mice 46, 47. Previous 
studies showed impaired heart function in 36-week old LDLR deficient mice 40, 41.  
Other reports suggested that LDLR deficient mice are prone to cardiac dysfunction, 
even on normal diet 48 or on very short-term (15 days) western-type diet 49. We 
could not confirm these observations. It may be that our intervention was too short 
lasting to elicit cardiac ischemia and subsequent damage. Thus, we suspect that 
the control mice in the present study were too young and atherosclerosis thereby 
not advanced enough for abnormalities in heart function to manifest. Alternatively, 
although the LDLR deficient mouse has resemblance with human coronary artery 
disease, the sequence of events is rather different from man and cardiac 




human disease. It thus remains to be determined whether BAS treatment benefits 
heart function in more advanced atherosclerosis.   
Numerous studies have previously shown that BAS-induced interruption of 
the enterohepatic circulation of bile acids leads to an enhanced hepatic cholesterol 
demand for bile acid synthesis 50-52.  Our data presented here demonstrate a BAS-
induced response for the increased demand for cholesterol biosynthesis in several 
ways.  First, we found a more than ~4-fold induction of the rate-limiting enzyme of 
cholesterol synthesis, Hmgcr, in BAS-treated mice. This is in line with the 
increased Hmgcr expression and fractional cholesterol synthesis we recently 
reported in Colesevelam HCL-treated lean and db/db mice on normal chow 50 but 
also supports an older study showing that cholestyramine increased Hmgcr activity 
~6-fold in gallstone patients 51. Secondly, we found BAS-induced reductions in 
plasma LDL-sized lipoproteins paralleling earlier human studies using 
cholestyramine 52, 53. Moreover, we demonstrate a BAS-induced increase in bile 
acid synthesis in several ways.  First, the BAS-induced more than 4-fold increase 
in fecal bile acid output is reflective of an increased hepatic synthesis. Second, via 
the BAS-induced increases in hepatic Cyp7a1, Cyp8b1 and Cyp27 mRNA levels, 
we demonstrate an induction in bile acid synthesizing transcriptional machinery, 
paralleling our earlier observations of increased bile acid transcriptional machinery 
and bile acid synthesis rate in BAS treated lean and db/db mice on normal chow 50.    
Importantly, our data show that 12 weeks of Colesevelam HCL treatment 
induces a new steady state in the enterohepatic flux of bile acids in 
hypercholesterolemic atherosclerotic mice.  For example within the model we 
studied, the calculated bile acid reabsorption was reduced to 50% in BAS-treated 
mice compared to control mice, which is higher than the BAS-induced 30% 
reduction in bile acid reabsorption observed in lean and db/db mice 50, indicating 
that the effect of BAS on bile acid metabolism is even greater in 
hypercholesterolemic mice.  Additionally, while previous studies report no effects 
of BAS on biliary lipid secretions 50, 53 and bile acid pool size 50, we observed 
profound reductions in biliary lipid secretion upon BAS here. These differences 
might be attributable to duration of treatment, diets or mouse strain studied. While 
the previous reports concern either Colesevelam HCL supplementation to normal 
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chow for two weeks in lean and obese diabetic db/db mice or 4 week 
cholestyramine administration to healthy normo-lipidaemic men, we studied the 
effects of BAS on an extreme model of atherosclerosis after 12 weeks of 
Colesevelam HCL supplementation to a western-type diet.  The decrease in biliary 
bile acid secretion is likely reflective of a decreased bile acid pool size and 
indicates that de novo bile acid synthesis adapted to a new steady state in BAS 
treated mice of this experiment.   
Additionally, BAS treatment exerted substantial effects on the cholesterol 
balance.  Under steady state conditions the amount of cholesterol from dietary 
input and endogenous synthesis equals fecal excretion. In this situation there is no 
accumulation of cholesterol in the body.  A positive cholesterol balance leads to 
accumulation of excess cholesterol within the body which can lead to formation of 
atherosclerotic plaque. The LDLR-deficient mouse has been long utilized as a 
murine model for atherosclerosis due to its inability of hepatic LDL-lipoprotein 
uptake which subsequently results in atherosclerosis.  However, the actual whole-
body cholesterol balance upon Ldlr deficiency has not been reported.  We show 
that Ldlr deficiency leads to cholesterol accumulation and that BAS treatment is 
effectively interfering herein leading to a substantial cholesterol loss which 
coincided with a reduction in atherosclerosis.  The involvement of a non-
hepatobiliary cholesterol excretion pathway appears to have a major contribution 
herein. BAS-treated mice displayed a substantial deficit between the fecal sterol 
excretion and the sum of dietary cholesterol intake and biliary cholesterol secretion. 
This demonstrates that BAS treatment strongly enhances cholesterol excretion 
from a non-hepatobiliary route.  We calculated the contribution of this non-
hepatobiliary cholesterol excretion pathway to be at least 2.3-fold enhanced.   
In summary, the present study shows that disruption of the enterohepatic 
circulation by BAS treatment substantially reduced atherosclerotic lesion size in 
hypercholesterolemic mice which coincided with profound changes in sterol 
metabolism, specifically leading to a massive cholesterol loss. A combination 
treatment of physical activity and BAS had no additive effects. Now that a new 




side-effects profile 54, 55, it may be imperative to re-evaluate the usefulness of BAS 
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       CHAPTER 8 
 







Lifestyle in western society has become increasingly sedentary while at the same 
time people are exposed to relatively cheap, more energy dense, low quality foods 
and experience more chronic stress.  As a result, imbalances in various functional 
aspects of life are emerging and the prevalence of conditions impairing 
physiological and mental functioning has risen dramatically.   
Described clinically by the presence of several metabolic impairments 1, 
the Metabolic Syndrome (MetS) has emerged as a major health concern in 
western society.  Because of the increasing prevalence and economic burden of 
MetS, efficient strategies targeting its complications are warranted.   
Type 2 diabetes is the most common complication of MetS. Type 2 
diabetes accelerates atherosclerosis, the major cause of death in the world.  To a 
large degree, type 2 diabetes and atherosclerosis can be attributed to imbalances 
in glucose and cholesterol metabolism.  Thus, restoring balance in glucose and 
cholesterol metabolism comprises a central feature within the treatment strategies 
for the MetS.  Physical activity and bile acid sequestrants (BAS), the former as 
lifestyle intervention and the latter as pharmacological intervention, act beneficial 
on glucose and cholesterol homeostasis under various metabolic imbalances 
implicated in MetS 2-21. However, the mediators underlying the benefits of physical 
activity and BAS on MetS risk factors are unclear. 
The aim of this thesis was to evaluate whether the physical activity and 
BAS-induced improvements in MetS risk factors are underlying specific 
modulations in glucose and cholesterol metabolism.  In the studies of this thesis 
we utilized Colesevelam HCL as BAS treatment and voluntary wheel running as 
physical activity intervention.  Colesevelam HCL is a new generation BAS which 
displays more efficiency and an improved side effect profile compared to 
conventional BAS 2, 22 . Voluntary wheel running is a low stress intervention, that 
contrary to forced exercise strategies does not change the eating behavior of mice  
23, 24.  
We evaluated the effect of BAS-treatment on glycemic control and atherosclerosis.  
We further established that physical activity beneficially modulates cholesterol 
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metabolism in lean mice and subsequently applied these findings within an 
atherosclerotic mouse model exposed to a running wheel. Furthermore, we tested 
whether a combination treatment of BAS with physical activity would yield further 
improvements in cholesterol homeostasis and atherosclerosis reduction compared 
to BAS treatment by itself.  
 
Bile acid sequestration in the Metabolic Syndrome 
Utilizing engineered mouse models that display specific metabolic derangements, 
we show in this thesis that Colesevelam HCL, as a specifically engineered BAS, is 
effective in improving a variety of Mets risk factors and associated complications.  
We first established that BAS induced improvements in plasma glucose levels 
(Chapter 2 and 3), HOMA-index and insulin sensitivity in the leptin- receptor 
deficient obese and diabetic db/db mouse (Chapter  3), which parallels the BAS-
induced improvements in glucose homeostasis reported for type 2 diabetic 
humans and other animal models of diabetes 25-28.  Then, confirming clinical 
findings in hypercholesterolemic patients 4, 5, 7, 29-31, we established that BAS 
provoked profound improvements in plasma lipids and lipoprotein profiles in 
atherogenic hypercholesterolemic mice (Chapter 7) and showed for the first time 
that BAS, substantially decreased atherosclerotic lesion size development in mice 
by its profound effects on cholesterol homeostasis (Chapter 7). 
 
Bile acid sequestration and glucose homeostasis  
BAS have recently emerged as agents that lower blood glucose and HbA1c levels 
in type 2 diabetes 14. So far, however the actual changes in hepatic and /    or 
peripheral glucose metabolism upon BAS have remained largely elusive.  We 
hypothesized that BAS improve glycemic control by depleting the bile acid pool, 
thereby altering the effects of various nuclear receptors that have implications for 
bile acid, lipid and glucose homeostasis.  To test this we carried out two studies 
using stable isotope techniques for analysis of glucose, cholesterol and bile acid 
metabolism in healthy lean and obese diabetic db/db mice fed normal chow 
supplemented with Colesevelam HCL (BAS) for two weeks. In one study (Chapter 




In another study we (Chapter 3), we tested whether the BAS-induced 
improvements in glucose homeostasis are brought about by modulations in hepatic 
glucose fluxes.  
Measuring the bile acid kinetics of cholate (Chapter 2), we first showed 
that db/db mice display an altered bile acid metabolism and thereby support the 
previously reported increase in the bile acid pool size in db/db mice 32 . Additionally, 
we, for the first time, showed an increased rate of bile acid synthesis in db/db mice.  
Surprisingly, BAS had no effect on the bile acid pool size nor biliary bile acid 
secretion rates despite a massively induced bile acid malabsorption in lean and 
db/db mice (Chapter 2). A lack of a BAS effect on bile acid pool size was recently 
confirmed in healthy and type 2 diabetic humans 33.  Moreover, the BAS-induced 
bile acid malabsorption and subsequent increased turnover of cholesterol (as 
demonstrated by increased de novo cholesterol and bile acid biosynthesis) 
coincided with an increase in hepatic lipogenesis that was dependent on FXR and 
LXR.  FXR and LXR have established roles in various metabolic pathways 
including bile acid and lipid metabolism. The BAS-induced increase in lipogenesis 
can potentially be attributed to reduced FXR activation. Activated by bile acids in 
the liver, FXR acts to inhibit lipogenesis by inhibiting LXR-induced activation of 
SREBP1c 34, which is a lipogenic transcription factor.  Furthermore, BAS increased 
de novo cholesterol synthesis, which was expected in order to generate substrate 
for bile acid synthesis.  Intriguingly, the BAS-induced increased turnover of 
cholesterol did not reduce cellular cholesterol stores, in fact hepatic cholesterol 
content tended to be increased, reflecting that the increase in cholesterol synthesis 
was massive and more than to generate substrates for the compensatory increase 
in de novo bile acid synthesis. Such massive increase in cholesterol biosynthesis 
could allow for generation of oxysterols which activate LXR, and thereby  
lipogenesis 35. 
Further, we, and others 36-38, thought that BAS mediate their glucose 
lowering actions through direct interference of bile acid signaling pathways in the 
enterohepatic system, because those pathways also involve nuclear receptors with 
established roles in glucose homeostasis, specifically LXR and FXR 38-41. 
Modulation of such pathways could then translate into altered hepatic glucose 
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metabolism and thus improve glucose homeostasis. Herein, we suspected the bile 
acid pool size to decrease upon BAS leading to decreased signaling via FXR.. As 
discussed above, BAS treatment did not alter the bile acid pool size in db/db mice 
and as discussed below, the BAS-induced improvements in glucose homeostasis 
were not mediated by BAS effects on hepatic glucose metabolism.  This implies 
that BAS improve glucose homeostasis by alternate pathways not primarily linked 
to nuclear receptors implicated in bile acid and glucose homeostasis. 
By measuring in vivo glucose metabolism using the MIDA approach, we 
found that BAS treatment did not bring about its glucose lowering actions by 
improving the specific disturbances in hepatic glucose metabolism that we 
observed for db/db mice (Chapter 3).  Compared to lean mice, db/db mice 
displayed an increased glucokinase flux, glucose cycling rate and total hepatic 
glucose production rate.  Although treatment with BAS decreased blood glucose 
levels and de novo-glucose-6-phosphate synthesis in db/db mice, BAS treatment 
did not lead to ameliorations in any of these above stated disturbances of hepatic 
glucose metabolism.  Therefore, the liver could not be the mediator of the glucose 
lowering actions of BAS.  However, we observed that BAS targeted peripheral 
tissues.  Intriguingly, the BAS-induced increase in glucose metabolic clearance 
rate in db/db mice coincided with a reduced long-chain acylcarnitine content in 
their skeletal muscles. Long-chain acylcarnitines are intermediates of ß-oxidation. 
High intracellular levels of these molecules can be toxic and have shown to be 
reflective of an overloaded fatty acid oxidation. The consequence of this lack of 
capacity is an accumulation of substrates such as acyl-CoA’s in the mitochondria 
42, and ceramide and diacylglycerides in the cytosol, which in turn interfere with 
insulin stimulated glucose oxidation 42, 43.  Therefore, a BAS-induced reduction in 
skeletal muscle long-chain acylcarnitine content is reflective of a more efficient 
mitochondrial fatty acid oxidation. Concomitantly to the BAS-induced decreases in 
plasma fatty acid levels, BAS treated db/db mice displayed an improved HOMA-
index and increased glucose metabolic clearance rate, alltogether indicative of an 
improved insulin sensitivity.  Future studies elucidating the effects of BAS 




mitochondrial respiration are desirable in further determination of the specific 
effects of BAS in improving peripheral insulin sensitivity. 
The question is how BAS, by altering the enterohepatic circulation of bile 
acids, promote an improved insulin sensitivity in peripheral tissue. Which might be 
the responsible factors herein? Known for their effects on increasing metabolic rate, 
thyroid hormones might have a potential role. TGR5 activation in brown adipose 
tissue and skeletal muscle stimulates the conversion of inactive to active thyroid 
hormone which then by specific signaling pathways increases metabolic rate 44. 
However, the conversion of inactive to active thyroid hormone is catalyzed through 
activation of TGR5 by bile acids. Thus, granted that plasma bile acid levels were 
lower in BAS treated mice (Chapter 3) an implication for peripheral TGR5 
activation on BAS-induced glycemic control seems rather unlikely. Another 
candidate for the BAS-induced peripheral actions on glucose homeostasis is an 
incretin called glucagon-like-peptide-1 (GLP-1). BAS have recently been shown to 
increase the production of GLP-1 levels in insulin resistant, diet-induced obese rats 
and this has been associated with improved insulin sensitivity 11.  Moreover, 
incretins have been proven effective in treating type 2 diabetes 45.  Intriguingly, we 
observed an increased GLP-1 expression in the ileum of BAS treated db/db mice 
(Chapter 3, data not shown). Concomitantly, BAS induced a slight malabsorption 
of dietary fatty acids in lean and  db/db mice (Chapter 3, data not shown). This 
suggests that upon BAS treatment an increased amount of fatty acids is passing 
through the distal parts of the intestine, where fatty acids have been shown to 
induce GLP-1 by stimulation of L-cells 46.   
From our data and within the limits of our methods we concluded that 
changes in liver glucose metabolism do not mediate the glucose-lowering effect of 
BAS.  Utilizing the MIDA approach, however, we were not able to measure 
glycolysis. Thus, we cannot exclude a possibility for BAS to enhance glycolysis 
and to thereby affect hepatic and whole-body glucose metabolism. Indeed, upon 
BAS-treatment there was a trend for an increased glucokinase flux and an 
induction of pyruvate kinase, a glycolytic gene, in db/db mice. These observations 
in combination with the increased hepatic triglyceride contents in BAS treated mice 
(Chapter 2 and 3) which appeared to be mediated by an increased de novo 
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synthesis of fatty acids and fatty acid chain elongation (Chapter 2) are, in fact, 
speculative of an increased flux of glucose through glycolysis.  Thus, despite the 
fact that BAS treatment does not decrease hepatic glucose output, BAS potentially 
mediated an increased flux of glucose into hepatic triglyceride storage, further 
study is warranted to substantiate this hypothesis.  However, given the substantial 
improvements in peripheral glucose homeostasis upon BAS treatment, it seems 
rather unlikely that possible BAS-mediated increases in hepatic glycolysis have a 
major contribution to the improved glycemic control. 
 
Bile acid sequestration and cholesterol homeostasis 
Before statins emerged as the mainstream pharmacological treatment for 
hypercholesterolemic patients, BAS were the first choice to treat 
hypercholesterolemia. Numerous clinical studies demonstrated BAS to 
substantially improve total and LDL-cholesterol levels which was accompanied by 
considerable relative risk reductions in fatal and nonfatal myocardial infarction 29, 
as well as increased regression 4, 6, 7 and reduced progression 4-7 in coronary artery 
lesions. However, during their clinical use in the 1980s BAS treatment, then limited 
to cholestyramine and colestipol, proofed difficult due to poor tolerability pertaining 
to gastrointestinal side effects and due to their interactions with other commonly 
prescribed drugs 22. In the 1990s, Colesevelam HCL was specifically engineered 
for much better tolerability, efficacy and much reduced potential for drug 
interactions 2. While the cholesterol lowering effects of Colesevelam HCL have 
been widely reported 3, 8, 9, 21 and it even has been the first drug to be FDA-
approved for its effects on improving both glycemic control and cholesterol levels, 
its effects on atherosclerosis have not been reported so far. 
We evaluated the effects of Colesevelam HCL (BAS) on atherosclerosis in 
the Ldlr-deficient mouse (Chapter 7), an established mouse model of 
atherosclerosis. We observed profound effects of BAS on cholesterol homeostasis.  
BAS provoked a considerable switch from cholesterol accumulation to cholesterol 
elimination which was accompanied by a substantial reduction in atherosclerotic 
lesion size development, by ~78%. Clearly, our data warrant the re-evaluation of 




progression) in human trials. The effect of Colesevalam in mice not only highlights 
the central role of cholesterol in the pathogenesis of atherosclerosis but also 
shows that atherosclerosis development can be effectively reduced when targeting 
cholesterol accumulation.  Intriguingly, fecal sterol excretion was increased but 
biliary sterol secretion was markedly reduced upon BAS treatment, indicating that 
a non-hepatobiliary cholesterol excretion pathway accounted for the negative 
cholesterol balance upon BAS.  Upon calculation, we indeed found such pathways 
to be enhanced at least 4-fold by BAS treatment.  
The nature of this non-hepatobiliary cholesterol excretion pathway needs 
to be determined in future experiments. However, the existence of a transintestinal 
cholesterol efflux (TICE) route has over the last years gained considerable 
appreciation as more evidence has been gathered showing the intestine to actively 
secrete cholesterol 47.  Our data is suggestive of an enhanced TICE under BAS 
treatment. From our calculations, however, we cannot conclude which bodily 
cholesterol pools contributed to the BAS-induced increase in cholesterol excretion. 
Unfortunately, we were not able to quantify cholesterol absorption in these 
experiments. The low plasma plant sterol / cholesterol ratio, a surrogate marker of 
cholesterol absorption, is a first suggestion that BAS reduced cholesterol 
absorption. BAS could provoke a reduced cholesterol absorption by interfering with 
micelle formation. For absorption cholesterol needs to be incorporated into mixed 
micelles, since bile acids are bound to BAS, mixed micelle formation is most likely 
impaired. Future studies analyzing in vivo cholesterol fluxes, directly measuring 
cholesterol absorption, synthesis and contribution of intestinal shedding will be 
necessary to quantify cholesterol balance in these experiments.   
 
2. Physical activity in the Metabolic Syndrome 
Utilizing voluntary wheel running as a physical activity intervention to target MetS 
risk factors and associated complications, we observed improvements in a variety 
of MetS risk factors throughout the studies in this thesis. For example, physical 
activity led to a reduced bodyweight gain, reduced epididymidal white adipose 
tissue weight, improved lipoprotein profiles in hypercholesterolemic atherosclerotic 
mice (Chapter 5) and improved plasma lipid values in healthy lean chow-fed mice 
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(Chapter 4) and hypercholesterolemic atherosclerotic mice (Chapter 5). Thereby 
we confirm a long known beneficial role for physical activity in improving MetS risk 
factors like obesity 48-50 and hyperlipidemia 50, 51.  Furthermore, we show that a 
sufficient amount of physical activity significantly reduces atherosclerosis 
development in hypercholesterolemic atherosclerotic mice (Chapter 5), while a 
decreased amount is not clearly effective (Chapter 6).  Thus, we not only confirm 
clinical and experimental studies reporting beneficial effects of physical activity on 
atherosclerosis 15-20, 52, 53 but also that a higher level of physical activity leads to 
greater effects on cardiovascular risk reduction 13, 54.  
Despite the well established role of physical activity on MetS risk factors 
and complications, the mechanisms underlying these effects remain elusive. 
Inspired by limited past work showing that physical activity provokes alterations in 
cholesterol and bile acid metabolism 55-58, we questioned whether physical activity 
may enhance pathways leading to enhanced fecal sterol excretion (Chapter 4 and 
5) and if so, whether these pathways may play a considerable role in the physical 
activity-induced reduction of MetS risk factors and its major complication 
atherosclerosis (Chapter 6 and 7).  
 
Physical activity and cholesterol metabolism 
Instead of controlling the intensity of physical activity by exposing mice to forced 
exercise training, we, for a number of reasons, choose for the voluntary wheel 
running set up. First, it has previously been shown that already a two week 
exposure of healthy mice to a voluntary running wheel results in cardiac and 
skeletal muscle adaptations that are consistent with those of endurance exercise 59. 
Second, the voluntary wheel running set up provides an anti-stress intervention 23 
compared to forced exercise interventions, which have been found to cause 
chronic stress-like changes in the hypothalamic-pituitary-adrenal axis 24.  Third, 
reflecting the stress-response, upon forced exercise rodents do not increase their 
food intake 60, while rodents engaged in voluntary activity increase their food intake 
to compensate for the increased energy expenditure. Thus, the stress associated 
with forced exercise regimes results in an energy imbalance which by itself could 




indeed that physical activity as in voluntary wheel running enhanced whole body 
cholesterol turnover by decreasing cholesterol absorption and stimulating bile acid 
synthesis in healthy chow fed mice.  In hypercholesterolemic, atherosclerotic mice, 
we then showed that the reduction in atherosclerotic lesion size development 
coincided with an enhanced cholesterol turnover especially mediated by increased 
cholesterol turnover into bile acids, while cholesterol absorption did not appear 
affected in this model (Chapter 6). The ~45% reduction in atherosclerotic lesion 
size development that we found  upon voluntary exercise here, parallels previous 
studies that observed reductions ranging from 30-54% upon forced exercise in 
atherosclerotic hypercholesterolemic mouse models 10, 12, 18, 19. No study, however, 
has linked the beneficial effects of physical activity observed on atherosclerosis 
reduction to an increased cholesterol turnover before. Thus, by demonstrating here, 
for the first time, that physical activity increases cholesterol turnover while 
concomitantly reducing atherosclerotic lesion size development, we indicate that 
an increased cholesterol turnover might be a considerable driving factor for the 
physical activity-induced atherosclerosis reduction.  .   
Intriguingly, the enhanced cholesterol turnover upon physical activity was 
specific for an increased cholesterol conversion into bile acids. While physical 
activity induced marked increases in biliary bile acid secretions (up to 68%) and 
fecal bile acid loss (up to 93%), biliary secretion rates of cholesterol were 
unaffected and fecal excretion of neutral sterols was increased to a lesser degree 
(up to 34%) than the excretion of bile acids. The increased fecal bile acid excretion 
in physically active mice reflects an increase in de novo bile acid synthesis. To our 
surprise, the transcriptional machinery implicated in bile acid synthesis was not 
affected by exercise. Studying in vivo bile acid kinetics would provide detailed 
information on the actual alterations of physical activity on different aspects of bile 
acid metabolism and would be desirable. However, increases in de novo bile acid 
synthesis without concomitant increases in any of the major bile acid genes have 
also been reported by others 61, 62 and most likely underlie posttranscriptional 
mechanisms.  It is speculative therefore that physical activity regulates bile acid 
synthesis via metabolic control mechanisms. The increase in bile acid synthesis 
may be a physiological response on the increased energy demand. We observed 
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that physical activity increased dietary fatty acid absorption (Chapter 6, data not 
shown).  During physical activity, energy is depleted in energy expending tissues, 
such as skeletal muscle. Thus, a high demand for new energy manifests in these 
tissues.  In this regard, physical activity might, hypothetically, increase bile acid 
synthesis to increase the capacity for micelle formation; thereby fatty acid 
absorption and thus energy delivery to energy expending tissues.   
Importantly, although cholesterol turnover was found increased upon 
voluntary wheel running in healthy chow-fed mice as demonstrated by various 
parameters (Chapter 4), we did not observe an increased in vivo macrophage-to-
feces RCT in healthy chow-fed mice exposed the same experimental set-up 
(Chapter 5). To our surprise, despite unchanged HDL levels and in vivo RCT, 
running mice displayed an increased cholesterol efflux from macrophages towards 
plasma (Chapter 5).  An increased efflux capacity in trained athletes has previously 
been reported, however, with concomitantly higher levels in HDL 63.  From human 
data it is known, that trained endurance athletes have substantially higher HDL 
levels than healthy sedentary controls 64, 65. Moreover, it is known that physical 
activity increases HDL levels in previously sedentary individuals very modestly 65, 66, 
thus not substantially affecting the difference in HDL levels to trained endurance 
athletes 65. To make the issue even more complex, it has also been reported that 
runners have a ~2-time increased biological half-life of HDL proteins and that 
runners do not produce more HDL protein but catabolize less 64. However, no 
previous study has reported the effects of physical activity on HDL levels in healthy 
chow-fed mice. Moreover, differences in lipoprotein metabolism between mice and 
men have been documented, some of them directly pertaining to HDL 
metabolism67-69, likely explaining the lack of effect of physical activity on HDL 
levels we observed. Finally, HDL by itself may not be the best indicator for RCT 
per se, recent reports demonstrate it to be a rather dynamic cholesterol transporter 
with varying function and structure 70, 71. It has been suggested that preβ1-HDL 
might be a better marker for RCT than HDL 72, however, physical activity has 
shown differential effects on preβ1-HDL levels 63, 66. 
The puzzling finding then remains, why in vivo macrophage-to-feces RCT 




sterol excretion, and an increased cholesterol efflux from macrophages towards 
plasma in two-week running healthy chow-fed mice? The effects of voluntary 
wheel running on parameters of cholesterol metabolism are rather small (Chapter 
4), and the utilized method may possibly not be sensitive enough to pick up subtle 
changes. In fact, tracer recovery in livers and feces (bile acid and neutral sterol 
fractions) showed subtle, albeit not significant, increases in running mice (Chapter 
5). It is desirable to test in vivo macrophage-to-feces RCT in hypercholesterolemic, 
atherosclerotic mice running for 12 weeks, where effects of running were more 
striking compared to healthy chow-fed mice, especially pertaining to biliary bile 
acid secretion and fecal bile acid loss as already stated above. More work is 
needed to unravel the enigma of in vivo macrophage-to-feces RCT upon exercise. 
 
Beneficial effects of physical activity on hepatic triglyceride content 
Utilizing the voluntary running wheel as a lifestyle intervention for studies 
described in this thesis, we consistently observed reductions in hepatic fat 
deposition (Chapters 4 to 7). Increased hepatic fat deposition is associated with 
MetS, type 2 diabetes and cardiovascular disease 73, thus the favorable effect of 
voluntary wheel running on reducing hepatic fat storage provides further benefit in 
MetS risk reduction and is discussed below.  
Sources for hepatic triglycerides are free fatty acids from adipose tissue, 
de novo lipogenesis and chylomicron-derived fatty acids from dietary fat. In 
addition, hepatic triglyceride concentration is a function of hepatic oxidation and 
clearance of VLDL.  Both processes might be favorable altered upon exercise but 
thorough studies are missing to date.  There is a paucity of data showing the 
effects of physical activity on fatty liver in humans. An array of studies, however, 
shows that physical activity combined with dietary intervention yields 
improvements in liver tests and ameliorates fatty liver and  weight loss has been 
found fundamental in a reduction of fatty liver in humans 74. Recently, however, 
cardiorespiratory fitness was found to be the best predictor of changes in hepatic 
triglycerides independent of total and visceral adiposity 75.  
It is intriguing that lean and hypercholesterolemic mice exposed to a 
running wheel display reduced hepatic triglyceride stores, the magnitude of 
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reduction compared to respective control mice ranging from 1.4 to 1.9-fold 
(Chapters 4 to 7). This reduction was accompanied by reduced expression of key 
lipogenic genes (SREBP1c, FASN and SCD1) in running hypercholesterolemic 
atherosclerotic mice (Chapter 6).  Comparing hepatic triglycerides contents across 
the studies described in this thesis, it becomes apparent that Ldlr-deficient mice 
fed a western-type diet display enhanced triglyceride storage (Chapter 6 and 7) 
compared to chow-fed wildtype mice (Chapter 4 and 5). To date there are no 
reports describing the effects of physical activity, either forced or voluntary, on 
hepatic lipids in hypercholesterolemic mouse models. Yet, limited data show that 
high fat and low fat-fed wildtype mice display reduced hepatic triglyceride stores 
after treadmill exercise training 76, 77  and that swim training reduced hepatic fatty 
acid synthesis in C57BL6/J mice 78.  
The exact mediators pertaining to the beneficial effects of regular physical 
activity on hepatic triglycerides remain, so far, elusive and is beyond the scope of 
this thesis.  However, regular physical activity promotes specific skeletal muscle 
adaptations (i.e.: increased mitochondrial biogenesis, capillarization) that allow for 
an increased uptake of fatty acids, β-oxidation and skeletal muscle triglyceride 
storage 79.  These are all adaptations that become necessary to sustain a delivery 
of nutrients to this tissue during physical activity, and that may therefore also serve 
to partition fatty acids away from the liver. 
 
Effects of physical activity on cholesterol metabolism are dose-dependent 
We observed considerable differences in magnitude of running wheel 
activity and outcome parameters between two groups of hypercholesterolemic 
atherosclerotic mice of two different studies (Chapter 6 and 7). Although the 
experimental set-up was identical, the mice in the experiment of chapter 5 ran 
twice as much compared to the mice used in the experiment of chapter 6. 
Interestingly, the “lazy” mice showed no decrease in plasma cholesterol and 
diminished improvement of plaque formation indicating a direct relation between 
the extend of physical activity and these parameters. The difference in running 
wheel activity between the two studies closely paralleled the discrepancy in 




running twice as much displayed twice as much reduction in atherosclerotic lesion 
size development (Chapter 6 vs. Chapter 7). In fact calculating the area under the 
curve for the average distance ran per day for every  one of the 12 weeks and 
plotting this against lesion size for running mice of Chapter 6 and 7, we found a 
significant correlation between area under the curve and lesion size depicted in 








correlated. The area 
under the curve (AUC) 
was calculated by the 
average distance ran 
per day for every 12 
weeks of the running 
intervention. 
Subsequently AUC 
was plotted against 
atherosclerotic lesion 
size for running mice of 
chapter 6 and 7. 
 
Physical activity and bile acid sequestration as co-treatments in 
atherosclerosis 
As stated above, physical activity programs often do not result in sufficient risk 
reduction for reasons related to poor compliance or a more advanced risk profile of 
the subject. In these situations pharmacological intervention becomes necessary 
and is either prescribed by itself or as combination therapy with a lifestyle 
intervention, such as physical activity.   
BAS and voluntary wheel running by themselves clearly have differential 
effects on cholesterol metabolism.  The BAS-induced reduction in atherosclerosis 
coincided with a switch from a positive to a negative cholesterol balance with 
concomitant increases in non-hepatobiliary cholesterol excretion. In contrast, the 
reduction in atherosclerotic lesion size upon voluntary wheel running coincided 
with a marked effect on cholesterol turnover into bile acids.  Thus, we questioned 
whether a combination of the two treatments would provide further benefits on 
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atherosclerosis and cholesterol metabolism. We found that such a combination 
treatment did not yield additional benefits to BAS treatment alone, most likely 
because BAS effects on sterol metabolism are more dramatic and may override 
the more subtle effects of voluntary wheel running. 
Furthermore, our data clearly show that under severe 
hypercholesterolemia, as in Ldlr deficiency, BAS treatment is much more effective 
in the reduction of atherosclerosis than voluntary wheel running.  While, depending 
on activity levels, we found a range of ~20 – 45% in reduction of atherosclerotic 
lesion size in mice exposed to a voluntary running wheel (Chapter 6 and 5, 
respectively), the BAS effect was clearly stronger, yielding a reduction of ~78% 
(Chapter 6).  Similar observations were found for fecal and biliary parameters of 
cholesterol metabolism.    
 
Perspectives and conclusion 
The studies described in this thesis provide novel insights concerning cholesterol 
metabolism-modulated amelioration of MetS risk factors and associated 
complications by BAS and physical activity.  As stated in the discussion, questions 
arose specifically related to the mechanisms of a BAS-induced reduction of 
skeletal muscle long-chain acylcarnitines, the BAS-induced enhanced non-
hepatobiliary cholesterol excretion and the physical activity-stimulated bile acid 
synthesis and in vivo macrophage-to-feces RCT.  Using sophisticated methods, 
future studies are warranted to address these questions.  
Furthermore, the presented studies focused on the effect of BAS and 
physical activity in the development of complications associated with MetS using  
extreme mouse models. This thesis demonstrates that BAS and physical activity 
are beneficial in reducing MetS risk factors and associated complications when 
presenting with increased MetS risk suggesting a positive role for both treatments 
in managing the currently ever-increasing prevalence of MetS 
It now would be desirable to evaluate both treatments in the following: 
1. The prevention of MetS and its complications and test the effects of early-
life treatment and treatment maintenance on development of MetS and 
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The prevalence of the metabolic syndrome (MetS) has reached alarming 
dimensions in the Western World. MetS is comprised of a multitude of risk factors 
and can lead to serious complications like type 2 diabetes and atherosclerosis. Bile 
acid sequestrants (BAS), pharmacological agents that increase the fecal excretion 
of bile acids, and physical activity improve MetS and act beneficial in decreasing 
high blood glucose and high cholesterol levels, two components of MetS. 
However, underlying mechanisms are elusive. We evaluated whether the BAS and 
physical activity induced improvements in MetS are underlying specific changes in 
glucose-and cholesterol-handling in specific mouse models paralleling human 
disease.  
We found that BAS decrease blood glucose levels by peripheral actions 
and not by modulations of liver glucose handling. Specifically, we found BAS to 
increase the clearance of blood glucose which coincided with a number of 
parameters indicating improved peripheral insulin sensitivity and glucose 
utilization. Additionally, we found BAS treatment to substantially reduce 
atherosclerosis development in atherosclerosis-prone mice which is most likely 
mediated by a switch from bodily cholesterol accumulation to cholesterol loss.   
We further established that physical activity beneficially modulates 
cholesterol metabolism by enhancing its fecal excretion especially as bile acids but 
also as neutral sterols. This coincided with a reduced development of 
atherosclerosis and hepatic fat storage. Intriguingly, we found a negative 
correlation between the amount of physical activity and atherosclerosis 
development. 
Altogether, the studies of this thesis provide novel insights on how BAS 











De toename in het vorkommen van het metabole syndroom (MetS) in de Westerse 
Wereld is alarmeerend. MetS omvat meerdere risicofactoren die kunnen leiden 
diabetes type 2 en atherosclerose. Galzout-bindende harsen (BAS), 
farmacologische stoffen, die de fecale uitscheiding van galzouten verhogen, en 
fysieke inspanning hebben een positieve invloed op hoge bloedsuiker spiegels en 
hoge cholesterol waarden in het bloed,  twee belangrijke risico-factoren 
geassocieerd met MetS. Echter, de onderliggende mechanismen zijn onduidelijk. 
We hebben onderzocht hoe fysieke inspanning en BAS de genoemde 
verbeteringen in MetS veroorzaakten in specifieke muismodellen voor humane 
ziekten. BAS verlaagde de bloed glucose waarden door een reactie van de 
perifere weefsel, met name spier,  en niet door veranderingen van het lever 
glucose metabolisme. We vonden dat BAS een aantal parameters van perifere 
insuline gevoeligheid en glucose verbruik verbetert. BAS behandeling leidt tot een 
substantiële verlaging van atherosclerose ontwikkeling in atherosclerose gevoelige 
muizen, waarschijnlijk veroorzaakt door een omschakeling van cholesterol 
ophoping naar cholesterol uitscheiding. We stelden vast dat lichamelijke activiteit 
het cholesterol metabolisme positief beïnvloedt door verhoogde fecale excretie van 
cholesterol, vooral in de vorm van galzouten maar ook als neutrale sterolen. Dit 
veroozaakte waarschijnlijk vermindering  van atherosclerose en vet stapeling in de 
lever. Opvallend was de negatieve correlatie tussen mate van lichamelijke activiteit 
en ontwikkeling van atherosclerose. Samengevat geven de studies in dit 
proefschrift nieuwe inzichten in hoe BAS en lichamelijke activiteit de risico-factoren 












Das metabolische Syndrom (MetS) hat Besorgnis-erregende Maße in der 
westlichen Welt erreicht. MetS wird durch eine Vielfalt von Risikofaktoren 
charakterisiert und kann zu ernsthaften Komplikationen wie Typ 2 Diabetes und 
Arteriosklerose führen. Gallensäurerhemmer (BAS), pharmakologische Mittel, die 
die fäkale Ausscheidung der Gallensäuren erhöhen und sportliche Aktivität 
verbessern MetS.  Beide wirken vorteilhaft bei der Senkung hoher Blutglukose-und 
Cholesterin- Spiegel, zweier Merkmale des MetS. Doch die zugrunde liegenden 
Mechanismen sind nicht eindeutig. Wir untersuchten ob die durch BAS und durch 
körperliche Bewegung verursachten Verbesserungen in MetS durch spezifische 
Veränderungen im Glukose- und Cholesterin-Stoffwechsel hervorgerufen werden.  
Hierfür verwendeten  wir spezifische Mäusemodelle, die menschliche Störungen 
des Mets wiederspiegeln. Wir fanden, dass die BAS-induzierte Senkung der 
Blutglukose durch Vorgänge im peripheren Gewebe, speziell in der 
Skelettmuskulatur, und nicht durch Modulation des Leber-Glukose-Stoffwechsels 
hervorgerufen wird.  Im speziellen, BAS erzielt die Räumung von Glukose aus dem 
Blut, was mit Parametern zusammentraf, die auf eine verbesserte periphere 
Insulinempfindlichkeit und Glukoseverbrauch hinweisen.  Zusätzlich führt BAS-
Behandlung zu einer wesentlichen Verminderung in Arterioskleroseentwicklung in  
Arteriosklerose-empfindlichen Mäusen führte, höchstwahrscheinlich durch einen 
Wechsel von  körperlicher Cholesterinansammlung zu Cholesterinverlust dur BAS. 
Der Cholesterinstoffwechsel wird weiterhin vorteilhaft von körperlicher Belastung 
beeinflusst denn körperliche Bewegung führt zu einer Erhöhung der fäkalen 
Cholesterinausscheidung insbesondere als Gallsäuren, aber auch als neutrale 
Sterolen,.   Dieses traf zusammen mit einer verringerten Ausbildung von 
Arteriosklerose und Fettablagerung in der Leber.  Außerdem fanden wir eine 
negative Korrelation zwischen Dauer der körperlicher Belastung und 
Arterioskleroseentwicklung. Insgesamt verleihen die Studien dieser Dissertation 
neue Einblicke darauf, wie BAS und körperliche Bewegung die Risikofaktoren und 
Komplikationen von MetS positiv beeinflussen. 
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Stammtisch Pintelier: Ulli, Reinhard, Carlos, Arne: Prost! 
 
I am grateful to all my friends who kept supporting me from far away, who never 
stopped inspiring me, who visited me and /or traveled with me during the last 4 
years. I feel at home with y’all from distant places: Anne (Toelle): Woofs and 
Poodle-Power forever my dear friend whether in Texas, Sanibel, Mc-Gregor Blvd., 
Istanbul or G-city.  Cheasty con mucho gusto no suggestion nicargyüse yoghurt, 
human pyramids and good wine. Judy and Ashmi, thanks for visiting numerous 
times, coming to Columbus for me, your creativeness and good vibes.  I have good 
friends in you that I would not want to miss. Waqas ! Your good energy always 
carries over. Thanks for all the encouragement. You rock. Christine (for being a 
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goldmine of valuable advice), Kathrin (Wo ist Jutta?), all of Austin BT, Conny,  
Nicole and Julia. 
 
Xavier, I am so happy that we met and to have the time with you is beautiful.  A big 
warm thank you for your dear support in the last months. 
 
Herzlichen Dank an meine Familie.  Insbesondere: 
Thomas, schön, daβ Du mein Bruder bist, auf Dich ist immer Verlaβ, und das hat 
mich oft beruhigt.  Anja, mit Dir ist gut Kirschen essen! Danke für Eure Besuche in 
G-city und Euren Humor. Mutti & Vati, vielen Dank für Euer „Über-die-Schultern-
spucken“, Eure Versuche zu verstehen was ich eigentlich mach und das 
Weitervermitteln der Meiβnerischen Zähheit. Ich bewundere wie Ihr mit den 
gegenwertigen Schwierigkeiten umgeht und wünsche mir noch viele schöne Zeiten 










Maxi Meissner was born in the spring of 1980 in Berlin (GDR). A few years later, 
the family, comprised of Angela, a civil engineer, Wolfgang, a biology and 
chemistry teacher, and the two children, Thomas and Maxi, moved to  Schwedt, a 
small town at the German-Polish border. 
At the turn of the 19th century Schwedt was known for its tobacco 
production. In the 1960-ies when Schwedt was the end-point of a petrol pipeline 
coming from Russia, the town developed into a young industrial East-German 
model city.  Quickly, whole new neighborhoods consisting of socialist apartment 
buildings emerged.  Such apartments had good sanitary conditions and were 
highly desirable, also to the Meißners. 
Maxi’s affinity for physical activity was sparked early. As part of East-
German ideology, children were screened for their potential at different sports. Like 
her brother Thomas, Maxi was invited to try the sport of rowing at the age of 8.  To 
Maxi, staying afloat in a rowing shell seemed more fun than spending time with her 
violin. As the years passed, Maxi got to know every cubic m spanning the 
picturesque shoreline of the Friedrichsthaler Wasserstrasse.   At the age of 15 she 
took the opportunity to explore new waters and moved to Potsdam where she 
attended the Eliteschule des Sports and moved herself in a boat up and down the 
river Havel.  Then and there Maxi’s interest for exercise physiology manifested.  
She wondered why the sports scientists pricked her ear for blood so frequently that 
it often turned purple. Fascinated by their work, Maxi also realized that their 
training advice was worthwhile to follow; she won gold at the Junior-World 
Championships twice. 
Luckily, for Maxi, who wanted to travel, the walls around East Germany 
had long disappeared when in 1998 she was recruited for rowing by American 
universities. At the age of 19, she started studies in exercise physiology at The 
Ohio State University in Columbus, Ohio. During the next four years, Maxi 
experienced the “American way of life”.  The days were very long with the first 
rowing practice starting at 5:30 and so much to do. Maxi realized that 5 hours of 
sleep is not good and was happy when her contract as a rower, her time as a 
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student neared its end and the blisters on her hand developed into smooth skin.  
After gaining experience working in cardiac and pulmonary rehabilitation at the 
Ohio State Hospitals Center for Wellness and Prevention, Maxi’s interests 
switched from exercise performance towards physical activity in disease 
prevention and therapy. 
To pursue a masters degree in exercise physiology, focusing on cardiac 
metabolism, she moved to Austin, Texas at the age of 24. She was fascinated with 
her studies and her curiosity about the interactions of lifestyle and disease grew 
deeper.  Austin with its creative inhabitants, abundant natural beauties, its 
independent arts and music scene, Austin BT and its good weather year around 
was a love affair at first sight.   
However, wondering whether she liked living in Europe, close to her 
family, Maxi decided to search for a PhD-position in Europe. In the fall of 2006, she 
took on a PhD-position (“The role of Fxr in energy expenditure”) at the Laboratory 
of Pediatrics at the University of Groningen where the working environment 
appeared perfect for learning and growing while tasting European life and being 
closer to family.   
During her stay in Groningen Maxi not only enjoyed the ups and downs of 
being a PhD student, but learned that balance is important for well-being.  In her 
work she missed the direct application of her work to people and decided to fill that 
desire by transferring her enthusiasm for ashtanga yoga onto others in her free 
time.  In May 2010, Maxi became a certified ashtanga yoga teacher and now 
enjoys teaching ashtanga to anyone who wants to learn (www.moxieyoga.com). 
After putting down the pipettes, Maxi enjoys swimming in open water, 
being in nature, checking out life music, reading, playing the djembe (badly), 
traveling, meeting people, the brain science podcast and avocados.  In the future, 
Maxi’s work will continue to contribute to society’s well-being at large; in a basic 
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